Attention:
The content of this ebook reflects information received and processed by June 12, 2018. All participants are encouraged to use the congress web app which is updated in “real time” at http://tts.guide.
STOP! TTS GREEN VISION – REDUCE OUR ECOLOGICAL FOOTPRINT

DON'T PRINT THIS BOOK! LOOK AT WHAT YOU COULD BE SAVING BY NOT PRINTING:

TTS has made it its mission to reduce the environmental impact of the Congress. As such, the Final Program is available for downloading onto your electronic devices. If you still think that you need a printed copy, please print it and bring your own. A pocket guide (program overview with room numbers) will be included in the registration materials.

<table>
<thead>
<tr>
<th>PHYSICAL QUANTITY</th>
<th>US SYSTEM</th>
<th>METRIC SYSTEME</th>
<th>INSTANCE IN EVERYDAY LIFE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pages</td>
<td>600,000</td>
<td>600,000</td>
<td></td>
</tr>
<tr>
<td>Ton of paper</td>
<td>2.89 tons</td>
<td>2.89 tons</td>
<td></td>
</tr>
<tr>
<td>Wood Use</td>
<td>11 tons</td>
<td>11 tons</td>
<td>69 trees</td>
</tr>
<tr>
<td>Net Energy</td>
<td>94 million BTU's</td>
<td>99 GJ</td>
<td>1 home/year</td>
</tr>
<tr>
<td>Greenhouse Gases</td>
<td>16,188 pounds</td>
<td>16,188 pounds</td>
<td>1 car/year</td>
</tr>
<tr>
<td>CO2 equiv.</td>
<td>CO2 equiv.</td>
<td>CO2 equiv.</td>
<td></td>
</tr>
<tr>
<td>Water Consumption</td>
<td>66,047 gallons</td>
<td>250,000 liters</td>
<td>1/10 of an Olympic-sized swimming pool</td>
</tr>
<tr>
<td>Solid Waste</td>
<td>5,554 pounds</td>
<td>2.5 tons</td>
<td>1/4 garbage truck</td>
</tr>
<tr>
<td>Purchased Energy</td>
<td>64 million BTU's</td>
<td>68 GJ</td>
<td>1 home/year</td>
</tr>
<tr>
<td>Sulfur dioxide (SO2)</td>
<td>77 pounds</td>
<td>35 kg</td>
<td>14 18-wheelers/year</td>
</tr>
<tr>
<td>Particulates</td>
<td>18 pounds</td>
<td>8 kg</td>
<td>2 buses/year</td>
</tr>
<tr>
<td>Hazardous Air Pollutants (HAP)</td>
<td>8 pounds</td>
<td>3.6 kg</td>
<td></td>
</tr>
<tr>
<td>Volatile Organic Compounds (VOCs)</td>
<td>9 pounds</td>
<td>4 kg</td>
<td></td>
</tr>
<tr>
<td>Total Reduced Sulfur (TRS)</td>
<td>1 pounds</td>
<td>0.45 kg</td>
<td></td>
</tr>
<tr>
<td>Total Suspended Solids (TSS)</td>
<td>50 pounds</td>
<td>22.7 kg</td>
<td>1 home/3 months</td>
</tr>
<tr>
<td>Chemical Oxygen Demand (COD)</td>
<td>57 pounds</td>
<td>26 kg</td>
<td>1 home/6 weeks</td>
</tr>
<tr>
<td>Biochemical Oxygen Demand (BOD)</td>
<td>29 pounds</td>
<td>13 kg</td>
<td>1 home/2 months</td>
</tr>
</tbody>
</table>

USE THE TTS 2018 CONGRESS WEB APP

NO DOWNLOAD REQUIRED!

To view the app, go to http://tts.guide and sign in using the same username/password that was sent to you by email on June 21.

Web App Highlights:
- Browse the final program and abstracts
- See who's attending and start networking now
- Build your personalized Congress agenda with the help of easy and efficient search functions
- Connect and engage with attendees, speakers, sponsors and exhibitors before, during and after TTS 2018
- Look up colleagues and schedule meetings with your colleagues
- Note taking
- General Congress information

WiFi Access
SSID: TTS2018

How to connect in a few simple steps:
Step 1: Connect to the TTS2018 SSID
Step 2: Log-in page should appear automatically
Step 3: Click “Log In”
Step 4: Open any website in any browser if splash page doesn’t appear

Troubleshooting
- Ensure cookies are enabled on your device
- Visit the staff in the registration area for help in connecting

<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Messages</td>
</tr>
<tr>
<td>Congress Committees List</td>
</tr>
<tr>
<td>Young Investigator Scientific Awards</td>
</tr>
<tr>
<td>Mentee-Mentor Awards</td>
</tr>
<tr>
<td>Congress Policies</td>
</tr>
<tr>
<td>Floor Plans</td>
</tr>
<tr>
<td>Congress Information</td>
</tr>
<tr>
<td>Networking Events</td>
</tr>
<tr>
<td>Corporate Symposia</td>
</tr>
<tr>
<td>Exhibit Information</td>
</tr>
<tr>
<td>Detailed Program</td>
</tr>
<tr>
<td>Pre-Congress Activities</td>
</tr>
<tr>
<td>Saturday, June 30</td>
</tr>
<tr>
<td>Sunday, July 1</td>
</tr>
<tr>
<td>Main Program</td>
</tr>
<tr>
<td>Monday, July 2</td>
</tr>
<tr>
<td>Tuesday, July 3</td>
</tr>
<tr>
<td>Wednesday, July 4</td>
</tr>
<tr>
<td>Thursday, July 5</td>
</tr>
<tr>
<td>Poster List</td>
</tr>
<tr>
<td>Presenter Index</td>
</tr>
</tbody>
</table>

SPONSOR ACKNOWLEDGEMENT

The 27th International Congress of The Transplantation Society extends its appreciation to the following sponsors for their support.

**PREMIER LEVEL**

- **Astellas**

**PRINCIPAL LEVEL**

- **Roche**

**MAJOR LEVEL**

- **Baskent Üniversitesi**
- **BriteLife**
- **Chiesi**
- **Comunidad de Madrid**
- **madrid**
- **NOVARTIS**
- **ONE LAMBDA**
- **QIAGEN**

**CONTRIBUTOR LEVEL**

- **neovii**

**SUPPORTER LEVEL**

- **JDRF**
- **Beckman Coulter Life Sciences**
WELCOME MESSAGE - TTS

It is with great pleasure and anticipation that we wish to welcome you to the 27th International Congress of The Transplantation Society here in Madrid.

TTS has recognized the leading role of Spain in donation and transplantation, with the Spanish Model having become a reference worldwide. TTS and Organización Nacional de Trasplantes (ONT) were awarded the Prince of Asturias Award (considered as the Spanish equivalent of the Nobel Prize) in 2010 in the field of International Cooperation in recognition of their joint efforts in promoting ethical practices in transplantation.

Together with our partners in the Sociedad Madrileña de Trasplante (SMT) and the Sociedad Española de Trasplante (SET), we have brought together a high-profile scientific program committee with the aim of developing a broad and exciting agenda that will cover a diverse array of topics, ranging from cutting-edge science to the latest controversies in ethics and public policy. Issues relevant to developing transplant programs, organ donation and procurement will be a highlight for many participants.

The destination and host city of the congress, Madrid, is a cosmopolitan metropolis that combines modern infrastructure with extensive cultural and artistic heritage. Madrid boasts the status of a financial, administrative and corporate center, while at the same time remaining a tolerant, passionate and lively city. Its individual artistic tradition effortlessly embraces multiple external influences, both past and present, thus highlighting the city’s continuing openness to new ideas. Located in the center of Spain, Madrid has excellent air and land connections with major destinations within, and outside, the peninsula.

Enjoy this unique Congress and drive your outcome!

Nancy Ascher  
TTS President & Congress Chair

José María Morales  
Congress Vice-Chair

WELCOME MESSAGE - SET

On behalf of the Spanish Society of Transplantation, it is my great pleasure to welcome you to Madrid and to the 27th International Congress of the Transplantation Society in partnership with our Society and the Sociedad Madrileña de Trasplantes.

We are very excited to have won the bid to host this important congress in Madrid. By this election, TTS is recognizing the leading role of Spain in donation and transplantation, with the Spanish model being a reference worldwide. We hope to follow in the successful footsteps of the past meetings in Hong Kong and San Francisco.

The Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in transplant medicine, primarily in the areas of organ donation, immunotherapy and tissue engineering and Big Data in transplantation medicine.

Many distinguished transplant physicians and scientists have joined the faculty and will take part in this Congress. Abstracts will be presented in the form of oral and poster sessions and will include superb scientific material that was carefully selected by the Scientific Program Committee from over 1,700 abstracts, many of them submitted by our Spanish colleagues. It’s a certainty that all these studies, originating from faculties from over 60 countries, together with the plenary and state-of-the-art sessions, symposia and networking events, will assure that the meeting will be a major scientific event.

I would like to express our gratitude to the TTS Council and the TTS International Headquarter staff for their excellent arrangements in all aspects of the Congress, to their dedicated staff, colleagues, and friends, for their untiring work in planning and arranging this meeting. And of course to the pharmaceutical industry for their continuous support towards medical education.

We hope that you will enjoy the Congress and that your interaction with your colleagues from many different countries will stimulate a creative exchange of ideas and will be personally rewarding. Lastly but by no means least, we also hope and trust that you will enjoy your visit to the very beautiful and exciting city of Madrid.

Wishing you all a heartfelt welcome for what promises to be an outstanding educational and cultural event: TTS 2018.

Yours sincerely,

Valentin Cuervas-Mons  
President
On behalf of the Sociedad Madrileña de Trasplantes I am pleased to welcome you to Madrid, venue of the 27th International Congress of The Transplantation Society. This congress has been prepared with special attention to exchange the latest advances in the field of organ donation and transplantation, both in its clinical and research aspects and for you to enjoy our magnificent city.

Spain is a world leader in donation and transplants and Madrid is one of the most important cities in our country in this activity. Actually, the donation and transplant program pioneers in the development of uncontrolled donation after cardiac death and donation in elderly patients are from Madrid.

Madrid has a splendid cultural, historical and culinary offer that you should be enjoying during the free time of the congress. It is one of the friendliest cities in the world where nobody feels like a foreigner and where anyone you meet is willing to hear from you with the admiration of someone who is learning from your experience.

I hope that during your stay you will feel like those who inhabit this city and say, to highlight how nice and loving the city is “from Madrid to heaven”.

Yours sincerely,

Amado Andrés Belmonte
Presidente de la Sociedad Madrileña de Trasplantes

---

**Executive Committee**

Nancy Ascher, San Francisco, CA, USA (Congress Chair)
José María Morales, Madrid, Spain (Congress Vice-Chair)
Philip J. O’Connell, Westmead, Australia (Scientific Program Committee Chair)
Kyung-Suk Suh, Seoul, Korea (TTS 2020 Representative)
Mehmet Haberal, Ankara, Turkey (TTS President-Elect)

**Finance Committee**

Nancy Ascher, San Francisco, CA, USA (Chair)
Amado Andrés Belmonte, Madrid, Spain
Daniel Casanova, Santander, Spain
Valentín Cuervas-Mons, Madrid, Spain
Gabriel E. Gondolesi, Buenos Aires, Argentina

**Host Country Liaison Committee (Spain)**

José María Morales, Madrid
Josep M. Grinyo, Barcelona
Beatriz Domínguez-Gil, Madrid
Valentín Cuervas-Mons, Madrid

**Scientific Program Committee**

Philip J. O’Connell, Westmead, Australia (Chair)
Carla C. Baan, Rotterdam, Netherlands
Marcelo Cantarovich, Montreal, QC, Canada
Shane T. Grey, Darlinghurst, Australia
Josep M. Grinyo, Barcelona, Spain

**Program Sub-Committee Chairs**

- **Postgraduate Courses**
  - Clinical Co-Chairs
    - Medhat Askar, Dallas, TX, USA
    - Marcelo Cantarovich, Montreal, QC, Canada

- **Basic Science Co-Chairs**
  - Fadi Issa, Oxford, UK
  - Megan Levings, Vancouver, BC, Canada
  - Birgit Sawitzki, Berlin, Germany

---

**CONGRESS COMMITTEES**
The TTS Young Investigator Scientific awards are offered by The Transplantation Society to offer trainees from all regions an opportunity to attend this important Congress. Selection of the award winners is based on the scientific merit of their abstract submissions.

These awards are supported by the Roche Organ Transplantation Research Foundation (ROTRF).

Rebeca Arroyo Hornero, United Kingdom

424.6 CO-STIMULATORY MODULATION OF HUMAN REGULATORY T CELLS FOR ENHANCED IMMUNOTHERAPY

Yarl Balachandran, United States

527.5 DELINEATION OF THE VIRAL AND HOST CELL GENOMIC ALTERATIONS IN EBV-POSITIVE PTLD

Florence Bonisconti, Argentina

P.382 CLINICAL UTILITY OF A MODIFIED QRT-PCR FOR TRYPANOSOMA CRUZI DETECTION IN TRANSPLANT PATIENTS

Xiaoyong Chen, People’s Republic of China

303.3 CHARACTERIZATION OF A CD23+CD43+ REGULATORY B CELL SUBSET IN HUMAN THAT INDUCED BY MESENCHYMAL STEM CELLS

Aravind Cherukuri, United States

318.1 PROSPECTIVE MULTICENTER VALIDATION OF HUMAN TRANSITIONAL B CELL CYTOKINES AS A PREDICTIVE BIOMARKER IN RENAL TRANSPLANTATION

Fang Kuan Chiou, Singapore

627.4 POORER LONG-TERM SURVIVAL ASSOCIATED WITH MONOMORPHIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER SOLID ORGAN TRANSPLANTATION IN CHILDREN

Dominik Chittka, United States

316.1 DSA PLUS TCMR LEADS TO POOR OUTCOMES IN RENAL ALLOGRAFT RECIPIENTS AND THIS IS MARKEDLY EXACERBATED BY NON-ADHERENCE

Helong Da, People’s Republic of China

421.2 DISTAL ABDOMINAL AORTA COULD SERVE AS AN OUTFLOW TRACT FOR EN BLOC KIDNEY TRANSPLANTATION FROM INFANT DONORS WITH EXTREMELY LOW BODY WEIGHT

CONGRESS COMMITTEES

Program Sub-Committee Chairs

TTS 2018 Congress Sessions

- Anesthesia Management and Critical Care
  John Klinck, Cambridge, UK
  Claus Niemann, San Francisco, CA, USA

- Basic Science and Translational Science
  Qi Zhi Tang, San Francisco, USA
  James A. Hutchinson, Regensburg, Germany
  Nancy Kwan Man, Hong Kong, Hong Kong

- Cellular and Regenerative Therapies
  Maria Koulmanda, Boston, MA, USA
  Stephen Strom, Stockholm, Sweden

- Complications
  Peter J. Friend, Oxford, UK
  Hiroto Egawa, Tokyo, Japan

- Donation & Procurement
  Susan Gunderson, Minneapolis, MN, USA
  Helen Opdam, Canberra, Australia
  Eduardo Rocha, Rio de Janeiro, Brazil

- Ethics, Community, Economics and DOI
  Rudolf Garcia-Gallont, Guatemala, Guatemala
  Beatriz Dominguez-Gil, Madrid, Spain
  Elmi Muller, Cape Town, South Africa
  Peter G. Stock, San Francisco, CA, USA

- Heart & Lung
  Tobias Deuse, San Francisco, CA, USA
  Anne I. Dipchand, Toronto, ON, Canada

- Histocompatibility
  Peter W. Nickerson, Winnipeg, BC, Canada
  Elaine F. Reed, Los Angeles, CA, USA

- Infectious Diseases
  Michael G. Ison, Chicago, IL, USA
  Nassim Kamar, Toulouse, France

- Intestine and Multivisceral Transplantation
  Gabriel E. Gondolesi, Buenos Aires, Argentina
  Andreas Pascher, Berlin, Germany

- Kidney
  Christophe Legendre, Paris, France
  Robert A. Montgomery, New York, NY, USA
  Ron Shapiro, New York, NY, USA

- Transplant Immunosuppression
  Stephan Busque, Stanford, CA, USA
  Steve J. Chadban, Camperdown, Australia
  Dirk R.J. Kuypers, Leuven, Belgium

- Liver
  Jan Lerut, Brussels, Belgium
  Claus Niemann, San Francisco, CA, USA
  Kyung-Suk Suh, Seoul, Korea

- Paediatrics
  Carlos G. Esquivel, Stanford, CA, USA
  Mignon McCulloch, Cape Town, South Africa

- Pancreas & Islet
  James F. Markmann, Boston, MA, USA
  Lorenzo Piemonti, Milan, Italy

- Registries
  Curie Ahn, Seoul, Korea
  Bertram L. Kasiskie, Minneapolis, MN, USA

- Sex and Gender in Transplantation
  Elaine F. Reed, Los Angeles, CA, USA
  Lorie J. West, Edmonton, AB, Canada

- Transplantation Nursing
  Sandra A. Cupples, Potomac, MD, USA
  Christiane Kugler, Freiburg, Germany

- Vascularized Composite Allotransplantation
  Vijay S. Gorantla, Pittsburgh, PA, USA
  Emmanuel Morelon, Lyon, France

- Xenotransplantation
  David K.C. Cooper, Birmingham, AL, USA
  Chung-Gyu Park, Seoul, Korea
Nicole De La Mata, Australia
620.1 STROKE MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS: A RETROSPECTIVE POPULATION-BASED COHORT STUDY USING DATA LINKAGE

Reinier de Vries, United States
615.2 EXTENDING THE HUMAN LIVER PRESERVATION TIME FOR TRANSPLANTATION BY SUPERCOOLING

Su Kah Goh, Australia
420.7 DONOR-SPECIFIC CELL-FREE DNA AS AN EMERGING BIOMARKER OF ORGAN REJECTION AFTER LIVER TRANSPLANTATION

Christian Heim, Germany
626.2 BLOCKADE OF TYROSINE KINASES AS PREVENTIVE STRATEGY AGAINST CARDIAC ALLOGRAFT VASCULOPATHY IN A MURINE AORTIC TRANSPLANT MODEL

Charlotte A. Lee, United Kingdom
523.2 THE ANTI-INFLAMMATORY EFFECT OF ALPHA-1 ANTITRYPSIN IN HEPATOCYTE TRANSPLANTATION

Xiaoqian Ma, People’s Republic of China
304.4 CORD BLOOD DERIVED REGULATORY MACROPHAGES (MREG) – AN ALTERNATIVE SOURCE FOR MREG-BASED CELL THERAPY IN TRANSPLANTATION

Berenice Mbiribindi, United States
518.2 NK CELL RECOGNITION OF PEPTIDES ENCODED BY EBV LATENT CYCLE PROTEINS

Hiroyuki Ogasawara, Japan
424.8 A COMPARISON OF THE TRANSPLANT EFFICIENCY BETWEEN INTRAPORTAL AND INTRASPLENIC PROCEDURES IN HEPATOCYTE TRANSPLANTATION

Brenda Rosales, Australia
302.5 CANCER MORTALITY IN TRANSPLANT RECIPIENTS IN AUSTRALIA AND NEW ZEALAND: A NATIONAL COHORT STUDY FROM 1980 TO 2013

Akhil Sharma, United States
316.6 PRO-INFLAMMATORY B CELLS PREDICT PROGRESSIVE MINIMAL EARLY RENAL ALLOGRAFT INFLAMMATION WHICH IS ASSOCIATED WITH POOR GRAFT OUTCOMES

Nicole Shockcor, United States
622.3 END STAGE RENAL DISEASE AS A COMPLICATION OF FACE TRANSPLANT

Ashley Suah, United States
303.4 ACQUIRED RESISTANCE TO TRANSPLANTATION TOLERANCE AS A RESULT OF PRIOR PREGNANCY REQUIRES B CELLS

Patrick Trotter, United Kingdom
419.4 TRANSPLANTATION OF KIDNEYS FROM DCD AND DBD DONORS WHO DIED AFTER LIGATION ASPHYXIATION: THE UK EXPERIENCE

Marike van der Zwan, The Netherlands
326.1 EFFICACY OF RABBIT ANTI-THYMOCYTE GLOBULIN THERAPY FOR SEVERE ACUTE REJECTION IN KIDNEY TRANSPLANT PATIENTS USING CALCINEURIN INHIBITOR AND MYCOPHENOLATE MOFETIL BASED IMMUNOSUPPRESSIVE THERAPY

Karen Waller, Australia
590.1 INCIDENCE, PREVALENCE AND RESIDUAL INFECTION RISK OF HIV IN INCREASED RISK GROUPS PRESENTING AS POTENTIAL ORGAN DONORS IN AUSTRALIA; A SYSTEMATIC REVIEW AND META-ANALYSIS

Casey J. Ward, United States
592.1 REVERSAL OF DIABETES AND PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACE WITH NOVEL PARATHYROID GLAND CO-TRANSPLANTATION

Cheng Yang, People’s Republic of China
516.4 PREDICTION OF RENAL ALLOGRAFT CHRONIC REJECTION USING A MODEL BASED ON CONTRAST ENHANCED ULTRASONOGRAPHY

Yuanfei Zhao, Australia
608.3 IN-VIVO COSTIMULATION-BLOCKADE INDUCED FOXP3 TREGS FROM DEREG MICE WITH NEONATAL ISLET CELL CLUSTER TOLERANT XENOGRRAFTS EXIST MEMORY TREGS PHENOTYPE
The Transplantation Society (TTS) along with the collaboration of its Affiliated Societies celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards by recognizing the efforts of basic scientists who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

The Awards will be given on Monday, July 2, during the International Transplantation Science Mentee-Mentor Networking Event to be held from 17:45 to 18:45 in the North Convention Centre, 1st floor (attendance by invitation only).

### TTS-Indian Society of Organ Transplantation Awards

Mentee: Sahil Bagai  
Mentor: Manish Rathi  
P.348 CORRELATION OF PRETRANSPLANT GLUCOSE METABOLISM AND NONALCOHOLIC FATTY LIVER DISEASE WITH THE DEVELOPMENT OF POST TRANSPLANTATION DIABETES MELLITUS

Mentee: Manish Balwani  
Mentor: Pankaj Shah  
P.681 KNOWLEDGE REGARDING BRAIN DEATH AND ORGAN DONATION LAWS AMONG MEDICAL STUDENTS

Mentee: Akhilesh Jaiswal  
Mentor: Narayan Prasad  
P.256 INTER-INDIVIDUAL VARIABILITY OF TACROLIMUS TOUGH LEVEL MAY BE DUE TO DIFFERENTIAL P-GLYCOPROTEIN EXPRESSION ON PBMCS IN RENAL TRANSPLANT RECIPIENT

Mentee: Mohan Patel  
Mentor: Manoj Gumbers  
P.233 PHARMACO-DYNAMICS OF CSA AND TACROLIMUS AND ITS EFFECT ON ANTIVIRAL DRUGS IN HCV POSITIVE KIDNEY TRANSPLANT RECIPIENTS.

### TTS-Canadian Society of Transplantation Awards

Mentee: Ibrahim Adam  
Mentor: Lori J. West  
318.6 ANTIBODY RESPONSE TO NON-SELF BLOOD GROUP A-ANTIGEN DEPENDS ON CD4 T CELLS, FORIGEN PROTEIN AND CD22 INTERACTION

Mentee: Minal Borkar  
Mentor: Lee Anne Tibbles  
316.8 EPIGENETIC INHIBITORS AS POTENTIAL ANTI-VIRAL TREATMENT AGAINST BK POLYOMA VIRUS ASSOCIATED NEPHROPATHY: AN ELUCIDATION OF MECHANISM

Mentee: Nicholas Dawson  
Mentor: Megan Levings  
C494.6 HUMANIZATION AND PRE-CLINICAL VALIDATION OF AN ANTI-HLA-A*02:01 CHIMERIC ANTIGEN RECEPTOR FOR USE WITH REGULATORY T CELLS TO ENHANCE TRANSPLANT TOLERANCE

Mentee: Avery Lam  
Mentor: Megan Levings  
586.5 HUMAN REGULATORY T CELL POTENTIAL FOR TISSUE REPAIR VIA IL-33/ST2 AND AMPHIREGULIN

### TTS-Japan Society for Transplantation Award

Mentee: Asuka Tanaka  
Mentor: Yuka Tanaka  
619.7 DONOR CONDITIONING WITH RECIPIENT-DERIVED PD-L1/PD-L2-EXPRESSING B CELLS PREVENTS LETHAL ACUTE GVHD IN A FULLY ALLOGENEIC MOUSE MODEL

### TTS-Nederlandse Transplantatie Vereniging Award

Mentee: Jesus M. Sierra Parraga  
Mentor: Martin Hoogduijn  
424.3 MONOCYTIC CELLS PHAGOCYTOSE THERAPEUTIC MESENCHYMAL STEM CELLS, WHICH INDUCES POLARIZATION, RELOCATION AND IMMUNE REGULATION
MENTEE-MENTOR AWARDS

TTS-Sociedad Española de Trasplante Awards
Mentee: Patricia Conde-Sanroman
Mentor: Jordi C. Ochando
P.430 TARGETING TRAINED IMMUNITY PROMOTES ORGAN TRANSPLANT ACCEPTANCE

Mentee: Maria García-Conde Delgado
Mentor: Iago Justo Alonso
603.3 LIVER TRANSPLANTATION FROM DONOR AFTER CARDIAC DEATH (DCD) MAASTRICHT TYPE IIA, OUR EXPERIENCE AFTER 10 YEARS

Mentee: Oana Anisa Nutu
Mentor: Iago Justo Alonso
P.835 INFLUENCE OF GRAFT STEATOSIS ON THE OUTCOME OF LIVER TRANSPLANTATION

TTS-Turkish Transplantation Society Award
Mentee: Selin Akad
Mentor: Feride I. Sahin
P.485 IMPACT OF MMP2, MMP9 AND TIMP2 GENE POLYMORPHISMS ON ALLOGRAFT REJECTION IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS

TTS-Transplantation Society of Australia and New Zealand Awards
Mentee: Sam R. Adhikary
Mentor: Hong Chee Chew
C495.3 IN VIVO DEPLETION OF DIVIDING DONOR CELLS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE CAN REDUCE THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN A HUMANISED MOUSE MODEL

Mentee: Maria García-Conde Delgado
Mentor: Iago Justo Alonso
323.5 DONATION AFTER CIRCULATORY DEATH HEART TRANSPLANTATION: AN UPDATE OF CURRENT PRACTICES AND OUTCOMES

The Transplantation Society Awards
Mentee: Jianing Fu, United States
Mentor: Megan Sykes, United States
619.4 CLONAL AND FUNCTIONAL ANALYSIS REVEALS THE CAPACITY OF ALLOGRAFT T CELLS TO JOIN THE CIRCULATING POOL AFTER HUMAN INTESTINAL TRANSPLANTATION

Mentee: Ahmer Hameed, Australia
Mentor: Wayne Hawthorne, Australia
593.6 A NATIONAL REGISTRY ANALYSIS OF AORTIC VERSUS DUAL IN SITU PERFUSION FOR RETRIEVAL OF THE DBD LIVER

Mentee: Melisa Pucci Molineris, Argentina
Mentor: Gabriel E. Gonzolesi, Argentina
522.1 PANETH AND INTESTINAL STEM CELLS ARE DIFFERENTIALLY AFFECTED DURING WORSENING OF ACUTE CELLULAR REJECTION IN SMALL BOWEL TRANSPLANTATION COMPARED TO INTESTINAL ISCHEMIA REPERFUSION INJURY AND GRAFT VERSUS HOST DISEASE

Mentee: Elisa Montanari, Switzerland
Mentor: Iago Justo Alonso
P.430 TARGETING TRAINED IMMUNITY PROMOTES ORGAN TRANSPLANT ACCEPTANCE

Mentee: Maria García-Conde Delgado
Mentor: Iago Justo Alonso
P.835 INFLUENCE OF GRAFT STEATOSIS ON THE OUTCOME OF LIVER TRANSPLANTATION

TTS-Transplantation Society of Australia and New Zealand Awards
Mentee: Sam R. Adhikary
Mentor: Hong Chee Chew
C495.3 IN VIVO DEPLETION OF DIVIDING DONOR CELLS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE CAN REDUCE THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN A HUMANISED MOUSE MODEL

Mentee: Maria García-Conde Delgado
Mentor: Iago Justo Alonso
323.5 DONATION AFTER CIRCULATORY DEATH HEART TRANSPLANTATION: AN UPDATE OF CURRENT PRACTICES AND OUTCOMES
All attendees must respect these policies as part of the contractual commitment that they made at the time of registration. Failure to comply may result in removal / denied access to the Congress.

**Congress Public Safety and Security**

For security reasons, all delegates will be issued a badge onsite that is required to be worn at all times during the Congress and at any organized functions. Badge swapping is strictly prohibited.

All individuals entering the venue may be subject to a visual and possibly a physical body search; packages and baggage may also be searched or screened before entering the venue, and at any time during the event. All physical body searches will be done professionally, in privacy, in a courteous manner, and respectful of gender.

**Recording of Presentations is Strictly Prohibited**

No individual or entity - including a presenting author - may electronically record or broadcast any portion of the TTS 2018 (including their own presentation) without prior written consent of TTS 2018. Please see the staff at the Congress Registration desk. Unauthorized recording (audio, video, still photography, etc.) of presentations during sessions, posters, workshops, tutorials, etc., without the express written consent of TTS 2018 and individual authors is strictly prohibited. TTS 2018 reserves the rights to any approved audio and video production of presentations.

Press representatives must receive a Press Pass which implies photo/recording permission from TTS 2018.

**Photo Policy**

Photographing formal presentations, posters, or displays without permission of the presenter is forbidden.

**Policy on Respectful Dialogue**

Participants are expected to keep criticism constructive, and avoid personal attacks in sessions, in online discussion boards and in social media. Debate of ideas is encouraged, allowing delegates to enjoy a lively and stimulating congress.

---

**Policy on Social Media Use and Congress Web App**

We encourage the use of social media (LinkedIn, Twitter, Facebook, and Instagram) and the Congress web app before, during, and after the Congress in order to share information and to network with others. However, we ask all congress participants to adhere to the following guidelines:

- Whenever possible, use the hashtag #tts2018 to discuss the Congress.
- Communicate with respect and consideration for others, keeping criticism constructive.
- Blog, post or tweet about what you are hearing and learning, but refrain from sharing information when the speaker explicitly requests this. Talks are tweetable and shareable by default, but speakers can request that specific details or slides not be shared.
- Provide feedback to the Congress committees, we encourage participants to post and discuss topics of interest as well as ideas for future meetings.
- Do not engage in rudeness or personal attacks.
Venue

TTS 2018 will be held at the IFEMA North Convention Center and Hall 10.

All TTS 2018 events will take place at the IFEMA North Convention Centre - 1st Floor and Hall 10, unless otherwise indicated. Satellite meeting space for committee and section meetings are located on the mezzanine corridors located on top of Halls 9 and 10.

**IFEMA Feria de Madrid**

Avda. del Partenón, 5  
Madrid, Spain 28042  
Tel: (34) 91 722 30 00  
Fax: (34) 91 722 58 01  
e-mail: lineafema@ifema.es  
Website: www.ifema.es

### Operating Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Registration</th>
<th>Speaker Ready Room (N109)</th>
<th>Exhibit Hall 10</th>
<th>Luggage Check ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 30</td>
<td>08:00-17:30</td>
<td>08:00-17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>July 1</td>
<td>08:00-20:00</td>
<td>08:00-18:00</td>
<td>19:00-20:00</td>
<td></td>
</tr>
<tr>
<td>July 2</td>
<td>08:00-17:30</td>
<td>08:00-16:30</td>
<td>09:30-17:30</td>
<td></td>
</tr>
<tr>
<td>July 3</td>
<td>08:00-17:30</td>
<td>08:00-16:30</td>
<td>09:30-17:30</td>
<td></td>
</tr>
<tr>
<td>July 4</td>
<td>08:00-17:30</td>
<td>08:00-17:00</td>
<td>09:30-15:00</td>
<td>08:00-19:00</td>
</tr>
<tr>
<td>July 5</td>
<td>08:00-13:30</td>
<td>08:00-10:00</td>
<td></td>
<td>08:00-14:00</td>
</tr>
</tbody>
</table>
Accreditation / CME

The 27th International Congress of The Transplantation Society, Madrid, Spain, 30/06/2018-05/07/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 38 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

- 30.06.2018 - 8,00
- 01.07.2018 - 7,00
- 02.07.2018 - 7,00
- 03.07.2018 - 7,00
- 04.07.2018 - 6,00
- 05.07.2018 - 3,00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

Business Centre

Please note that the Congress will not feature a business center. The post office located at IFEMA and accessible from the “Avenida”, offers photocopy and printing services.

Certificate of Attendance

A personalized Certificate of Attendance will be available from your dashboard when you log into your account once you have collected your badge at the Congress. Certificates of Presentation can be requested at the Speaker Ready Room starting Monday, July 2. Please note that the Certificate reflects the Presenter’s name and mentions the abstract authors.

Charging Stations

Participants can charge their devices at the TTS Booth in Hall 10 or by use of the electrical outlets in the session rooms. Please do not leave your phone unsupervised. Charging your phone is at your own risk.

Congress Evaluation

The Congress evaluation form will be available on the dashboard of the Congress web app as of 14:00 on July 3rd. You can print your CME certificate upon completion of the Congress evauation form. TTS and all Congress Committees will appreciate your constructive feedback.

Emergency / First Aid

For any emergency or first aid services inside IFEMA, please contact any TTS or IFEMA staff or use a house phone.

Information

Should you require any assistance during the Congress, please call the registration desk directly at 0917-223101.

Language

English is the official language of the Congress. Therefore, the program will be presented in English only.

Liability

The Organizing Committee and/or The Transplantation Society and/or any of suppliers shall not be held liable for personal accidents or losses or damage to private property of registered participants of the TTS 2018 Congress. Participants should make their own arrangements with respect to personal insurance.

Lounge Areas

Four networking areas have been designated for registered participants in the Exhibit area (Hall 10):

- TTS Booth
- Young Members Corner
- Rewind and Unwind Lounge
- Soccer Lounge

Lost and Found

Any lost and found items will be held at the registration desk for the duration of the Congress. Any unclaimed items will be disposed of at the end of the Congress.
### Luggage Check
The luggage check will be open during the hours listed below, at a cost of 3 Euros per item.
- **July 4**: 08:00-19:00
- **July 5**: 08:00-14:00

### Lunch Menu

<table>
<thead>
<tr>
<th>DAY</th>
<th>OPTION 1</th>
<th>OPTION 2</th>
<th>OPTION 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>JUNE 30</strong></td>
<td>Turkey sandwich with lettuce, tomato, mustard and honey and fusilli side salad</td>
<td>Baked vegetables with rosemary on baguette and fusilli side salad</td>
<td>Cesar salad with chicken</td>
</tr>
<tr>
<td><strong>JULY 1</strong></td>
<td>Serrano ham with tomato on baguette with veggie side salad</td>
<td>Sweet raw onion, fresh spinach, olive oil and goat cheese sandwich with veggie side salad</td>
<td>Quinoa salad with nuts, modena vinegar and olive oil on mixed greens with chicken, and baby tomato with a pepper and dill sauce</td>
</tr>
<tr>
<td><strong>JULY 2</strong></td>
<td>Ham and brie wrap with tomato, spinach and spices and quinoa side salad</td>
<td>Tuna wrap with spinach, celery, walnuts and mayonnaise and quinoa side salad</td>
<td>Spinach salad with blueberries, onion, raisins, feta cheese, olive oil, vinegar, salt, pepper, garlic and bread bun</td>
</tr>
<tr>
<td><strong>JULY 3</strong></td>
<td>Turkey with lettuce, tomato, mustard and honey sandwich with veggie side salad</td>
<td>Smoked salmon sandwich on poppy seed bread with cream cheese and dill and veggie side salad</td>
<td>Spanish omelette with simple side salad</td>
</tr>
<tr>
<td><strong>JULY 4</strong></td>
<td>Beef pastrami sandwich on tomato bread with arugula, fried onion and mayonnaise with cesar side salad</td>
<td>Goat cheese wrap with gourmet lettuces, roasted peppers, honey and nuts with cesar side salad</td>
<td>Ham and cheese meal size salad</td>
</tr>
</tbody>
</table>

### Parking
IFEMA offers onsite parking opportunities at a daily maximum rate of 15 Euros, at the charge of the user.

### Press
There is no media room available during the Congress. Representatives from the press can register for a media pass at the Registration Desk. Official media credentials must be presented.

### Professional Photo Booth at TTS Booth
Come to the TTS Booth and get your portrait photo taken professionally. This is a great opportunity to update your profile photo on your social media.

### Public Notice – Smoking
IFEMA is a smoke-free environment. Smoking is forbidden in all areas.

### Public Transportation
TTS 2018 registration fees include the Madrid transportation pass. IFEMA is located on the pink line and the stop is called “Campo de las naciones”. 
Registration
For security and regulation purposes, all attendees are required to wear their name badge at all times during the Congress in order to participate in the Scientific Sessions, Networking Events and to access the Exhibit Area. Badge swapping is strictly prohibited.

Badge Colour Identification:

<table>
<thead>
<tr>
<th>Role</th>
<th>Colour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegate Member &amp; Delegate</td>
<td>Blue</td>
</tr>
<tr>
<td>Post-Graduate Course Delegate, Speaker &amp; Chair</td>
<td>Pink</td>
</tr>
<tr>
<td>Pre-Congress Workshop Delegate, Speaker &amp; Chair</td>
<td>Purple</td>
</tr>
<tr>
<td>Student/Fellow/Trainee</td>
<td>Yellow</td>
</tr>
<tr>
<td>Organizing Committee</td>
<td>Light Blue</td>
</tr>
<tr>
<td>TTS Leadership</td>
<td>Black</td>
</tr>
<tr>
<td>Congress Invited Speaker &amp; Chair</td>
<td>Red</td>
</tr>
<tr>
<td>Staff &amp; Volunteer</td>
<td>Orange</td>
</tr>
<tr>
<td>Sponsor</td>
<td>Grey</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Green</td>
</tr>
<tr>
<td>Media</td>
<td>Brown</td>
</tr>
</tbody>
</table>

Lost Badges
In the event of a lost or forgotten badge, an administrative fee of $25 USD will be charged for the reprinting of the badge after verification of identification (passport, driving license, or other recognized identification paper).

Web Recordings
Sponsored by Roche
All registered attendees will have the chance to view the Congress Session recordings online through the TTS 2018 website and on the Congress web app for up to a year after the Congress. Only presentations for which TTS received pre-authorization from the presenter will be available online for viewing.

Wellness Area
Sponsored by the World Transplant Games Federation and Fit for Life.
A wellness area for yoga, stretching, meditation, mindfulness, and relaxation has been designated for registered participants. Find some time to join a yoga class or simply meditate or relax during some quiet time.

<table>
<thead>
<tr>
<th>TIME</th>
<th>MONDAY, JULY 2</th>
<th>TUESDAY, JULY 3</th>
<th>WEDNESDAY, JULY 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:15</td>
<td>Yoga</td>
<td>Yoga</td>
<td>Yoga</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Stretching</td>
<td>Stretching</td>
<td>Relaxation</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
<td>Stretching</td>
</tr>
<tr>
<td>13:15-13:30</td>
<td>Stretching</td>
<td>Stretching</td>
<td>Relaxation</td>
</tr>
<tr>
<td>13:30-13:45</td>
<td>Relaxation</td>
<td>Relaxation</td>
<td>Relaxation</td>
</tr>
<tr>
<td>13:45-14:00</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
</tr>
<tr>
<td>14:00-14:15</td>
<td>Meditation</td>
<td>Meditation</td>
<td>Meditation</td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>Stretching</td>
<td>Stretching</td>
<td>Stretching</td>
</tr>
<tr>
<td>14:30-14:45</td>
<td>Relaxation</td>
<td>Relaxation</td>
<td>Relaxation</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Stretching</td>
<td>Stretching</td>
<td>Relaxation</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Relaxation</td>
<td>Relaxation</td>
<td>Relaxation</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Stretching</td>
<td>Stretching</td>
<td>Stretching</td>
</tr>
<tr>
<td>15:45-16:00</td>
<td>Relaxation</td>
<td>Relaxation</td>
<td>Relaxation</td>
</tr>
<tr>
<td>16:00-16:15</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
<td>Mindfulness</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>Meditation</td>
<td>Meditation</td>
<td>Meditation</td>
</tr>
</tbody>
</table>

Services courtesy of Yoga Center S.L. Madrid
Young Members Corner and Activities

The Young Members Corner is a gathering and relaxation area for trainees. This is also where trainees can sign-up to the guided poster tours.

June 30  Post-Graduate Course
July  1  Post-Graduate Course
          Orientation Session at 17:30
July  2  Guided Poster Tours
July  3  Guided Poster Tours
          YMC Event: Azotea Del Círculo
          C/Marqués de Casa Riera nº 2.

Attendance at Lunch & Learn Sessions is highly recommended.

Congress Orientation Session
Sunday, July 1 - 17:30-17:50
Room N-104

Opening Ceremony
Sunday, July 1 - 18:00-19:00
Plenary Hall inside Hall 10
(included in registration fees)

Welcome Reception
Sunday, July 1 - 19:00-20:00
Exhibit Area - Hall 10
(included in registration fees)

Women in Transplantation (WIT) Networking Event
Tuesday, July 3 - 17:30-19:30
Colón Room, 2nd Floor, North Convention Center
(By pre-registration only)

Young Members Networking Event
Tuesday, July 3 - 20:00-23:00
Azotea Del Círculo, C/Marqués de Casa Riera nº 2
(Reservation fee applies)

Congress Networking Event
Wednesday, July 4 - starting at 20:00
Palacete de los Duques Pastranas
(Ticketed Event - By pre-registration only: Tickets will be available for purchase at the Registration Desk until Tuesday, July 3 at 10:00.)

Closing Ceremony
Thursday, July 5 - 12:30-13:30
Room N-103/N-104
Monday, July 2, 2018

Lunch Symposium sponsored by Astellas
13:30–14:30

Yesterday's Intervention, Tomorrow's Outcome: Improving the Transplant Journey

Chair: Stefan Schneeberger (Austria)
MONIQUE'S TRANSPLANT JOURNEY: HOW COULD WE HAVE MADE A DIFFERENCE?
KEY CLINICAL INTERVENTIONS TO ADDRESS:
NON-ADHERENCE
- Stefan Schneeberger (Austria)
VARIABILITY
- Teun van Gelder (The Netherlands)
UNDER-IMMUNOSUPPRESSION AND DSAS
- Daniel Serón (Spain)

Evening Symposium sponsored by Chiesi
16:30–17:30

Might Different Patients Need Different Approaches?
New Concepts on Tacrolimus Metabolism and Pharmacokinetics

Chair: Julio Pascual (Spain)
CLINICAL SENSITIVITY TO TACROLIMUS PHARMACOKINETICS
- Rainer Oberbauer (Austria)
TACROLIMUS FAST METABOLIZES: HOW TO IDENTIFY THEM BEYOND RACE AND GENOTYPE
- Klemens Budde (Germany)

Tuesday, July 3, 2018

Lunch Symposium sponsored by Bridge to Life
13:30–14:30

Kidney & Liver Hypothermic Machine Perfusion: The Role of Oxygen

Chair: Rutger Ploeg (United Kingdom)
THE ROLE OF OXYGEN IN HYPOTHERMIC MACHINE PERFUSION
- Philipp Dutkowski (Switzerland)
CLINICAL EXPERIENCE WITH HYPOTHERMIC OXYGENATED PERFUSION OF LIVERS AND KIDNEYS
- Matteo Ravaioli (Italy)

Evening Symposium sponsored by Qiagen
16:30–17:30

Improving Management of Transplanted Patients with Viral Load Assays and Specific Cell-Mediated Immune Response Monitoring

Chair: José María Aguado (Spain)
COMPARISON OF INTRACELLULAR CYTOKINE STAINING VS. QUANTIFERON-CMV FOR THE MONITORING OF CELL-SPECIFIC IMMUNITY AGAINST CMV IN KIDNEY TRANSPLANT RECIPIENTS
- José María Aguado (Spain)
A RANDOMIZED TRIAL OF QFN-CMV DIRECTED ANTIVIRAL PROPHYLAXIS VS. STANDARD-OF-CARE TO REDUCE LATE CMV REACTIVATION FOLLOWING LUNG TRANSPLANTATION
- Glen Westall (Australia)
Wednesday, July 4, 2018

**Lunch Symposium sponsored by One Lambda**

**13:30–14:30**

*The Molecular Microscope® Diagnostic System: Insights into Disease Mechanisms Shared By All Organ Transplants*

Chair: Philip F. Halloran (Canada)

**MOLECULAR MICROSCOPE® ANALYSIS OF KIDNEY (MMDX-KIDNEY) AND LUNG (MMDX-LUNG) TRANSPLANT BIOPSIES**

- Philip F. Halloran (Canada)

**MOLECULAR DIAGNOSTICS IN SOLID ORGAN TRANSPLANT: THE 2017 BANFF PERSPECTIVE**

- Alexandre Loupy (France)

**THE MMDX-HEART SYSTEM: CLINICAL IMPLICATIONS AND POTENTIAL UTILITY**

- Luciano Potena (Italy)

Q&A

**Evening Symposium sponsored by Novartis**

**16:15–17:15**

*Transforming Transplantation: From Large Scale Clinical Trials to Daily Practice*

Chair: Julio Pascual (Spain)

**WELCOME AND INTRODUCTION**

- Julio Pascual (Spain)

**LATEST DATA FROM THE TRANSFORM STUDY – THE EFFECT OF EVEROLIMUS ON LONG-TERM OUTCOMES AFTER KIDNEY TRANSPLANTATION**

- Julio Pascual (Spain)

**PERSPECTIVE ON RENAL FUNCTION**

- Christophe Legendre (France)

**INSIGHTS ON THE INTRODUCTION OF A DE NOVO IMMUNOSUPPRESSIVE REGIMEN**

- Franco Citterio (Italy)

Q&A AND CLOSING REMARKS
**Exhibit Hours**

- **Sunday, July 1**
  - 17:30–19:00
  - Exhibit Hall open for delegates to access the Plenary for the Opening Ceremonies only.

- **Sunday, July 1**
  - 19:00–20:00
  - Welcome Reception

- **Monday, July 2**
  - 09:30–17:30

- **Tuesday, July 3**
  - 09:30–17:30

- **Wednesday, July 4**
  - 09:30–15:00

---

**Exhibitor**

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aferetica</td>
<td>40</td>
</tr>
<tr>
<td>Astellas Pharma Europe Ltd Medical Information</td>
<td>8</td>
</tr>
<tr>
<td>Astellas Pharma Europe Ltd</td>
<td>16</td>
</tr>
<tr>
<td>Baskent University</td>
<td>10</td>
</tr>
<tr>
<td>Bridge to Life</td>
<td>2</td>
</tr>
<tr>
<td>CAST 2019 (Asian Society of Transplantation)</td>
<td>32</td>
</tr>
<tr>
<td>China Organ Harvest Research Center</td>
<td>64</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>51</td>
</tr>
<tr>
<td>CytoSorbents Europe GmbH</td>
<td>39</td>
</tr>
<tr>
<td>Dr. Franz Köhler Chemie GmbH</td>
<td>42</td>
</tr>
<tr>
<td>European Society for Organ Transplantation</td>
<td>78</td>
</tr>
<tr>
<td>Glycorex Transplantation AB</td>
<td>7</td>
</tr>
<tr>
<td>Hansa Medical AB</td>
<td>30</td>
</tr>
<tr>
<td>Institut George Lopez</td>
<td>28</td>
</tr>
<tr>
<td>International Transplant Nurses Society</td>
<td>33</td>
</tr>
<tr>
<td>KOTRY / KODA / KONOS / Vitallink</td>
<td>70</td>
</tr>
<tr>
<td>Neovii Pharmaceuticals AG</td>
<td>24</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>54</td>
</tr>
<tr>
<td>Numares</td>
<td>27</td>
</tr>
<tr>
<td>One Lambda, Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Organ Assist</td>
<td>41</td>
</tr>
<tr>
<td>Organ Recovery Systems</td>
<td>6</td>
</tr>
<tr>
<td>OrganOx Ltd</td>
<td>38</td>
</tr>
<tr>
<td>Oxford Immunotec</td>
<td>53</td>
</tr>
<tr>
<td>Oxiplenish</td>
<td>9</td>
</tr>
<tr>
<td>Peter Morris Centre for Evidence in Transplantation</td>
<td>71</td>
</tr>
<tr>
<td>QIAGEN GmbH</td>
<td>4</td>
</tr>
<tr>
<td>QUOD, University of Oxford</td>
<td>72</td>
</tr>
<tr>
<td>Scanlan International Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Sociedad Argentina de Trasplantes</td>
<td>73</td>
</tr>
<tr>
<td>Sociedad de Transplantes de America Latina y del Caribe</td>
<td>31</td>
</tr>
<tr>
<td>TPM-DTI Foundation</td>
<td>69</td>
</tr>
<tr>
<td>Transplant Connect</td>
<td>50</td>
</tr>
<tr>
<td>Turkish Transplant Foundation</td>
<td>66</td>
</tr>
<tr>
<td>Wisepress Book Shop</td>
<td>74</td>
</tr>
</tbody>
</table>
DETAILED PROGRAM

Saturday, June 30, 2018
### SATURDAY, JUNE 30, 2018

#### POST-GRADUATE COURSES

**08:30-10:45  100 - Joint Session 1: Academic Survival Kit**  
**Chairs:** Medhat Askar, United States and Megan Levings, Canada

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>100.1</td>
<td>Roadmap to the PGC</td>
<td>Medhat Askar, United States and Megan Levings, Canada</td>
</tr>
<tr>
<td>100.2</td>
<td>Transplant Educator</td>
<td>Medhat Askar, United States</td>
</tr>
<tr>
<td>100.3</td>
<td>Preparing an abstract and a manuscript</td>
<td>Jeremy R. Chapman, Australia</td>
</tr>
<tr>
<td>100.4</td>
<td>How to write a grant</td>
<td>Roslyn B. Mannon, United States</td>
</tr>
<tr>
<td>100.5</td>
<td>How to prepare and present slides</td>
<td>Marcelo Cantarovich, Canada</td>
</tr>
</tbody>
</table>

**10:45-11:15**  
**Coffee Break**  
Foyer Area (NCC)

**11:15-13:15  101 - Basic Science: Innate Immune Response & Microbiome**  
**Chairs:** Bernard Vanhove, France and Sarah Cromé, Canada

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>101.1</td>
<td>Inflammatory triggers and receptors - DAMPs and PAMPs</td>
<td>Maria Koulmanda, United States</td>
</tr>
<tr>
<td>101.2</td>
<td>Inflammasome-mediated inflammation</td>
<td>Carmen Peralta, Spain</td>
</tr>
<tr>
<td>101.3</td>
<td>Alarmins and their receptors in control of the allo-immune response</td>
<td>Avery J. Lam, Canada</td>
</tr>
<tr>
<td>101.4</td>
<td>Microbiome analysis</td>
<td>Jonathan S. Bromberg, United States</td>
</tr>
</tbody>
</table>

**11:15-13:15  102 - Clinical Science: The Transplant Fitting Room**  
**Chairs:** Dominique E. Martin, Australia and Peter W. Nickerson, Canada

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>102.1</td>
<td>Pre-transplant work-up</td>
<td>Shaifali Sandal, Canada</td>
</tr>
<tr>
<td>102.2</td>
<td>Histocompatibility testing (pre &amp; post)</td>
<td>Peter W. Nickerson, Canada</td>
</tr>
<tr>
<td>102.3</td>
<td>Management of the highly sensitized patient</td>
<td>Robert A. Montgomery, United States</td>
</tr>
<tr>
<td>102.4</td>
<td>Ethical dilemmas in SOT</td>
<td>Dominique E. Martin, Australia</td>
</tr>
</tbody>
</table>

**13:15-14:15**  
**Lunch Break**  
Foyer Area (NCC)

**14:15-16:15  103 - Basic Science: T Cells**  
**Chairs:** Birgit Sawitzki, Germany and Carla C. Boan, Netherlands

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>103.1</td>
<td>Allorecognition by the adaptive immune system: Direct, indirect, and semidirect</td>
<td>Gavin Pettigrew, United Kingdom</td>
</tr>
<tr>
<td>103.2</td>
<td>CD4 effector T cells: Activation, costimulation, Th repertoire (including TFH cells), and (Finally) exhaustion!</td>
<td>Bernard Vanhove, France</td>
</tr>
<tr>
<td>103.3</td>
<td>Tissue-resident immune cells</td>
<td>Sarah Cromé, Canada</td>
</tr>
<tr>
<td>103.4</td>
<td>Utilizing TCR &amp; BCR-Seq to study antigen-specific immune responses</td>
<td>Megan Sykes, United States</td>
</tr>
</tbody>
</table>
### 14:15-16:15  104 - Clinical Science: Dealing with the Aftermath  N-104

**Chairs:** Germaine Wong, Australia and Jay Fishman, United States

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>104.1</td>
<td>Donor derived infections</td>
<td>Jay Fishman, United States</td>
</tr>
<tr>
<td>104.2</td>
<td>Transplant infectious diseases</td>
<td>Camille Kotton, United States</td>
</tr>
<tr>
<td>104.3</td>
<td>Transplant malignancies</td>
<td>Germaine Wong, Australia</td>
</tr>
<tr>
<td>104.4</td>
<td>Cardiovascular and metabolic complications</td>
<td>Gregory Alan Knoll, Canada</td>
</tr>
</tbody>
</table>

### 16:15-16:45  Coffee Break  Foyer Area (NCC)

### 16:45-18:45  105 - Basic Science: B Cells and Innate Immune System  N-103

**Chairs:** Megan Sykes, United States and Gavin Pettigrew, United Kingdom

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>105.1</td>
<td>Update on B cell activation, memory and antibody secreting cells</td>
<td>Olivier Thaunat, France</td>
</tr>
<tr>
<td>105.2</td>
<td>Targeting B cells and Ab-producing cells</td>
<td>Gavin Pettigrew, United Kingdom</td>
</tr>
<tr>
<td>105.3</td>
<td>Adaptive function of NK cells &amp; macrophages</td>
<td>Jordi Ochando, Spain</td>
</tr>
<tr>
<td>105.4</td>
<td>Innate lymphoid cells</td>
<td>Estela Paz-Artal, Spain</td>
</tr>
</tbody>
</table>

### 16:45-18:45  106 - Clinical Science: Precision Thinking  N-104

**Chairs:** Valeria Mas, United States and Teun Van Gelder, Netherlands

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>106.1</td>
<td>Systems biology</td>
<td>Valeria Mas, United States</td>
</tr>
<tr>
<td>106.2</td>
<td>Biomarkers of graft function &amp; failure</td>
<td>Minnie M. Sarwal, United States</td>
</tr>
<tr>
<td>106.3</td>
<td>Immunosuppression</td>
<td>Christophe Legendre, France</td>
</tr>
<tr>
<td>106.4</td>
<td>Pharmacogenomics &amp; precision medicine</td>
<td>Teun Van Gelder, Netherlands</td>
</tr>
</tbody>
</table>
## WTGF: Optimizing Recovery after Solid Organ Transplant – The Role of Physical Activity, Exercise and Sport (#WTGF search on WebApp)

### 08:30-10:30  120 - Evidence for Exercise and Physical Activity in Solid Organ Transplant

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Introductions and Opening Remarks</td>
<td>Marcelo Cantarovich</td>
<td>Canada, Chris Thomas, Australia</td>
</tr>
<tr>
<td>08:30</td>
<td>Physical impairments in solid organ transplant candidates and recipients – what is the impact on transplant outcomes?</td>
<td>Sunita Mathur</td>
<td>Canada</td>
</tr>
<tr>
<td>08:30</td>
<td>Evidence for pre-habilitation and rehabilitation in solid organ transplantation</td>
<td>Tania Janaudis-Ferreira</td>
<td>Canada</td>
</tr>
<tr>
<td>08:30</td>
<td>Models of integrating regular physical activity into post-transplant care</td>
<td>Ka Foon Chau</td>
<td>Hong Kong</td>
</tr>
</tbody>
</table>

### 10:30-11:00  Coffee Break

### 11:00-12:30  121 - World Transplant Games Federation – Fit for Life!

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Launch of the fit for life toolkit: A tool for engaging transplant recipients in a physically active lifestyle</td>
<td>Chris Thomas</td>
<td>Australia</td>
</tr>
<tr>
<td>11:00</td>
<td>The role of technology in encouraging the transplant community to take the first steps to a life of movement</td>
<td>Liz Schick</td>
<td>Switzerland</td>
</tr>
</tbody>
</table>

### 12:30-13:30  Lunch Break

### 13:30-15:00  122 - Transplant Recipients Leading their Peers in Physical Activity

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>How Fit for Life and Billion Steps Challenge brings together the Canadian transplant community</td>
<td>Claude JA Laflamme</td>
<td>Canada</td>
</tr>
<tr>
<td>13:30</td>
<td>Taking exercise to the extreme – what are the limitations for transplant recipients</td>
<td>Gerardo Reyna</td>
<td>Spain</td>
</tr>
<tr>
<td>13:30</td>
<td>Patient partnerships in research and knowledge translation: Experience from the CAN-RESTORE network</td>
<td>Sunita Mathur, Tania Janaudis-Ferreira</td>
<td>Canada</td>
</tr>
</tbody>
</table>

### 15:00-15:30  Coffee Break

### 15:30-17:30  123 - High-Performance Athletes and Sports Participation Post-Transplantation

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Sports participation in transplant athletes</td>
<td>Sheila Leddington-Wright</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>15:30</td>
<td>10 years of Transplantoux in Belgium – an integrated approach</td>
<td>Diethard Monbaliu</td>
<td>Belgium</td>
</tr>
<tr>
<td>15:30</td>
<td>Volvo Ocean Race 2017: Transplant athlete preparation and participation (ending with the BBC video)</td>
<td>Paul N. Harden, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Program wrap-up</td>
<td>Marcelo Cantarovich, Chris Thomas</td>
<td>Canada, Australia</td>
</tr>
</tbody>
</table>
Women in Transplantation
Advancing Women in Transplantation through Leadership and Advocacy of Issues Related to Sex and Gender
(#WIT search on WebApp)

08:30-10:00  130 - Increasing Leadership of Women in Transplantation: Challenges and Solutions  N-111
Chairs: Megan Sykes, United States and Christine S. Falk, Germany
130.1 Tools for leadership success
Lori J. West, Canada
130.2 Creating a culture of support not competition
Lisa A. Robinson, Canada
Panel discussion

10:00-10:30  Coffee Break  Foyer Area (NCC)

10:30-12:00  131 - Why is Advocacy Needed? Gender Disparities in Transplantation  N-111
Chair: Curie Ahn, Korea
131.1 Gender disparities in access to transplantation
Anette Melk, Germany
131.2 A Bioethics perspective on gender disparities in transplantation
Germaine Wong, Australia
Panel discussion

12:00-13:00  Lunch Break  Foyer Area (NCC)

13:00-15:00  132 - Research on Issues of Sex and Gender in Transplantation  N-111
Chairs: Roslyn B. Mannion, United States and Bethany Foster, Canada
132.1 Sex, drugs and pharmacology
TBA
132.2 Immunological consequences of pregnancy and impact of subsequent transplantation
Anita Chong, United States
132.3 Impact of the H-Y antigen on solid organ transplant outcomes
Stefan G. Tullius, United States
Panel discussion

15:00-15:30  Coffee Break  Foyer Area (NCC)

15:30-17:30  133 - Creating a Culture of Success & Steps to Improve Equity  N-111
Chairs: Lori J. West, Canada and Elaine F. Reed, United States
133.1 How is the new generation tacking gender equity in transplantation?
Maria Irene Bellini, United Kingdom
133.2 Improving gender equity in transplantation: what can professional societies do?
Vassilios Papalois, United Kingdom
133.3 Gender disparities in academia—how does transplantation compare with other fields?
Deborah Adey, United States
Panel discussion
TTS Transplantation Science Committee
Virtual Global Transplantation Laboratory (vGTL)
Overcoming Pitfalls in Immune Monitoring in Clinical Transplantation Trials: perspectives from the experts (#vGTL search on WebApp)

**08:30-10:00  140 - Immune Monitoring in the Real World**  
**Chairs: Fadi Issa, United Kingdom and Shane T. Grey, Australia**

140.1 Introduction & experience in the ONE Study  
**Edward K. Geissler**, Germany

140.2 Pitfalls and lessons from the ONE Study and beyond  
**Birgit Sawitzki**, Germany

140.3 Designing novel mechanistic studies in clinical trials  
**Carla C. Baan**, Netherlands

Questions and Answers  
**Shane T. Grey**, Australia

**10:00-10:30 Coffee Break**  
**Foyer Area (NCC)**

**10:30-12:30  141 - Standardization and Success**  
**Chairs: Shane T. Grey, Australia and Fadi Issa, United Kingdom**

141.1 Biobanking in transplantation  
**Maria Kaisar**, United Kingdom

141.2 Measuring donor-reactive T cells for clinical trials and metrics to measure success  
**Qizhi Tang**, United States

141.3 How reliable is your assay? Approaches to standardize and harmonize immune monitoring in clinical trials  
**Megan Levings**, Canada

141.4 Challenges in setting up and running a Treg trial  
**Fadi Issa**, United Kingdom

Questions and Answers  
**Shane T. Grey**, Australia
Cell Transplants vs Stem Cell Therapy  
Organized by the Cell Transplant and Regenerative Medicine Society (CTRMS)  
(#CTRMS search on WebApp)

13:30-15:00  150 - Session 1: Cellular and Regenerative Therapies  

Chair: Ewa Ellis, Sweden

150.1  Innate vs. adaptive immunity in cell transplant tolerance  
Maria Koulmanda, United States

150.2  Pros and cons of using human stem cell derived b-cells for the treatment of diabetes  
Klearchos K. Papas, United States

150.3  Hepatocytes and mesenchymal stem cells as therapeutic options for the treatment of liver diseases, lessons from animal models  
Peggy Stock, Germany

15:00-15:30  Coffee Break  

15:30-17:00  151 - Session 2: Cellular and Regenerative Therapies  

Chair: Maria Koulmanda, United States

151.1  From translational research to clinical application: where the rubber hits the road  
Giuseppe Pettinato, United States

151.2  Neonatal donors for hepatocyte transplantation  
Ewa Ellis, Sweden

151.3  Therapeutic potential of placenta-derived stem cells for liver diseases  
Toshio Miki, United States
DETAILED PROGRAM

Sunday, July 1, 2018
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairs</th>
<th>Presenters/Details</th>
</tr>
</thead>
</table>
| 09:00-10:30  | 200 - Basic Science: Immune Regulation & Flow Standardisation | N-103    | Chairs: QiZhi Tang, United States and Fadi Issa, United Kingdom         | 200.1 Regulatory T and B cells<br>Megan Levings, Canada  
200.2 Tolerogenic function of innate immune cells<br>Xian C. Li, United States  
200.3 Strategies to standardize and objectify assays e.g. flow cytometry automated gating<br>Birgit Sawitzki, Germany |
| 09:00-10:30  | 201 - Clinical Science: Becoming Precise     | N-104    | Chairs: Philip F. Halloran, Canada and Michael Mengel, Canada           | 201.1 Transplant pathology<br>Michael Mengel, Canada  
201.2 Liquid biopsy<br>Sean Agbor-Enoh, United States  
201.3 Molecular microscope<br>Philip F. Halloran, Canada |
| 10:30-11:00  | Coffee Break                                 |          |                                                                        | Foyer Area (NCC)                                                                   |
| 11:00-12:30  | 202 - Basic Science: The Future of Organ Transplant Replacement | N-103    | Chairs: Minnie M. Sarwal, United States and Hiroto Egawa, Japan         | 202.1 Genomics & epigenomics in transplantation<br>Daniel G. Maluf, United States  
202.2 Cellular therapy for liver disease and liver regeneration<br>Anil Dhawan, United Kingdom  
202.3 Gene-specific nucleases (CrispCas, TALEN...)<br>Marc Guell, United States |
| 11:00-12:30  | 203 - Clinical Science: Clinical Crowdsourcing | N-104    | Chairs: Marcelo Cantarovich, Canada and Medhat Askar, United States    | 203.1 TCR NGS based evidence for differential diagnosis and personalized therapy in BKV nephropathy<br>Ulrik Stervbo, Germany  
203.2 Day to day decision in multi-visceral transplantation immunosuppression<br>Marina Pérez-Flecha González, Spain  
203.3 The great pretender: when what you see, is not what you get. An unusual presentation of lung cancer on a post kidney transplant patient<br>Bryan Christian Gaza Ilagan, Philippines |
| 12:30-13:30  | Lunch Break                                  |          |                                                                        | Foyer Area (NCC)                                                                   |
| 13:30-15:30  | 204 - Joint Session 2: Future Look at Organ Shortage | N-104    | Chairs: Edward K. Geissler, Germany and David K.C. Cooper, United States | 204.1 Tolerance<br>Giorgio Raimondi, United States  
204.2 Xenotransplantation<br>Alfred J. Tector III, United States  
204.3 Bioengineering and regeneration of solid organs: Current status and future directions<br>Giuseppe Orlando, United States  
204.4 Advanced biomarkers of graft function & failure<br>Nina Babel, Germany |
| 15:30-16:00  | Coffee Break                                 |          |                                                                        | Foyer Area (NCC)                                                                   |
205 - Joint Session 3: Transplant Mathaton

Chairs: Marcelo Cantarovich, Canada and Birgit Sawitzki, Germany

205.1 How to understand and use and statistics
Joseph Kim, Canada

205.2 Big data in transplantation
Dorry Segev, United States

205.3 Take home message (Clinical Path)
Marcelo Cantarovich, Canada

205.4 Take home message (Basic Science Path)
Birgit Sawitzki, Germany
## Optimizing Outcomes by Prevention and Management of Post-Transplant Infections
Organized by the Transplant Infectious Disease (TID) Section
(#TID search on WebApp)

### 08:30-08:40  220 - Welcome Message  N-105

**220.1 Welcome Address**

*Nassim Kamar*, France

### 08:40-10:10  221 - Donor-Derived Infections and Organ Vigilance Around the World  N-105

**Chair:** *Michael G. Ison, United States*

221.1 Donor-derived infection cases (2 cases)

*Nicole M. Theodoropoulos*, United States

221.2 Organ vigilance: background and US perspective

*Cameron Wolfe*, United States

221.3 Organ vigilance: EU perspective

*Sophie Lucas-Samuel*, France

221.4 Organ vigilance: Australian perspective

*Helen I. Opdam*, Australia

221.5 Organ vigilance: global/WHO perspective

*Jose Ramon Nunez*, Switzerland

### 10:15-11:00  222 - Transplant ID – Lessons Learned from Current Literature  N-105

**Chair:** *Clarisse Machado, Brazil*

222.1 Top 10 papers in transplant infectious diseases

*Camille Kotton*, United States

222.2 Case 1

*Michele I. Morris*, United States

### 11:00-11:30  Coffee Break  Foyer Area (NCC)

### 11:30-13:00  223 - Controversies in Transplant Infectious Diseases: The Expert Showdown  N-105

**Facilitator:** *Hans H. Hirsch, Switzerland*

223.1 Use of HCV positive donors - Pro

*Jose Maria Morales*, Spain

223.2 Use of hepatitis C positive donors - Con

*Jay Fishman*, United States

Debate Discussion

223.3 Use of donors with multi-drug resistant organisms - Pro

*Stephanie Pouch*, United States

223.4 Use of donors with multi-drug resistant organisms - No

*Paolo A. Grossi*, Italy

Debate Discussion

223.5 HIV transplantation

*Elmi Muller*, South Africa

### 13:00-14:00  Lunch Break  Foyer Area (NCC)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 14:00-16:00             | 224 - Addressing the Threat of Infections Post-Transplant | 14:00-16:00 | Silvia Vidal Campos, Brazil | 224.1 Prevention and treatment of CMV Francisco M. Marty, United States  
                          |                                                     |              |                           | 224.2 BK virus nephropathy Brian J. Nankivell, Australia  
                          |                                                     |              |                           | 224.3 New options in the management of multi-drug resistant bacteria Jean Ralph Zahar, France  
                          |                                                     |              |                           | 224.4 Parasitic infections: Prevention, diagnosis and management Alice Song, Brazil  
                          |                                                     |              |                           | 224.5 Diarrhea in transplantation Diana Florescu, United States  |
| 16:00-16:30             | Coffee Break                                        | 16:00-16:30 | Foyer Area (NCC)          |                                                            |
| 16:30-17:30             | 225 - Cows and Zebras: Challenging Cases in Transplantation | 16:30-17:30 | Ban Hock Tan, Singapore   | 225.1 Case 2 Edward A. Dominguez, United States  
                          |                                                     |              |                           | 225.2 Case 3: Liver transplantation for fulminant hepatitis due to yellow fever Alice Song, Brazil  
                          |                                                     |              |                           | 225.3 Case 4 Stephanie Pouch, United States  |
PRE-CONGRESS WORKSHOPS

SUNDAY, JULY 1, 2018

Declaration of Istanbul 10th Anniversary Symposium
Organized by the Declaration of Istanbul Custodian Group (DICG)
(#DOI search on WebApp)

09:00-09:10 230 - Welcome and Overview of Organ Trafficking
Welcome and overview of organ trafficking
Dominique E. Martin, Australia and Elmi Muller, South Africa

09:10-10:30 231 - Evaluating Prospective Living Donors and Transplant Recipients
Chairs: Jacob Lavee, Israel and Curie Ahn, Korea
Case presentations: Learnings from suspected cases of attempted organ trafficking involving resident patients

09:10-10:30 231.1 SOUTH AFRICA
Elmi Muller, South Africa

09:10-10:30 231.2 INDIA
Sanjay S. Nagral, India

09:10-10:30 231.3 NEW ZEALAND
Ian D. Dittmer, New Zealand

09:10-10:30 231.4 MEXICO
Rafael Reyes-Acevedo, Mexico
Panel Discussions
Case presentations: Learnings from suspected cases of attempted organ trafficking involving non-resident patients

09:10-10:30 231.5 SPAIN
Beatriz Dominguez-Gil, Spain

09:10-10:30 231.6 PHILIPPINES
Benita Padilla, Philippines

09:10-10:30 231.7 COSTA RICA
Amalia Matamoros, Costa Rica
Panel Discussions

10:30-11:00 232 - Suggested Strategies for Preventing and Managing Organ Trafficking in the Clinical Setting
Chairs: Jacob Lavee, Israel and Curie Ahn, Korea

10:30-11:00 232.1 Psychosocial evaluation-getting the essential elements right and tailoring to the local environment
Dominique E. Martin, Australia

10:30-11:00 232.2 Communicating concerns with other transplant programs while respecting patients' rights to privacy and confidentiality
Mona Alrukhaimi, United Arab Emirates

11:00-11:30 Coffee Break Foyer Area (NCC)

11:30-13:00 233 - Managing Patients Who Returns After Transplantation Aboard that May Have Involved Organ Trafficking
Chairs: Adeera Levin, Canada and Faissal Shaheen, Saudi Arabia

11:30-13:00 233.1 Potential indicators of organ trafficking
Jacob Lavee, Israel

11:30-13:00 233.2 Clinical issues in management-medical
Gabriel Danovitch, United States

11:30-13:00 233.3 Clinical issues in management-surgical
Riadh A.S. Fadhil Al Noaman, Qatar

11:30-13:00 233.4 Ethical issues in management
Alexander M. Capron, United States

11:30-13:00 233.5 Building systems to support management
Marta López-Fraga, France
General Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-16:00</td>
<td><strong>234 - Welcome and Introduction to the Declaration of Istanbul Custodian Group</strong></td>
<td>N-106</td>
<td><strong>Chairs:</strong> Dominique E. Martin, Australia and Elmi Muller, South Africa</td>
</tr>
<tr>
<td>234.1</td>
<td>Welcome from DICG co-chairs</td>
<td></td>
<td>Elmi Muller, South Africa and Dominique E. Martin, Australia</td>
</tr>
<tr>
<td>234.2</td>
<td>A brief history of the declaration and its development</td>
<td></td>
<td>Jeremy R. Chapman, Australia</td>
</tr>
<tr>
<td>234.3</td>
<td>The Declaration of Istanbul and DICG in action- achievements and impact</td>
<td></td>
<td>Beatriz Dominguez-Gil, Spain</td>
</tr>
<tr>
<td>234.4</td>
<td>Updating the declaration- a review of the public consultation</td>
<td></td>
<td>Dominique E. Martin, Australia</td>
</tr>
<tr>
<td>234.5</td>
<td>Introducing the 2018 edition of the Declaration of Istanbul</td>
<td></td>
<td>Alexander M. Capron, United States</td>
</tr>
<tr>
<td>234.6</td>
<td>Implications of the update internationally - TTS (The Transplantation Society)</td>
<td></td>
<td>Nancy Ascher, United States</td>
</tr>
<tr>
<td>234.7</td>
<td>Implications of the update internationally - ISN (International Society of Nephrology)</td>
<td></td>
<td>David Harris, Australia</td>
</tr>
<tr>
<td>234.8</td>
<td>Implications of the update internationally - WHO (World Health Organization)</td>
<td></td>
<td>Jose Ramon Nunez, Switzerland</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Coffee Break</td>
<td>Foyer Area (NCC)</td>
<td></td>
</tr>
<tr>
<td>16:30-17:30</td>
<td><strong>235 - Implications of the Update at the Regional Level</strong></td>
<td>N-106</td>
<td><strong>Chairs:</strong> Dominique E. Martin, Australia and Elmi Muller, South Africa</td>
</tr>
<tr>
<td>235.1</td>
<td>Oceania</td>
<td></td>
<td>Philip J. O’Connell, Australia</td>
</tr>
<tr>
<td>235.2</td>
<td>Africa</td>
<td></td>
<td>Elmi Muller, South Africa</td>
</tr>
<tr>
<td>235.3</td>
<td>Asia</td>
<td></td>
<td>Benita Padilla, Philippines</td>
</tr>
<tr>
<td>235.4</td>
<td>Europe</td>
<td></td>
<td>Axel Rahmel, Germany</td>
</tr>
<tr>
<td>235.5</td>
<td>Latin America</td>
<td></td>
<td>Rudolf Garcia-Gallont, Guatemala</td>
</tr>
<tr>
<td>235.6</td>
<td>Middle-East</td>
<td></td>
<td>Mona Alrukhaimi, United Arab Emirates</td>
</tr>
<tr>
<td>235.7</td>
<td>North America</td>
<td></td>
<td>Gabriel Danovitch, United States</td>
</tr>
<tr>
<td>235.8</td>
<td>Wrap-up by DICG Co-Chairs</td>
<td></td>
<td>Elmi Muller, South Africa and Dominique E. Martin, Australia</td>
</tr>
</tbody>
</table>
### Advancing to the Clinic
Organized by the International Xenotransplantation Association
(#XENO search on WebApp)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Venue</th>
<th>Chair(s)</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-11:00</td>
<td>240 - Xeno-Part 1</td>
<td>N-111</td>
<td>Chairs: Léo Hans Bühler, Switzerland and Manuel A. Pascual, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>240.1 Survival of pig organs in nonhuman primates: an update</td>
<td>David K.C. Cooper, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>240.2 Pathology of acute and subacute/chronic xenograft rejection</td>
<td>Akira Shimizu, Japan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>240.3 Treatment of acute humoral rejection: Lessons learned from allotransplantation</td>
<td>Manuel A. Pascual, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>240.4 Is PERV a real risk, and should it be eliminated?</td>
<td>Linda Scobie, United Kingdom</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break</td>
<td>Foyer Area (NCC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-13:00</td>
<td>241 - Xeno-Part II</td>
<td>N-111</td>
<td>Chairs: David K.C. Cooper, United States and Chung-Gyu Park, Korea</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>241.1 Production of genetically-engineered pigs using new tools</td>
<td>Eckhard Wolf, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>241.2 Xenotransplantation of hepatocytes, an alternative to liver transplantation for acute liver failure?</td>
<td>Léo Hans Bühler, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>241.3 China and xenotransplantation: an update</td>
<td>Shaoping Deng, People's Republic of China</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch Break</td>
<td>Foyer Area (NCC)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Transplantation Nursing 101
Organized by TTS Education Committee and the International Transplant Nurses Society (#ITNS search on WebApp)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Code</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-11:00</td>
<td>250 - Solid Organ Transplant Immunology</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>250.1 Basic immunology core</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Caner Süsal, Germany</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>250.2 Clinical immunology core</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>251 - Intestinal Transplantation</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>251.1 Intestinal transplant core and patient care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Gabriel E. Gondolesi, Argentina</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>252 - Kidney and Pancreas</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252.1 Kidney/pancreas core</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Peter I. Abrams, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252.2 Specific issues in kidney/pancreas transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Peter G. Stock, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>Lunch Break</td>
<td></td>
<td>Foyer Area (NCC)</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>253 - Liver Transplantation</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>253.1 Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>AnneMarie Liapakis, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>253.2 Surgical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>254 - Comprehensive Care of the Transplant Patient</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>254.1 Psychological considerations, special population, role of transplant coordinators and social workers and multidisciplinary communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Joyce A. Trompeta, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>255 - Lung Transplantation</td>
<td>N-112</td>
<td>N-112</td>
</tr>
<tr>
<td></td>
<td>Chair: <em>Sukru H. Emre, United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>255.1 Specific issues in lung transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Christopher Wigfield, United States</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Key Issues in Paediatric Solid Organ Transplantation
Organized by the International Pediatric Transplant Association (IPTA)
 (#IPTA search on WebApp)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:10</td>
<td><strong>270 - Cutting Edge Developments in Paediatric Solid Organ Transplantation</strong></td>
<td>N-111</td>
</tr>
<tr>
<td></td>
<td>Chair: Mignon McCulloch, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>270.1 Review of key paediatric clinical transplant papers in the last 2 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Burkhard Tönshoff, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>270.2 Review of key basic science papers/developments in the last 2 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Alexander, Australia</td>
<td></td>
</tr>
<tr>
<td>15:15-16:00</td>
<td><strong>271 - Endocrine and Metabolic Challenges following Paediatric Solid Organ Transplantation</strong></td>
<td>N-111</td>
</tr>
<tr>
<td></td>
<td>Chair: Anne Dipchand, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>271.1 Obesity, metabolic syndrome, PTDM following transplant in childhood</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mignon McCulloch, South Africa</td>
<td></td>
</tr>
<tr>
<td>16:00-16:15</td>
<td><strong>Coffee Break</strong></td>
<td>Foyer Area (NCC)</td>
</tr>
<tr>
<td>16:15-17:30</td>
<td><strong>272 - Challenges to Long Term Survival following Paediatric Solid Organ Transplantation</strong></td>
<td>N-111</td>
</tr>
<tr>
<td></td>
<td>Chair: Mignon McCulloch, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>272.1 Adherence intervention trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anne Dipchand, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>272.2 Tumor risk following solid organ transplantation in childhood</td>
<td></td>
</tr>
<tr>
<td></td>
<td>George V. Mazariagos, United States</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Venue</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>TTS 2018 CONGRESS OPENING EVENTS</td>
<td></td>
</tr>
<tr>
<td>17:30-17:50</td>
<td>Congress Orientation Session</td>
<td>N-104</td>
</tr>
<tr>
<td>18:00-19:00</td>
<td>Opening Ceremony (doors open at 17:30)</td>
<td>Hall 10 – Plenary</td>
</tr>
<tr>
<td>19:00-20:00</td>
<td>Welcome Reception</td>
<td>Hall 10 – Exhibition</td>
</tr>
</tbody>
</table>

285.1 DICG
Elmi Muller, South Africa and Dominique E. Martín, Australia
MONDAY, JULY 2, 2018

SCIENTIFIC PROGRAM

08:30-09:30 Oral Abstract Session (Liver) N-101
300 - Recipient Management

Chairs: Kyung-Suk Suh, Korea and John J. Fung, United States

300.1 Revascularization time matters in liver transplantation: Prolonged implantation of marginal grafts independently predicts inferior transplant outcomes in the short and long term
Betina Buchholz, United Kingdom

300.2 Evaluation of enhanced recovery program in liver transplanted patients: Can we beat the benchmarks in liver transplantation?
Benny Wang, Sweden

300.3 Oncologic outcomes of ABO incompatible living donor liver transplantation for hepatocellular carcinoma
Jee Youn Lee, Korea

300.4 Delisting of liver transplant candidates with chronic HCV infection after viral eradication: Outcome 2 years after delisting. A European study
Carmen Vinaixa, Spain

300.5 Surgical categorization improve outcomes and organ utilization in liver transplantation
Humberto Bohorquez, United States

300.6 CMV-hyperimmunoglobulin improves early outcome in critically ill liver transplant patients by a combination of antiviral, anti-inflammatory and positive immunomodulatory capabilities
Arno Kornberg, Germany

08:30-09:30 Oral Abstract Session (Kidney) N-102
301 - Antibody Mediated Rejection 1

Chairs: Jongwon Ha, Korea and Julio Pascual, Spain

301.1 Defining response to standard of care treatment of kidney recipients with antibody-mediated rejection: Role of C1q-binding donor-specific anti-HLA antibodies
Yassine Bouatou, France

301.2 The role of donor-derived cell-free dna in the identification of injury in kidney allografts with antibody-mediated rejection or de novo dsa: A pilot study
Longshan Liu, People's Republic of China

301.3 C1q-binding donor-specific anti-HLA antibodies for clinical decision making in kidney recipients with antibody-mediated rejection receiving standard of care treatment
Carmen Lefaucheur, France

301.4 Is Banff 2013 classification of renal allograft pathology superior to 2007 Banff in detecting and managing cases of antibody-mediated rejection?
Daniel Burguete, United States

301.5 Significance of antibody-mediated vascular rejection (AMVR) on graft survival: Correlation with pure antibody-mediated rejection (AMR)
Nurhan Ozdemir, Turkey

301.6 Divergent role of programmed death –Lig and 1 (PD-L1) in renal allografts with antibody-mediated rejection (AMR)
B. Handan Ozdemir, Turkey

08:30-09:30 Oral Abstract Session (Kidney) N-105
302 - Recurrence and Cancer

Chairs: Ifeoma I. Ulasa, Nigeria and Oriol Bestard Matamoros, Spain

302.1 Apolipoprotein A-ib as biomarker of FSGS recurrence after kidney transplantation: Diagnostic performance in a prospective cohort and assessment of its prognostic value
Conxita Jacobs Cachá Jr., Spain

302.2 Rituximab does not prevent focal and segmental glomerulosclerosis recurrence after renal transplantation in patients at risk
Pilar Auñón, Spain

302.3 APRIL serum levels relate to recurrence of IgA nephropathy
Luis Martin-Penagos, Spain

302.4 MRP2 24 CT is associated with an increased risk of neoplasia and serious infection among renal transplant recipients
Beatriz Rodriguez-Cubillo, Spain

302.5 Cancer mortality in transplant recipients in Australia and New Zealand: A national cohort study from 1980 to 2013
Brenda M. Rosales, Australia

302.6 Analysis of the incidence and site of post-transplant cancer in patients with pre-transplant malignancies
Christian Unterrainer, Germany
08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences) N-106

303 - B Cell Biology

Chairs: Anita Chong, United States and Nancy Kwan Man, Hong Kong

303.1 Ex vivo expanded regulatory B cells promote allograft survival through IL-10-dependent pathway
Kang Mi Lee, United States

303.2 DD9+ regulatory b lymphocytes control chronic lung inflammation by inducing effector T cell apoptosis
Carole Brosseau, France

303.3 Characterization of a CD23+CD43+ regulatory B cell subset in human that induced by mesenchymal stem cells
Xiaoyong Chen, People's Republic of China

303.4 Acquired resistance to transplantation tolerance as a result of prior pregnancy requires B cells
Ashley N. Suah, United States

303.5 Lymphocytes B development after kidney transplantation
Maciej Zielinski, Poland

303.6 Phenotypic and clonal analysis of recipient B cells and plasma cells entering graft mucosa reveals an association with rejection and evolution towards a resident memory phenotype after human intestinal transplantation
Megan Sykes, United States

08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences) N-107/108

304 - Mononuclear Phagocytes

Chairs: Jordi Ochando, Spain and James A. Hutchinson, Germany

304.1 Mitochondrial damage-associated molecular patterns (MTDs) released from hepatic ischemia reperfusion induce inflammatory response
Qianni Hu, Canada

304.2 Generation of TIGIT+ Itregs by human regulatory macrophages before kidney transplantation
Paloma Riquelme, Germany

304.3 BTNl8 is expressed by human Mreg-induced FOXP3+ iTregs
Paloma Riquelme, Germany

304.4 Cord blood derived regulatory macrophages (Mreg) – an alternative source for Mreg-based cell therapy in transplantation
Xiaoqian Ma, People's Republic of China

304.5 DHRS9 is a stable marker of human regulatory macrophages
Florian Bitterer, Germany

08:30-09:30 Morning Symposium (Declaration of Istanbul) N-111

305 - New and Emerging Issues in Organ Trafficking and Travel for Transplantation

Chairs: Beatriz Dominguez-Gil, Spain and Rudolf Garcia-Gallont, Guatemala

305.1 Commercial transplants in the developing world
Elmi Muller, South Africa

305.2 Ethical concerns regarding global kidney exchanges
Alexander M. Capron, United States

305.3 When the poor donate but only the rich receive – barriers to equitable allocation of organs in developing countries
Sanjay S. Nagral, India

08:30-09:30 Morning Symposium (Sex and Gender in Transplantation) N-112

306 - Sex and Gender Research in Transplantation- Where Are We Now?

Chairs: Lori J. West, Canada and Bethany Foster, Canada

306.1 Where have we been and where are we going in sex and gender research in transplant? A scoping review
Ruth Sapir-Pichhadze, Canada

306.2 Donor sex related factors influencing transplant outcomes
Amanda J. Miller, Canada

306.3 Gender disparities in transplantation
Anette Melk, Germany
08:30-09:30 Morning Symposium (Transplantation Nursing)  
307 - Improving Patient Outcomes  

Chairs: Sandra A. Cupples, United States and Mara Ann McAdams DeMarco, United States

307.1 Fostering healthy lifestyles  
Christiane Kugler, Germany

307.2 Promoting transplant adherence  
Paolo De Simone, Italy

307.3 Improving psychosocial outcomes  
Anna Forsberg, Sweden

08:30-09:30 Morning Symposium (Education)  
308 - The Transplanter vs. The Educator - Ultimate Debate: Should Transplanters be Trained as Educators?

Chair: Marcelo Cantarovich, Canada

308.1 Introduction by Chair  
Marcelo Cantarovich, Canada

308.2 The Transplanter  
Jeremy R. Chapman, Australia

308.3 The Educator  
Medhat Askar, United States

Open debate discussion

08:30-09:30 Morning Symposium (Transplant Immunosuppression)  
309 - Current Immunosuppression: “Can This Old Dog Be Taught New Tricks?”

Chairs: Christine S. Falk, Germany and TBA

309.1 Re-targeting JAK/STAT signaling in solid organ transplantation?  
Helio S. Tedesco Jr, Brazil

309.2 Alemtuzumab and Infliximab join forces: Together we are strong  
Petra Reinke, Germany

309.3 Proteasome inhibition before and after transplantation  
E. Steve Woodle, United States

09:45-11:15 Oral Abstract Session (Liver)  
315 - Living Donor in Liver Transplantation

Chairs: John J. Fung, United States and Kyung-Suk Suh, Korea

315.1 Long-term outcomes after living liver donation: Analysis of national data base  
Suk Kyun Hong, Korea

315.2 Evaluation of the learning curve for pure laparoscopic donor right hepatectomy by analyzing 115 consecutive cases in an experienced adult living donor liver transplant center  
Suk Kyun Hong, Korea

315.3 Proposal for new selection criteria considering pre-transplant muscularity and visceral adiposity in living donor liver transplantation  
Yuhei Hamaguchi, Japan

315.4 Renal function outcomes with everolimus plus reduced-exposure tacrolimus in de novo living donor liver transplantation: 24-month results from the H2307 study  
Kyung-Suk Suh, Korea

315.5 Living donor liver transplantation for alcoholic liver disease: The North American experience  
Hillary J. Braun, United States

315.6 Aggressive graft volume reduction in pediatric living donor liver transplantation under one year old patients  
Takehisa Ueno, Japan

315.7 Retransplantation after living donor liver transplantation: Analysis of data from the A2All study  
Garrett R. Roll, United States

315.8 Liver regeneration rate analysis in living donor liver transplantation  
Lilia Martinez de la Maza, Spain

315.9 Excellent perioperative and long-term outcomes with lower graft-to-recipient weight ratio for living donor liver transplantation  
Tiffany CL Wong, Hong Kong
09:45-11:15 Oral Abstract Session (Kidney) N-102
316 - Acute Cellular Rejection and Polyoma

Chairs: Ifeoma I. Ulasi, Nigeria and Peter G. Stock, United States

316.1 DSA plus TCMR leads to poor outcomes in renal allograft recipients and this is markedly exacerbated by non-adherence
Dominik Chittka, United States

316.2 Inflammation in scarred areas (i-IF/TA): Defining the response to standard treatment of T cell-mediated rejection in kidney recipients
Alexandre Loupy, France

316.3 Application of RNA-seq derived diagnostic algorithms of T-cell mediated kidney rejection (TCMR) to publicly available DNA microarray-based gene expression datasets
Zijie Wang, People's Republic of China

316.4 Non-invasive diagnostic of renal allograft rejection via urine metabolites using NMR-spectroscopy
Miriam C. Banas, Germany

316.5 Genome-wide diagnostic of renal allograft rejection via urine metabolites using NMR-spectroscopy
William S. Oetting, United States

316.6 Non-invasive diagnostic of renal allograft rejection via urine metabolites using NMR-spectroscopy
Dominik Chittka, United States

316.7 Application of RNA-seq derived diagnostic algorithms of T-cell mediated kidney rejection (TCMR) to publicly available DNA microarray-based gene expression datasets
Alexandre Loupy, France

316.8 Application of RNA-seq derived diagnostic algorithms of T-cell mediated kidney rejection (TCMR) to publicly available DNA microarray-based gene expression datasets
Zijie Wang, People's Republic of China

316.9 Application of RNA-seq derived diagnostic algorithms of T-cell mediated kidney rejection (TCMR) to publicly available DNA microarray-based gene expression datasets
Miriam C. Banas, Germany

09:45-11:15 Oral Abstract Session (Kidney) N-103
317 - Deceased Donor Issues

Chairs: Alejandro Niño-Murcia, Colombia and Francisco Del Río, Spain

317.1 Extended case series investigating vascular remodeling following whole pancreas transplantation
John Moir, United Kingdom

317.2 Matching graft life expectancy with patient life expectancy
Lisa L. Mumford, United Kingdom

317.4 Early outcomes and risk factors for kidney transplantation with controlled circulatory death donor (cDCD) in a nationwide strategy. Spanish multicentre SENTRA-GEODAS-Group
Jose Portoles Sr., Spain

317.5 Dual kidney transplantation as a strategy to use elderly donors: A systematic review
Nuria Montero, Spain

317.6 Two decades of Eurotransplant senior program (ESP): Time on dialysis independently impacts patient survival, allograft survival and quality of life after kidney transplantation
Natalie Otto, Germany

317.7 Factors impacting delayed graft function from uncontrolled donors after circulatory death
Natividad N. Calvo Romero Sr., Spain

317.8 Kidney transplantation from uncontrolled donors after circulatory death: Data from an observational cohort
Natividad N. Calvo Romero Sr., Spain
09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)  
318 - Antibody Responses  

N-104

Chairs: Shane T. Grey, Australia and Frans H.J. Claas, Netherlands

318.1 Prospective multicenter validation of human transitional B cell cytokines as a predictive biomarker in renal transplantation
Aravind Cherukuri, United States

318.2 B cell immune repertoire sequencing identifies pre-transplant rejection risk
Silvia Pineda, United States

318.3 B-cell depletion with rituximab exacerbates anti-donor CD4+ T-Cell responses in patients with donor-specific anti-human leukocyte antigen antibodies
Kentaro Ide, Japan

318.4 IgM immunotherapy restores immune homeostasis and reverses hyperglycemia in new-onset type 1 diabetes
Kenneth Brayman, United States

318.5 Specific immunomodulation of alloantibody responses
Christian Schuetz, United States

318.6 Antibody response to non-self blood group a-antigen depends on CD4 T cells, forigen protein and CD22 interaction
Ibrahim Adam, Canada

318.7 De novo DSA in the setting of stable renal allograft function is a benign finding
Richard J. Knight, United States

318.8 HLA-DQ specific alloantibodies modify allogenic endothelial cell immunogenicity and impair the expansion of anti-inflammatory Foxp3 high regulatory T lymphocytes
Amy R. Cross, France

318.9 DSA with TCMR identifies high risk renal transplant recipients that can be predicted by proinflammatory transitional B cells
Dominik Chittka, United States

09:45-11:15 Oral Abstract Session (Donation & Procurement)  
319 - Living Donation-Kidney  

N-105

Chairs: Adibul Hasan Rizvi, Pakistan and Susan Gunderson, United States

319.1 Impact after live donor nephrectomy: A comparative follow-up study
Shiromani Janki, Netherlands

319.2 Factors related to suboptimal recovery of renal function after living donor nephrectomy
Yuji Hidaka, Japan

319.3 Obesity is associated with increased risk of mortality among living kidney donors
Brittany A. Shelton, United States

319.4 Prevalence and impact of chronic postsurgical pain following laparoscopic donor nephrectomy: A cross-sectional cohort study
Moira H. Bruintjes, Netherlands

319.5 Inclusion of incompatible directed deceased donor organs in kidney transplant exchanges
Ernesto P. Molmenti, United States

319.6 3D endoscopic donor nephrectomy versus robot-assisted donor nephrectomy: A detailed comparison of two prospective cohorts
Evalyn E.A.P. Mulder, Netherlands

319.7 Single centre experience of altruistic non-directed kidney donation
Katharina J. Schumacher, United Kingdom

319.8 Clinical utility and interpretation of CKD stages in living kidney donors
Allan Massie, United States

319.9 Pre-donation renal function, early post-donation renal function, and subsequent ESRD risk in living kidney donors
Allan Massie, United States
09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences) N-106
320 - Mechanisms of Allograft Rejection

Chairs: Birgit Sawitzki, Germany and Xian C. Li, United States

320.1 CD47 overcomes early loss of pancreatic islet grafts transplanted intraportally
Esma S. Yolcu, United States

320.2 Missing-self triggers NK-mediated microvascular injuries and chronic rejection of allogenic kidney transplants
Alice Koenig, France

320.3 Glycolytic bias in mTORC2 deficient dendritic cells potentiates antigen-specific immunity and accelerates graft rejection
Alicia R. Watson, United States

320.4 TEMRA CD8 T cells from human kidney transplant recipients exhibit potent anti-donor reactivity and induce GVHD in humanized mouse model
Lola Jacquemont, France

320.5 Characterization of acute cellular rejection in the different layers of rat transplanted intestines
Martin Rumbo, Argentina

320.6 Adipose-derived stromal cells attenuate acute rejection and graft vasculopathy in rodent vascularized composite allotransplantation
Pranitha J. Kamat, Switzerland

320.7 Immunotoxin in the absence of P-glycoprotein allows selective target cell killing in the semi-direct antigen presentation pathway following organ transplantation
Lucy J. Meader, United Kingdom

09:45-11:15 Oral Abstract Session (Infectious Diseases) N-107/108
321 - Reducing the Impact of Infections on Transplant Patients

Chairs: Hans H. Hirsch, Switzerland and Silvia Vidal Campos, Brazil

321.1 A prospective multi-center observational trial to evaluate a CMV-specific ELISpot Assay in solid organ transplant (SOT) recipients: The PROTECT study
Camille Kotton, United States

321.2 Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in kidney transplant recipients
Bernhard Banas, Germany

321.3 Significance of cytomegalovirus specific T lymphocytes in kidney transplant recipients
Maciej Zielinski, Poland

321.4 High frequencies of CMV-specific CD8 and CD4 T Cell subsets are needed pretransplant to protect from CMV replication in kidney transplant recipients treated with thymoglobulin
Teresa Bellon, Spain

321.5 Treatment of HBV-recurrence after liver transplantation – 30 years of experience
Eva M. Teegen, Germany

321.6 High incidence of anal human papillomavirus infection in HIV-infected solid organ transplant recipients
Peter V. ChinHong, United States

321.7 Risk factors for fungal infections after liver transplantation: A matched cohort analysis
Dieter Hoyer, Germany

321.8 INH prophylaxis in renal transplant recipients: A follow-up of 5 years
Anwar Naqvi, Pakistan

321.9 HIV, HBV, AND HCV Screening with NAT AND Serology in the OPO Setting
Nicole M. Theodoropoulos, United States
MONDAY, JULY 2, 2018

09:45-11:15 Oral Abstract Session N-111

322 - Best Abstracts from the Sociedad Española de Trasplante (SET)

Chairs: Daniel Seron, Spain and Jose Maria Aguado, Spain

322.1 Increase in proinflammatory CD14++CD16+ monocytes in samples from aspiration cytology compared with peripheral blood in kidney transplant patients with borderline rejection
   Teresa Vazquez, Spain

322.2 Toll-Like Receptor 9 -1486C/T genetic polymorphism is associated with hepatocarcinoma recurrence after liver transplantation
   Maria Jesus Citores Sanchez, Spain

322.3 KDPI score: A comparison with classical ECD/SCD classification in predicting outcomes
   Carlos Arias-Cabral, Spain

322.4 Urinary miRNA as a potential biomarker in kidney transplantation
   Francesc E. Borràs-Serres, Spain

322.6 MicroRNAs in kidney hypothermic machine perfusion fluid as novel biomarkers for graft function. Have changes in normalization guidelines support previous results?
   Victoria Gomez Dos Santos, Spain

322.7 Usefulness of delayed introduction of tacrolimus in kidney transplants (KT) with Type III-DCD
   Lara Ruiz Martinez, Spain

322.8 Fosfomycin for the treatment of asymptomatic bacteriuria and cystitis in kidney transplantation: New uses of an old antibiotic in the era of multidrug-resistance
   Jose Maria Aguado, Spain

322.9 Methods used to determine brain death diagnosis among actual organ donors in Spain
   Beatriz Mahillo, Spain

09:45-11:15 Oral Abstract Session (Heart and Lung) N-112

323 - Heart Transplantation

Chairs: Christopher Wigfield, United States and Irene Bello, Spain

323.1 Frailty predicts mortality after heart transplantation
   Peter S. MacDonald, Australia

323.2 Molecular assessment of heart transplant biopsies: Emergence of the injury dimension
   Philip F. Halloran, Canada

323.3 HLA sensitization in end-stage heart failure patients supported by extracorporeal membrane oxygenation
   Ozgur Ersoy, Turkey

323.4 Coronary angiography of potential cardiac donors increases cardiac transplantation rates
   Andreas Zuckermann, Austria

323.5 Donation after circulatory death heart transplantation: An update of current practices and outcomes
   Hong Chee Chew, Australia

323.6 The importance of the histopathological findings of surveillance biopsies in the monitoring of acute antibody-mediated rejection (AMR) in cardiac allograft recipients with or without clinical symptoms: Single center experience
   Aysen Terzi, Turkey

323.7 Mediterranean and low-fat diets reduce cardiovascular disease after both heart and lung transplantation: Results from a randomised trial with 12 month follow up
   Timothy R. Entwistle, United Kingdom

323.8 Does body size matter for continuous-flow ventricular assist device implantation for bridge to transplantation?
   Minoru Ono, Japan

323.9 ECMO use post DCD Heart Transplantation: A retrospective study
   Arjun Iyer, Australia
**MONDAY, JULY 2, 2018**

**SCIENTIFIC PROGRAM**

**Oral Abstract Session (Registry and Transplantation Nursing) N-113**

2018 - Patient Oriented Approach and Global Status

Chairs: Christiane Kugler, Germany and Curie Ahn, Korea

324.1 Recovery, symptoms and well-being one to five years after lung transplantation - a multi-center study

Anna Forsberg, Sweden

324.2 Comparing the effect of an educational course about organ donation on knowledge and attitudes of nurses and nurse supervisors

Omid Ghobadi, Iran (Islamic Republic of)

324.3 Increasing number of pancreas transplantations in the Czech Republic

Lenka Nemetova, Czech Republic

324.4 Immunosuppressive medication adherence and its associated factors in renal transplant recipients

Hongxia Liu, People's Republic of China

324.5 “preventing” is a new model of application for mobile phones to assess and improve immunosuppressant’s adherence in renal transplant recipients; preliminary observational study evaluating usability

Jorge Morales-Barria, Chile

324.6 Perspective on pregnancy counseling for kidney transplant recipients

Yuki Yoshikawa, Japan

324.7 Latin America transplantations registry. Report 2015-2016

Francisco Gonzalez-Martinez, Uruguay

324.8 Worldwide distribution of solid organ transplantation and access of population to those practices

Beatriz Mahillo, Spain

**Mini-Oral Abstract Session (Pancreas & Islet) N-115/116**

325 - Islet and Pancreas Miscellaneous

Chairs: Thomas Kay, Australia and Daniel Casanova, Spain

325.1 A novel subcutaneous pancreatic islet transplantation method using the new device of recombinant peptide containing human type I collagen material with RGD motif (Arg-Gly-Asp)

Satomi Suzuki Uematsu, Japan

325.2 Human amniotic epithelial cells integrated into the islet heterospheroids enhance insulin secretion and protect islet cells from hypoxic injury

Vanessa Lavallard, Switzerland

325.3 BETA-2 score allows for convenient and precise monitoring of islet function and early detection of islet dysfunction

Piotr J. Bachul, United States

325.4 Comparative evaluation of simple indices using a single fasting blood sample to estimate beta cell function after total pancreatectomy with islet autotransplantation

Justyna E. Gołębiewska, Poland

325.5 Outcomes of enteric conversion of bladder drained pancreas; over a decade of experience at a single center

Samy M. Riad, United States

325.6 Delivery of pancreatic islets and single dose local immune suppression into subcutaneous space using injectable hydrogel provides indefinite survival of the graft in mouse model of diabetes

Shiva Pathak, Korea

325.7 Outcomes for islet transplantation in donation after circulatory death compared with donation after brain death in Australia

Wayne J. Hawthorne, Australia

325.8 Modification of polyurethane scaffolds for localised immunosuppression of subcutaneous islet transplantation

Francis Kette, Australia

325.9 One-year blood glucose level is the best metabolic marker for the prediction of late pancreas graft failure

Diego Cantarovich, France

325.10 A study of effectiveness of preceding solo-kidney transplantation for Type1 diabetes with end stage renal failure

Taihei Ito, Japan

325.11 Decline in pancreas transplantation numbers is accompanied with lower publication rates

Stan Benjamens, Netherlands

325.12 Incidence of de-novo donor specific anti-human leucocyte antigen (HLA antibodies (DSA) in simultaneous pancreas kidney (SPK) transplant patients: A comparison between alemtuzumab and basiliximab based immunosuppression regimes

John Moir, United Kingdom
09:45-11:15  Mini-Oral Abstract Session (Complications)  N-117/118

326 - Complications-Complications-Complications

Chairs: Johann Pratschke, Germany and Allison Tong, Australia

326.1  Efficacy of rabbit anti-thymocyte globulin therapy for severe acute rejection in kidney transplant patients using calcineurin inhibitor and mycophenolate mofetil based immunosuppressive therapy
Marieke van der Zwan, Netherlands

326.2  Predictive factors analysis of osteoporosis and fragility fractures after liver transplantation
Shuji Akimoto, Japan

326.3  Mechanical circulatory support before and after heart transplantation: Impact on survival
Calogero Falletta, Italy

326.4  Establishing a core outcome measure for graft health: A standardized outcomes in nephrology – kidney transplantation (SONG-Tx) consensus workshop report
Allison Tong, Australia

326.5  Differences in risk factors for graft and patient survival among renal transplant recipients with type 2 diabetes mellitus. Generation of a T2DM specific risk calculator
David J. Goodman, Australia

326.6  A simple strategy for diagnosis of PTDM in stable kidney transplanted patients
Amin M. Ussif, Norway

326.7  Intravenous immunoglobulin replacement therapy in solid organ transplantation with severe infections and secondary antibody deficiency: Proof of concept
Javier Carbone, Spain

326.8  Cardiovascular disease after kidney transplant from uncontrolled donation after circulatory death (uDCD)
Maria Molina, Spain

326.9  Outcomes of kidney transplantation in former non kidney solid organ transplant
Anders Åsberg, Norway

326.10  Primary Sjögren Syndrome associated with mixed cryoglobulinaemia in kidney transplant patient: A case report
Oscar A. Calle Mafla, Spain

326.11  Invasive fungal infection among transplant tourism patients
Issa Al Salmi, Oman

326.12  Impact of empagliflozin for the treatment of diabetes mellitus after heart transplantation
Peter S. MacDonald, Australia

09:45-11:15  328 - Leadership Series presented by the TTS Education Committee (Education)  N-114

328.1  Introduction to the TTS Leadership Series Program and Structure
Medhat Askar, United States

328.2  Success Story - Case 1
TBA

328.3  Success Story - Case 2
TBA

Panel Discussions

11:15-11:45  Coffee Break / Poster Viewing / Visit Exhibitors  Hall 10 – Exhibition

11:15-11:45  330 - TTS Innovation Session  Hall 10 – TTS Innovative Studio in TTS Booth

330.1  Maximizing the Visibility of your Research Paper: How can social media help
Carla C. Baan, Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Panel</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-13:15</td>
<td><strong>Plenary Session 1</strong></td>
<td>Hall 10 – Plenary</td>
</tr>
<tr>
<td></td>
<td><strong>335 - Improving Patient Outcomes - Organ Donation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Facilitator: <strong>Nancy Ascher, United States</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>335.1 Challenges to improving deceased organ donation - past, present and future</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Rafael Matesanz</strong>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>335.2 Molecular therapeutic targets to minimise ischemia reperfusion injury</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Carmen Peralta</strong>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>335.3 Normothermic perfusion – will it live up to its promise</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Peter J. Friend</strong>, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>13:15-14:45</td>
<td><strong>Lunch Break / Poster Viewing / Visit Exhibitors</strong></td>
<td>Hall 10 – Exhibition</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td><strong>Corporate Symposium</strong></td>
<td>Hall 10 – Plenary</td>
</tr>
<tr>
<td></td>
<td><strong>340 - Yesterday’s Intervention Tomorrow’s Outcome: Improving the Transplant Journey</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>See page 28 for details.</td>
<td></td>
</tr>
<tr>
<td>13:30-14:15</td>
<td><strong>Lunch and Learn (#LL1 search on WebApp)</strong></td>
<td>Retiro Room (NCC)</td>
</tr>
<tr>
<td></td>
<td><strong>350 - Lunch and Learn 1 (registration required)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.1 Differences between adult and pediatric liver transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Carlos O. Esquivel</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.2 Significance of sarcopenia in liver transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Toshimi Kaido</strong>, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.3 Critically ill liver transplant candidate</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Catherine Paugam-Burtz</strong>, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.4 Management of the HIV positive transplant recipient</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Peter G. Stock</strong>, United States and <strong>Elmi Muller</strong>, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.5 How I desensitize an HLA incompatible kidney transplant candidate</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Lionel Rostaing</strong>, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.6 Essentials of organ donor research</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Claus Niemann</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.7 Kidney paired donation (KPD) transplantation to increase donor pool</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Vivek Kute</strong>, India</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.8 Long term complications after kidney transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Germaine Wong</strong>, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.9 Sex at the bench and beyond: a discussion on the importance of including sex as a biological variable in research!</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Deborah J. Clegg</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.12 Technical tips in live donor hepatectomy including laparoscopic donor hepatectomy</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Kwang-Suk Suh</strong>, Korea</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.13 PSC and LT; allocation, timing, selection</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Christian P. Strassburg</strong>, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.14 Rejection under steroid-free belatacept therapy: What to expect and how to treat</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>E. Steve Woodle</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.16 Mapping out your career - finding your road to success</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Jayme E. Locke</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.17 Kidney transplant beyond the usual anatomy (For surgeons)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Alejandro Niño-Murcia</strong>, Colombia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.18 Precision transplant medicine: what’s next?</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Minnie M. Sarwal</strong>, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>350.19 Manuscript submissions</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Transplantation Journal Editor</strong></td>
<td></td>
</tr>
</tbody>
</table>
### MONDAY, JULY 2, 2018

#### 13:30-13:45  
**Plenary Speaker Interview**  
Hall 10 – TTS Innovative Studio in TTS booth  

345.1  
**Peter J. Friend**, United Kingdom

#### 14:45-16:15  
**State-of-the-Art Session (Liver)**  
**360 - Recurrent Liver Allograft Disease: How to Deal With**  

**N-101**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45-16:15</td>
<td><strong>State-of-the-Art Session (Liver)</strong></td>
<td><strong>360 - Recurrent Liver Allograft Disease: How to Deal With</strong></td>
</tr>
<tr>
<td></td>
<td><strong>N-101</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Philip J. O’Connell, Australia and Kyung-Suk Suh, Korea</strong></td>
<td></td>
</tr>
<tr>
<td>360.1</td>
<td>Acute versus chronic alcoholic liver disease: real incidence and how to prevent recurrence</td>
<td><strong>Christophe Moreno</strong>, Belgium</td>
</tr>
<tr>
<td>360.2</td>
<td>Recurrent Viral B and C disease: is the graft still salvageable?</td>
<td><strong>Marina Berenguer</strong>, Spain</td>
</tr>
<tr>
<td>360.3</td>
<td>Recurrent hepatocellular cancer: is there a place for surgery?</td>
<td><strong>Shusen Zheng</strong>, People’s Republic of China</td>
</tr>
</tbody>
</table>

#### 14:45-16:15  
**State-of-the-Art Session (Paediatrics)**  
**361 - Paediatric Transplantation: Challenges and Potential Solutions**  

**N-102**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45-16:15</td>
<td><strong>State-of-the-Art Session (Paediatrics)</strong></td>
<td><strong>361 - Paediatric Transplantation: Challenges and Potential Solutions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>N-102</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Mignon McCulloch, South Africa and Rebecca Greenberg, Canada</strong></td>
<td></td>
</tr>
<tr>
<td>361.1</td>
<td>Ethics of transplanting the non-adherent teen</td>
<td><strong>Grainne M. Walsh</strong>, United Kingdom</td>
</tr>
<tr>
<td>361.2</td>
<td>Long term outcomes of paediatric transplantation</td>
<td><strong>Carlos O. Esquivel</strong>, United States</td>
</tr>
<tr>
<td>361.3</td>
<td>Biomarkers for PTLD diagnosis and therapies</td>
<td><strong>Olivia M. Martinez</strong>, United States</td>
</tr>
</tbody>
</table>

#### 14:45-16:15  
**State-of-the-Art Session (Kidney)**  
**362 - Strategies for the Sensitized Patient**  

**N-103**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45-16:15</td>
<td><strong>State-of-the-Art Session (Kidney)</strong></td>
<td><strong>362 - Strategies for the Sensitized Patient</strong></td>
</tr>
<tr>
<td></td>
<td><strong>N-103</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Ron Shapiro, United States and Daniel Seron, Spain</strong></td>
<td></td>
</tr>
<tr>
<td>362.1</td>
<td>IdeS: a new approach to desensitization</td>
<td><strong>Robert A. Montgomery</strong>, United States</td>
</tr>
<tr>
<td>362.2</td>
<td>Anti-IL-6R Ab for the prevention and treatment of AMR</td>
<td><strong>Olivier Aubert</strong>, France</td>
</tr>
<tr>
<td>362.3</td>
<td>The role of the acceptable mismatch strategy for sensitized patients</td>
<td><strong>Frans HJ Claas</strong>, Netherlands</td>
</tr>
</tbody>
</table>

#### 14:45-16:15  
**State-of-the-Art Session (Basic Sciences and Translational Sciences)**  
**363 - New Therapeutic Approaches to Transplantation**  

**N-104**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45-16:15</td>
<td><strong>State-of-the-Art Session (Basic Sciences and Translational Sciences)</strong></td>
<td><strong>363 - New Therapeutic Approaches to Transplantation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>N-104</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Jordi Ochando, Spain and Birgit Sawitzki, Germany</strong></td>
<td></td>
</tr>
<tr>
<td>363.1</td>
<td>Mechanisms of organ injury and repair by macrophages</td>
<td><strong>Menna R. Clatworthy</strong>, United Kingdom</td>
</tr>
<tr>
<td>363.2</td>
<td>Systems biology of the intragraft regional immunoregulation in tumor recurrence after liver transplantation</td>
<td><strong>Nancy Kwan Man</strong>, Hong Kong</td>
</tr>
<tr>
<td>363.3</td>
<td>Nudging clinical Treg responses</td>
<td><strong>Qizhi Tang</strong>, United States</td>
</tr>
</tbody>
</table>

#### 14:45-16:15  
**State-of-the-Art Session (Donation & Procurement)**  
**364 - New Strategies to Increase Donation**  

**N-105**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45-16:15</td>
<td><strong>State-of-the-Art Session (Donation &amp; Procurement)</strong></td>
<td><strong>364 - New Strategies to Increase Donation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>N-105</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Susan Gunderson, United States and Marti Manyalich, Spain</strong></td>
<td></td>
</tr>
<tr>
<td>364.1</td>
<td>Donor intervention research - priorities and trends</td>
<td><strong>Claus Niemann</strong>, United States</td>
</tr>
<tr>
<td>364.2</td>
<td>Effective family approach practices</td>
<td><strong>Howard M. Nathan</strong>, United States</td>
</tr>
<tr>
<td>364.3</td>
<td>End of life care decision making impact on donation</td>
<td><strong>Kristina Krmpotic</strong>, Canada</td>
</tr>
</tbody>
</table>
### 14:45-16:15 State-of-the-Art Session (Cellular and Regenerative Therapies) N-106

**365 - Inflammation and Stem Cell Transplantation**

**Chairs:** Toshio Miki, United States and Ewa Ellis, Sweden

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>365.1 Stem cell therapy, hepatocytes, a source for liver regeneration</td>
<td>Anil Dhawan</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>365.2 Pursuing tolerance by blocking inflammation in islet transplantation</td>
<td>Maria Koummanda</td>
<td>United States</td>
</tr>
<tr>
<td>365.3 Advances in MR cell imaging</td>
<td>Frantisek Saudek</td>
<td>Czech Republic</td>
</tr>
</tbody>
</table>

### 14:45-16:15 State-of-the-Art Session (Histocompatibility) N-107/108

**366 - Cutting Edge of Allorecognition**

**Chairs:** Peter W. Nickerson, Canada and Elaine F. Reed, United States

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>366.1 Novel immune allorecognition pathways</td>
<td>Megan Sykes</td>
<td>United States</td>
</tr>
<tr>
<td>366.2 MHC: T-Cell receptor allorecognition interface</td>
<td>James McCluskey</td>
<td>Australia</td>
</tr>
<tr>
<td>366.3 MHC: B-Cell receptor allorecognition interface</td>
<td>Olivier Thaunat</td>
<td>France</td>
</tr>
</tbody>
</table>

### 14:45-16:15 State-of-the-Art Session (Intestine & Multivisceral Transplantation) N-111

**367 - The Future of Intestinal Transplantation**

**Chairs:** George V. Mazuriegos, United States and Jayme E. Locke, United States

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>367.1 The microbiome and its implications in ITX</td>
<td>Alexander Kroemer</td>
<td>United States</td>
</tr>
<tr>
<td>367.2 Current knowledge on regulation and impairment of motility after intestinal transplantation</td>
<td>Martin W. von Websky</td>
<td>Germany</td>
</tr>
<tr>
<td>367.3 Alloimmunity of the intestinal allotransplant</td>
<td>Martin Rumbo</td>
<td>Argentina</td>
</tr>
</tbody>
</table>

### 14:45-16:15 State-of-the-Art Session (Vascularized Composite Allotransplantation) N-115/116

**368 - Novel Technologies and Tools in VCA**

**Chairs:** Emmanuel Morelon, France and Stefan Schneeberger, Austria

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>368.1 Nanomedicine Strategies for VCA - Prospects and Potential</td>
<td>Jelena M. Janjic</td>
<td>United States</td>
</tr>
<tr>
<td>368.2 Vascularized composite allograft engineering - the new frontier</td>
<td>Benoit Lengele</td>
<td>Belgium</td>
</tr>
<tr>
<td>368.3 Cortical integration after VCA-relevance in hand and face transplants</td>
<td>Angela Sirigu</td>
<td>France</td>
</tr>
</tbody>
</table>

### 14:45-16:15 State-of-the-Art Session (Ethics, Community, Economics) N-117/118

**369 - Upholding the Ethics of Transplantation: The Global View**

**Chairs:** Beatriz Dominguez-Gil, Spain and Peter G. Stock, United States

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>369.1 Pakistan - the challenges and successes in transplantation</td>
<td>Adibul Hasan Rizvi</td>
<td>Pakistan</td>
</tr>
<tr>
<td>369.2 Establishment of a successful deceased donor program in Iran</td>
<td>Seyed Ali Malek-Hosseini</td>
<td>Iran (Islamic Republic of)</td>
</tr>
<tr>
<td>369.3 Achieving organ donor reform in China</td>
<td>Haibo Wang</td>
<td>People's Republic of China</td>
</tr>
</tbody>
</table>

---

66

27th International Congress of The Transplantation Society
### 16:30 to 17:30 - Campfire Sessions and Poster Session 1

#### 16:30-17:30 Campfire Session (Kidney)  
**C390 - Kidney Issues**

**Chairs:** E. Steve Woodle, United States and Olivier Aubert, France

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>C390.1</td>
<td>C1q assay to determine complement fixing of anti-human leukocyte antigen antibodies, but not immunoglobulin subclass identification, allows better prediction of kidney allograft outcomes in an Asian population</td>
<td>Rachel Teo, Singapore</td>
</tr>
<tr>
<td>C390.2</td>
<td>Development and internal validation of a prediction model for early hospital readmissions in kidney transplant recipients</td>
<td>Olusegun Famure, Canada</td>
</tr>
<tr>
<td>C390.3</td>
<td>Comparative results of transurethral incision with transurethral resection of the prostate in renal transplant recipients with benign prostate hyperplasia</td>
<td>Mehmet Sarier, Turkey</td>
</tr>
<tr>
<td>C390.4</td>
<td>Timing of double-J stent removal and occurrence of urological complications: A systematic review and meta-analysis</td>
<td>Isis J. Visser, Netherlands</td>
</tr>
<tr>
<td>C390.5</td>
<td>Patient and graft outcome among high immunologic risk renal transplant recipients</td>
<td>Jeffrey P. Mora, Philippines</td>
</tr>
<tr>
<td>C390.6</td>
<td>Higher rates of rejection in HIV-infected kidney transplant recipients on Ritonavir-boosted protease inhibitors-three-year follow up</td>
<td>Ron Shapiro, United States</td>
</tr>
</tbody>
</table>

#### 16:30-17:30 Campfire Session (Transplant Immunosuppression)  
**C391 - Transplant Immunosuppression**

**Chairs:** Christine S. Falk, Germany and Manikkam Suthanthiran, United States

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>C391.1</td>
<td>A limited sampling strategy to estimate whole blood and intra-lymphocyte exposure of everolimus in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators</td>
<td>Anders Åsberg, Norway</td>
</tr>
<tr>
<td>C391.2</td>
<td>Prediction of tacrolimus drug dosing and metabolism based on CYP3A5 polymorphism in Indian renal transplant recipients</td>
<td>Mohan Patel, India</td>
</tr>
<tr>
<td>C391.3</td>
<td>Acute antibody-mediated rejection and its treatment in kidney transplantation: Report from a national cohort study</td>
<td>Nancy Perrottet, Switzerland</td>
</tr>
<tr>
<td>C391.4</td>
<td>The suppressive function of the human regulatory macrophages in-vitro have more potency but not in-vivo</td>
<td>Yuanfei Zhao, Australia</td>
</tr>
<tr>
<td>C391.5</td>
<td>Tacrolimus exerts age-specific immunosuppressive effects linked to modifications of CD4+ T cells metabolism</td>
<td>Yeqi Nian, United States</td>
</tr>
<tr>
<td>C391.6</td>
<td>Effects of the de novo use of everolimus with reduced calcineurin inhibitor on wound healing events in the TRANSFORM study</td>
<td>Franco Citterio, Italy</td>
</tr>
</tbody>
</table>

#### 16:30-17:30 Campfire Session (Complications)  
**C392 - Infections and PTLD**

**Chairs:** Olivia M. Martinez, United States and TBA

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>C392.1</td>
<td>Epstein-Barr virus genome variation in post-transplant lymphoproliferative disorder</td>
<td>Olivia M. Martinez, United States</td>
</tr>
<tr>
<td>C392.2</td>
<td>Genomic status of the Epstein Barr virus and virus-associated PI3K/Akt/mTOR pathway dysregulation in post-transplant lymphoproliferative disorder</td>
<td>Marla C. McPherson, United States</td>
</tr>
<tr>
<td>C392.3</td>
<td>Unusual malignancies after small bowel transplantation in children: A European single centre experience</td>
<td>Undine Gerlach, Germany</td>
</tr>
<tr>
<td>C392.4</td>
<td>Elucidation of the miRNome in EBV-positive and EBV-negative PTLD</td>
<td>Yarl Balachandran, United States</td>
</tr>
<tr>
<td>C392.5</td>
<td>The MADELEINE (coMbinEd tAcrolimus anD EveroLimus Early ImmuNosupprEssion) study: CMV and BKV infections over the first 6 months post-transplant</td>
<td>Thomas Jouve, France</td>
</tr>
</tbody>
</table>
16:30-17:30 Campfire Session (Infectious Diseases)  
C393 - Donor-Derived and Early Post-Transplant Infections  
Hall 10 – Exhibition

Chairs: Michael G. Ison, United States and Clarisse Machado, Brazil

C393.1 Cut-Off of COBAS®Ampliprep/COBAS®Taqman® CMV test in transplant recipients receiving intermittent Ganciclovir (GCV) Prophylaxis  
Silvia Vidal Campos, Brazil

C393.2 The use of 16s ribosomal RNA PCR to investigate donor derived transport fluid infections in patients undergoing renal transplantation: a retrospective audit of 36 deceased donors  
John T. Black, United Kingdom

C393.3 Transmission of multiresistant bacteria from donor to recipient  
Maria Carrillo Cobarro, Spain

C393.4 Utility of multi locus sequence typing (MLST) in the investigation of a cluster of candida albicans infection in recipients of solid organs from a common donor  
Ines Ushiro-Lumb, United Kingdom

C393.5 Intestinal mucosal barrier disruption and microfold cells impairment were required for invasive fungal infection after living donor liver transplantation  
Jiang Liu, People’s Republic of China

C393.6 Tuberculosis among kidney transplant patients compared to dialysis and non-dialysis CKD patients over a decade period  
Issa Al Salmi, Oman

16:30-17:30 Campfire Session (Basic Sciences and Translational Sciences)  
C394 - None Plus Ultra?  
Hall 10 – Exhibition

Chairs: Qizhi Tang, United States and Menna R. Clatworthy, United Kingdom

C394.1 The importance of adjustment for confounding factors in biomarker studies to avoid misleading conclusions  
Maria P. Hernandez-Fuentes, United Kingdom

C394.2 Standardized whole-blood immunophenotyping panels on flow cytometry for transplant recipients and clinical trials  
Elvira Jimenez Vera, Australia

C394.3 Biomarkers: New tool to detect subclinical inflammation?  
Nuria Serra, Spain

C394.4 Can regulatory T cells help us as a biomarker of long-term kidney graft survival?  
Luis Humberto Galvan Espinoza, Spain

C394.5 Early enrichment and restitution of the peripheral blood Treg pool is associated with rejection-free stable immunosuppression after liver transplantation  
Akinbami R. Adenugba, Germany

16:30-17:30 Campfire Session (Xenotransplantation)  
C395 - New Approaches in Xenotransplantation  
Hall 10 – Exhibition

Chairs: David K.C. Cooper, United States and Kazuhiko Yamada, United States

C395.1 The value of glycated albumin for monitoring graft function in the non-human primate porcine islet transplantation model  
Hee Jung Kang, Korea

C395.2 Progress in xenogeneic lung transplantation using multi-transgenic donor pigs and targeted supportive drug treatments  
Lars Burdorf, United States

C395.3 Multitransgenic porcine fibroblasts are protected from immunoglobulin binding and complement deposition in a xeno-microfluidic model  
Riccardo Sfriso, Switzerland

C395.4 Recent progress in pig to non-human primate (nhp) solid organ xenotransplantation in Korea  
Ilk Jin Yun, Korea

C395.5 A novel and effective therapeutic approach to overcome refractory transplant-related anti-glycan Ab production  
Yuka Tanaka, Japan

C395.6 In vitro xenoantigen stimulated human Tr1 cells enhanced suppression of the xenogeneic T cell response with upregulated expression of CD39  
Xi Jin, People’s Republic of China
16:30-17:30 Campfire Session (Pancreas & Islet)  
C396 - Islet Transplantation  
Hall 10 – Exhibition

Chairs: Adam D. Barlow, United Kingdom and Lorenzo Piemonti, Italy

C396.1 Characterization of 3D-printed human regulatory T-cells  
Juewan Kim, Australia

C396.2 Development of the total pancreatectomy and autologous islet transplantation models as the step for allogenic islet transplantation experiments in the swine  
Kohei Miura, Japan

C396.3 Early infectious complications post total pancreatectomy with islet autotransplantation  
Justyna E. Gołębiewska, Poland

C396.4 Shielding human islets with human amniotic epithelial cells enhances islet engraftment and revascularization  
Fanny Lebreton, Switzerland

C396.5 Human mesenchymal stem cells derived exosomes enhance porcine islet resistance to hypoxia in islet transplantation  
Wei Nie, People's Republic of China

C396.6 The study of the influence on hIAPP deposition and dysfunction in INS-1 cell by calcineurin inhibitors  
Jialin Zhang, People's Republic of China

16:30-17:30 Campfire Session (Donation & Procurement)  
C397 - Knowledge and Attitudes  
Hall 10 – Exhibition

Chairs: Katja Empson, United Kingdom and Margaux N. Mustian, United States

C397.1 Revisiting transplant tourism regulations in the Philippines: How can we improve the practice?  
Campbell Fraser, Australia

C397.2 Factors influencing deceased donor consent rates in Cape Town, South Africa  
David A. Thomson, South Africa

C397.3 Does rapid growth in the number of donation after circulatory death donors equate to fewer brain dead donors and fewer organs transplanted?  
Jeffrey P. Orlowski, United States

C397.4 The weekend effect: An Australian cohort study analysing temporal trends in solid organ donation  
Angela C. Webster, Australia

C397.5 Results of kidney transplantation and re transplantation in Argentina 1998-2016  
Liliana Bisigniano IV, Argentina

C397.6 Clinicians' attitudes and perspectives on ante-mortem interventions in deceased organ donation: An international interview study  
Sara Shahrestani, Australia

16:30-17:30 Campfire Session (Heart and Lung)  
C398 - Heart and Lung  
Hall 10 – Exhibition

Chairs: Peter S. MacDonald, Australia and Maria G. Crespo-Leiro, Spain

C398.1 Dyslipidaemia after heart transplantation  
Maria M. Simonenko, Russian Federation

C398.2 Head to head comparison of speckle tracking strain echocardiography with invasive hemodynamic assessment for the detection of acute cellular rejection in cardiac allograft recipients  
Haldun Muderrisoglu, Turkey

C398.3 Left atrial longitudinal strain at the conduit phase: A new additional parameter in predicting elevated capillary wedge pressure in patients candidate for heart transplant  
Calogero Falletta, Italy

C398.4 Early postoperative acute kidney injury among heart transplant recipients: Incidence, risk factors and impact on clinical consequences  
Pinar Zeyneloglu, Turkey

C398.5 Effects of transcutaneous nerve stimulation on the autonomic balance of cardiac transplant recipients  
Beatriz Robert Moreira, Brazil

C398.6 Impact of a mobile pharmaceutical and healthcare programme on therapeutical adherence in heart transplant patients  
Mar Gomis, Spain
16:30-17:30  Campfire Session (Liver)  
**C399 - IS and Viral Hepatitis**  
*Hall 10 – Exhibition*

**Chairs:** Christian P. Strassburg, Germany and TBA

**C399.1** Cost effectiveness of immunosuppression withdrawal after liver transplantation  
*Tommaso Maria Manzia*, Italy

**C399.2** Mycophenolate mofetil effect and trough level under 2-year old in pediatric living donor liver transplantation  
*Takehisa Ueno*, Japan

**C399.3** New insights from the SILVER study; a 50% reduction in calcineurin inhibitors at day 30 achieves a temporary renal-sparing effect but does not impact on long-term renal function after liver transplantation  
*Bettina Buchholz*, United Kingdom

**C399.4** 22 years of experience in hepatic re-transplantation: Value of predictive survival scores  
*Gabriel E. Gondolesi*, Argentina

**C399.5** Long term nucleos(t)ide analog therapy after immunglobuline withdrawal in liver transplant recipients to prevent recurrent hepatitis B  
*Carmelo Loinaz*, Spain

**C399.6** Phase 1/2a trial of a bioartificial liver support system (LifeLiver) for acute liver failure patients  
*Seung Wook Han*, Korea

---

16:30-17:30  Poster Session 1 - Odd Poster Number Presentations  

*Detailed list of all the posters available on page 122*  
*All poster presenters with odd poster numbers shall be at their respective poster(s).*
### Other Events

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15-17:30</td>
<td>Corporate Symposium N-103, Might Different Patients Need Different Approaches? New Concepts on Tacrolimus Metabolism and Pharmacokinetics</td>
<td>N-103</td>
</tr>
<tr>
<td></td>
<td>See page 28 for details.</td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>Interview with SOTA Speakers Hall 10 – TTS Innovative Studio in TTS booth</td>
<td>Hall 10 – TTS Innovative Studio in TTS booth</td>
</tr>
<tr>
<td></td>
<td>375.1 James McCluskey, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Howard M. Nathan, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frans HJ Claas, Netherlands</td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>Case Competition Presentation 1 Hall 10 – TTS Innovative Studio in TTS booth</td>
<td>Hall 10 – TTS Innovative Studio in TTS booth</td>
</tr>
<tr>
<td></td>
<td>375.2 TCR NGS based evidence for differential diagnosis and personalized therapy in BKV nephropathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ulrik Stervbo, Germany</td>
<td></td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>Case Competition Presentation 2 Hall 10 – TTS Innovative Studio in TTS booth</td>
<td>Hall 10 – TTS Innovative Studio in TTS booth</td>
</tr>
<tr>
<td></td>
<td>375.3 Day to day decision in multi-visceral transplantation immunosuppression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marina Pérez-Flecha González, Spain</td>
<td></td>
</tr>
</tbody>
</table>
### 08:30-09:30 Mini-Oral Abstract Session (Liver) N-101

**08:30-09:30 Mini-Oral Abstract Session (Liver) N-101**

**400 - Recipient Selection and Viral Infections**

**Chairs:** Marina Berenguer, Spain and Christian P. Strassburg, Germany

1. **400.1** Predictive factors for death on a long waiting list for liver transplantation after an episode of acute on chronic liver failure
   - Speranta Iacob, Romania

2. **400.2** Impact of recipient age on long-term after liver transplantation: A double propensity score matching analysis
   - Concepción Gómez-Gavara, Spain

3. **400.3** Aging in liver transplantation: Does the interaction of donor and recipient age matter?
   - Nicholas Gilbo, Belgium

4. **400.4** OR extubation of liver transplant (LT) patients is associated with significantly less blood transfusion during surgery, acute renal failure and bacterial infection, and shorter hospital and ICU stay
   - Martin A. Maraschio, Argentina

5. **400.5** Impact of sarcopenic obesity on outcomes after liver transplantation; does sarcopenic obesity cause poor prognosis?
   - Naoko Kamo, Japan

6. **400.6** Evaluation of the renal graft function after hepatitis C virus treatment with interferon-free directly acting antiviral: A centre experience
   - Oscar A. Calle Mafla, Spain

### 08:30-09:30 Mini-Oral Abstract Session (Kidney) N-102

**08:30-09:30 Mini-Oral Abstract Session (Kidney) N-102**

**401 - Imunosuppression 1**

**Chairs:** Amado Andres Belmonte, Spain and TBA

1. **401.1** The results of the PRISM (prediction of rejection in sensitized patient blood samples) trial with a novel bioassay
   - Minnie M. Sarwal, United States

2. **401.2** Significant anti-CMV/BKV effect of a modern everolimus-based regimen compared to standard tacrolimus-MPA regimen in de novo kidney transplant recipients: Athena 12 months data on infections
   - Duska Dragun, Germany

3. **401.3** Mycophenolic acid therapeutic drug monitoring in de novo renal transplant patients and the related outcomes
   - Shiong Shiong Yew, Malaysia

4. **401.4** Evaluation of cell-mediated immune response by QuantiFERON Monitor® assay in kidney transplant recipients
   - Ivan Margeta, Croatia

5. **401.5** Effect of everolimus on body composition; 1-year after kidney transplantation
   - Mikiko Yoshikawa, Japan

6. **401.6** Tacrolimus - optimization of levels in kidney transplant
   - Joseph Kim, Canada

7. **401.7** Concurrent antibody-mediated rejection in post-transplant IgA nephropathy – diagnosis using a stepwise approach of graft morphology
   - Hyeon Joo Jeong, Korea

8. **401.8** The influence of polyomavirus infected glomerular cells on the development of glomerulopathy and the graft survival
   - Aysen Terzi, Turkey
08:30-09:30 Mini-Oral Abstract Session (Kidney) N-105
402 - Living Donor

Chairs: John S. Gill, Canada and Gabriel Danovitch, United States

402.1 Living kidney donation in Spain, a global strategy to increase this modality of transplantation
Maria Oliva Valentin, Spain

402.2 Prospective comparison between open and robot assisted kidney transplant: Our initial results
Anant Kumar, India

402.3 Comparative mortality of live kidney donors in the UK: 15 year cohort study
Nithya S. Krishnan, United Kingdom

402.4 Comparative morbidity outcomes in live kidney donors in the UK: 15 year cohort study
Nithya S. Krishnan, United Kingdom

402.5 Retroperitoneal single port versus transperitoneal multiport donor nephrectomy: A prospective randomised control trial
Navdeep Singh, India

402.6 Radioisotopic evaluation glomerular filtration rate (GFR) before and after kidney donation
Vincenzo Cantaluppi, Italy

402.7 CT based visceral fat measures predict complexity, complications and low clearance in living donor nephrectomy
Zubir Ahmed, United Kingdom

08:30-09:30 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences) N-106
403 - Human Immunology

Chairs: Megan Levings, Canada and Oriol Bestard Matamoros, Spain

403.1 Functional analysis of hepatic TCF7L2 gene polymorphism in glucose metabolism by allele-specific CRISPR/Cas 9 gene editing
Qi Ling, People's Republic of China

403.2 Single-cell analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus
Carla C. Baan, Netherlands

403.3 Pre-transplant immune markers of rejection risk in HIV-positive transplant recipients
Simon N. Chu, United States

403.4 Identifying shared patterns in the T cell receptor repertoire specific to IE-1 CMV
Marc Lucia Perez, United States

403.5 High numbers of donor-specific IL-21 producing cells predict rejection after kidney transplantation: A cross validation
Nicole M. van Besouw, Netherlands

403.7 Renal allograft transcription analysis reveals similar signature of acute T cell mediated rejection in patients treated with tacrolimus or belatacept
Marieke van der Zwan, Netherlands

08:30-09:30 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences) N-107/108
404 - T Cell Biology 1

Chairs: Xian C. Li, United States and James McCluskey, Australia

404.1 Th1/Th2 imbalance and early age to transplantation is associated to atopic dermatitis in heart-transplanted pediatric patients
Rafael Correa-Rocha, Spain

404.2 Peripheral blood regulatory T cells are diminished in kidney-transplant patients with chronic allograft nephropathy
Marco Antonio Carmona Jr., Mexico

404.3 Evidence for intrathymic clonal deletion in tolerance induction to limb allografts
Wensheng Zhang, United States

404.4 Alloactivation of human CD4+CD25+CD127loCD45RA-Fox3hi Treg population to induce potential alloantigen specific Treg
Nirupama D. Verma, Australia

404.5 Immunosuppressors (CsA, MPA) and IVIg act directly upon endothelial cells and differentially alter their ability to activate allogeneic T-CD4+
Julien Lion, France, Metropolitan

404.6 Tissue-resident memory T cells of donor origin are short-lived in renal allografts after transplantation
Kitty de Leur, Netherlands
08:30-09:30  Morning Symposium (Cellular and Regenerative Therapies)  N-111

405 - Clinical Applications in Stem Cells

Chairs: Maria Koulimanda, United States and Qizhi Tang, United States

405.1 Bottlenecks to clinical application of iPS
    Martin Hoogduijn, Netherlands

405.2 Clinical trials for stem-based regenerative medicine
    Toshio Miki, United States

08:30-09:30  Morning Symposium (Heart and Lung)  N-112

406 - The Future of Thoracic Transplantation

Chairs: Anne Dipchand, Canada and Olivier Bastien, France

406.1 Assessment of frailty and comorbidities
    Cynthia Gries, United States

406.2 Efforts to increase the lung donor pool
    Dirk Van Raemdonck, Belgium

406.3 Efforts to increase the heart donor pool
    Peter S. MacDonald, Australia

08:30-09:45  Morning Symposium (Xenotransplantation)  N-113

407 - Issues Relating to Clinical Xenotransplantation

Chairs: Alfred J. Tector III, United States and Muhammad Mohiuddin, United States

407.1 Are low anti-pig antibody levels essential to the success of pig organ xenotransplantation?
    Emanuele E. Cozzi C, Italy

407.2 Is encapsulated pig islet Tx preferable to free pig islet Tx?
    Rita Bottino, United States

407.3 Is pig genetic engineering essential for the success of xenotransplantation?
    Kazuhiko Yamada, United States

Presentation of the 2017 Carl-Gustav Groth Xeno Prize

Article published in the Xenotransplantation Journal (May/June 2017, Volume 24, Issue 3)

Testing of microencapsulated porcine hepatocytes in a new model of fulminant liver failure in baboons
Co-Authors: Zurab Machaidze and Heidi Yeh, United States

08:30-09:30  Morning Symposium (Intestine & Multivisceral Transplantation)  N-114

408 - Controversies in Intestinal Transplant

Facilitators: Alexander Kroemer, United States and Gabriel E. Gondolesi, Argentina

408.1 Should every country have an intestinal transplant program? Yes
    Rodrigo Vianna, United States

408.2 Should every country have an intestinal transplant program? No
    George V. Mazariegos, United States

Open debate discussion

408.3 Cipo: pre-emptive transplant - Yes
    Francisco Hernandez, Spain

408.4 CIPO: Pre-emptive transplant - No
    Florence Lacaille, France

Open debate discussion
### Morning Symposium (Paediatrics)

**08:30-09:30**

#### 409 - Trends in Paediatric Transplantation

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>409.1</td>
<td>Paediatric PTLD pearls</td>
<td>Stephen D. Marks, United Kingdom</td>
</tr>
<tr>
<td>409.2</td>
<td>Donor specific antibodies in paediatrics</td>
<td>Burkhard Tönshoff, Germany</td>
</tr>
<tr>
<td>409.3</td>
<td>Ethical issues in paediatric transplantation: an update on current issues</td>
<td>Rebecca Greenberg, Canada</td>
</tr>
</tbody>
</table>

### Morning Symposium (Donation & Procurement)

**08:30-09:30**

#### 410 - Opt Out - New Experiences in Presumed Consent

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>410.1</td>
<td>The Wales experience</td>
<td>Katja Empson, United Kingdom</td>
</tr>
<tr>
<td>410.2</td>
<td>The US opt in experience</td>
<td>Susan Gunderson, United States</td>
</tr>
<tr>
<td>410.3</td>
<td>Opt in-opt out - the European experience</td>
<td>Bernadette BJJM. Haase-Kromwijk, Netherlands</td>
</tr>
</tbody>
</table>

### Mini-Oral Abstract Session (Liver)

**09:45-11:15**

#### 415 - Malignancies and Complications

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>415.1</td>
<td>Validated nomogram for prediction of recurrence in HCC within Milan criteria</td>
<td>Ka-Wing Ma, Hong Kong</td>
</tr>
<tr>
<td>415.2</td>
<td>Hepatic artery doppler flow changes during cholangitis in liver transplantation patients</td>
<td>Funda Ulu Öztürk, Turkey</td>
</tr>
<tr>
<td>415.3</td>
<td>Liver transplantation and auxiliary partial orthotopic transplantation outcomes in Wilson’s disease: Results of a single center</td>
<td>Ebru H. Ayyazoglu Soy, Turkey</td>
</tr>
<tr>
<td>415.4</td>
<td>Factors associated with the development of chronic kidney disease after liver transplantation</td>
<td>Marit Kalisvaart, United Kingdom</td>
</tr>
<tr>
<td>415.5</td>
<td>Prediction of outcome of donation after circulatory death liver transplantation – the concept of hypotension exposure</td>
<td>Michael A. Fink, Australia</td>
</tr>
<tr>
<td>415.6</td>
<td>Interventional radiology in complication management after pediatric liver transplantation</td>
<td>Artem Monakhov, Russian Federation</td>
</tr>
<tr>
<td>415.7</td>
<td>Technical determinants of cholangiopathy in liver transplantation</td>
<td>Jose Alvarez-Casas, United States</td>
</tr>
<tr>
<td>415.8</td>
<td>Liver blood flow after right lobe living donor liver transplantation with middle hepatic vein</td>
<td>Oleg Kotenko, Ukraine</td>
</tr>
<tr>
<td>415.9</td>
<td>Comprehensive complication index measure at moment of post-liver transplant discharge well predicts long-term survival</td>
<td>Fabio Melandro, Italy</td>
</tr>
<tr>
<td>415.10</td>
<td>Therapy of patient with recurrent HCC after liver transplantation with T-cells transiently expressing HBV-specific TCR</td>
<td>Zhao Qiang, People’s Republic of China</td>
</tr>
<tr>
<td>415.11</td>
<td>Impact of sarcopenia on the outcomes after living-donor liver transplantation</td>
<td>Taiga Wakabayashi, Japan</td>
</tr>
<tr>
<td>415.12</td>
<td>Retrospective analysis of using the modified in pediatric recipients of left lateral segment liver graft</td>
<td>Sergey Gautier, Russian Federation</td>
</tr>
</tbody>
</table>
### Oral Abstract Session (Kidney) N-102
09:45-11:15  
**416 - Allocation & Others**

**Chairs:** Ron Shapiro, United States and Eduardo Miñambres, Spain

1. **Working towards a new deceased donor kidney offering scheme in the UK**  
   Lisa L. Mumford, United Kingdom

2. **Mortality and kidney transplantation outcomes among chronic dialysis patients who are seropositive for hepatitis C virus**  
   Deirdre Sawinski, United States

3. **Virtual crossmatch permits kidney sharing; avoiding transplant into unintended recipients**  
   Garrett R. Roll, United States

4. **Relative risk over time of donor and recipient factors on kidney graft survival**  
   Ernesto P. Molmenti, United States

5. **Sharing one, keeping one policy for kidney allocation increases inequity in kidney transplantation**  
   Javier Dominguez, Chile

6. **A novel tool to define the immunogenicity of HLA mismatches**  
   Cynthia SM Kramer, Netherlands

7. **Effect of a good oral - dental care protocol on inflammation and oral lesions in renal transplant patients: A randomized control study**  
   Raj Kumar Sharma, India

8. **Results of kidney transplantation in very old age recipients using kidneys from very old donors**  
   Hernando Trujillo, Spain

### Oral Abstract Session (Kidney) N-103
09:45-11:15  
**417 - Ageing in Transplantation & Others**

**Chairs:** Elmi Muller, South Africa and Jayme E. Locke, United States

1. **Successful deceased donor kidney transplantation of highly sensitized candidates across positive cross match and strong donor-specific HLA-DP antibodies without desensitization**  
   Raja Rajalingam, United States

2. **Cognitive impairment and graft loss in kidney transplant recipients**  
   Mara Ann McAdams DeMarco, United States

3. **Frailty, inflammation, and waitlist mortality among patients with end-stage renal disease on the kidney transplant waitlist**  
   Mara Ann McAdams DeMarco, United States

4. **The impact of age-matching on graft function and graft survival after living donor kidney transplantation**  
   Jee Youn Lee, Korea

5. **Validation of an integrative and dynamic prognostic score for response to therapy in solid organ transplants**  
   Alexandre Loupy, France

6. **Pre-transplant assessment of AMR risk by novel donor/recipient non-HLA variants**  
   Silvia Pineda, United States

7. **Hepatitis C virus infection in kidney transplant recipients: final results from a Spanish multicenter study**  
   Carmen Gonzalez-Corvillo, Spain

8. **Allograft outcome following retransplantation of patients with failed first kidney allograft attributed to non-adherence**  
   Revathy Manickavasagar, Australia

   Monika Ashwin, Canada
09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences) N-104

418 - IRI Mechanisms

Chairs: Nancy Kwan Man, Hong Kong and Edward K. Geissler, Germany

418.1 The intestinal-liver axis of FGF15-FGFR4-PPAR? Signal control liver ischemia reperfusion injury through regulating autophagy
Zhao Qiang, People’s Republic of China

418.2 CSAR2 deficiency shows enhanced regeneration capacity after renal ischemia reperfusion injury via AKT and FGF dependent mechanisms
Faikah Gueler, Germany

418.3 Differential impact of autophagy on innate and adaptive immune cells characterizes alloimmune responses in aging
Stefan G. Tullius, United States

418.4 Ischemia reperfusion injury significantly differs between lung vs. heart transplantation with respect to lead cytokines and correlation to clinical outcome
Christine S. Falk, Germany

418.5 Hypoxia induces inflammatory response and cell death by promoting NLRP3 inflammasome activation via ROS-TXNIP axis in pancreatic β cells
Cheng Chen, People’s Republic of China

418.6 Neutrophil-macrophage communications via inflammasome pathway induced graft injury after LDLT
Hui Liu, Hong Kong

418.7 Effect of prolonged cold ischemia on intragraft gene expression profiles
Enver Akalin, United States

418.8 Expression of DAP12 and its triggering co-receptor TREM2 plays a key role in regulation of liver DC function and control of liver ischemia-reperfusion injury
Toshimasa Nakao, United States

09:45-11:15 Oral Abstract Session (Donation & Procurement) N-105

419 - Maximizing Organ Utilization

Chairs: Kristina Krmpotic, Canada and Katja Empson, United Kingdom

419.1 Hard-to-place kidney offers: Granular examination of donor risk factors for discard
Reinier Narvaez, United States

419.2 Exploring the viability of kidneys discarded in the US: A comparison of kidney utilization patterns and outcomes in the US and France
Olivier Aubert, France

419.3 Allograft and patient outcomes of a tumourectomized kidney transplant program: the Western Australia experience
Bulang He, Australia

419.4 Transplantation of kidneys from DCD and DBD donors who died after ligature asphyxiation: The UK experience
Patrick B. Trotter, United Kingdom

419.5 The extra corporeal membrane oxygenation (ECMO) in the deceased donors after brain death with severe hemodynamic instability allow to optimize the viability of organs procured for transplantation
KE Qin, People’s Republic of China

419.6 Does acute kidney injury contraindicate transplantation of kidneys from very small pediatric donors? Single-center analysis of 68 en bloc kidney transplants from donors ≤15 kg
Christoph Troppmann, United States

419.7 Outcomes from livers transplanted from deceased donors with end-stage renal disease
Marty T. Sellers, United States

419.8 High risk donor kidneys should be used in pediatric kidney transplant recipients
Malcolm MacConmara, United States

419.9 Altered expression of inflammation genes in preimplantation kidney biopsies of extended criteria donors
Mario M. Abbud-Filho, Brazil
TUESDAY, JULY 3, 2018

09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)  N-106
420 - Immune Monitoring

Chairs: Carla C. Baan, Netherlands and Marcos Lopez Hoyos, Spain

420.1 Plasma donor-derived cell-free DNA quantification by massively multiplex PCR distinguishes kidney transplant acute rejection
Minnie M. Sarwal, United States

420.2 HEARTBIT: a novel biosignature for detection of acute cellular rejection of heart allografts
Ji-Young Kim, Canada

420.3 A signature of gene expression in peripheral blood that enables earlier detection of acute rejection in kidney transplant recipients
Maria P. Hernandez-Fuentes, United Kingdom

420.4 Inclusion of CD8 monitoring improves the prognostic capacities of the kidney transplant failure score
Lola Jacquemont, France

420.5 Urinary TIMP-2 predicts the presence and duration of delayed graft function in DCD kidney transplant recipients
Johan W. de Fijter, Netherlands

420.6 Urinary C-X-C motif chemokines 13 is a noninvasive biomarker of antibody-mediated renal allograft rejection
Dajin Chen, People's Republic of China

420.7 Donor-specific cell-free DNA as an emerging biomarker of organ rejection after liver transplantation
Su Kah Goh, Australia

09:45-11:15 Oral Abstract Session (Complications)  N-107/108
421 - Kidney Complications

Chairs: Rafael Reyes-Acevedo, Mexico and Hiroto Egawa, Japan

421.1 DCD and AKI allografts offer a valuable platform to study molecular pathways underlying successful adaptive repair of the kidney after damage
Giuseppe Orlando, United States

421.2 Distal abdominal aorta could serve as an outflow tract for en bloc kidney transplantation from infant donors with extremely low body weight
Helong Dai, United States

421.3 The effect of perioperative antiplatelet / anticoagulant therapy on the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation - a dual center retrospective cohort study of 2000 kidney transplant recipients
Tamar A.J. van den Berg, Netherlands

421.4 Comparison of removing double-J stent with and without cystoscopy in kidney transplant patients: A randomized clinical trial
Mohammad Nadjafi-Semnani, Iran (Islamic Republic of)

421.5 Searching for new biomarkers more specific for graft loss after renal transplantation by thrombosis: IgA aB2GPI CIC
Manuel Serrano Blanco, Spain

421.6 Pre-transplant antibodies IgA anti Beta 2 Glycoprotein I: A new predicto of early graft thrombosis after renal transplantation in the real medicine setting. An observational, multicenter and prospective study
Manuel Serrano Blanco, Spain

421.7 Comparative analysis of postoperative complications after kidney transplantation: Uncontrolled DCD vs DBD grafts, are they the same?
Felix Guerrero-Ramos, Spain

421.8 Angioplasty versus medical treatment of transplant renal artery stenosis: An observational prospective study
Kajohnsak Noppakun, Thailand

421.9 Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice
Jose Maria Morales, Spain
TUESDAY, JULY 3, 2018

SCIENTIFIC PROGRAM

09:45-11:15 Oral Abstract Session (Education) N-111
422 - Innovations in Transplant Education I

Chairs: Ruth Sapir-Pichhadze, Canada and Christiane Kugler, Germany

422.1 Latin American and Caribbean Transplantation Society (STALYC) update online interactive courses program
Alejandro Niño-Murcia, Colombia

422.2 Integrating outreach for different aspects of chronic kidney disease care: A TTS transplantation leadership development series project
Kenneth J. Woodside, United States

422.3 Teaching principles of deceased organ donation through a massive open online course - it’s place in the world
David A. Thomson, South Africa

422.4 Retrospective study of the training visits modality: a cooperative expertise exchange program in China between China organ transplantation development foundation and donation and transplantation institute Barcelona
Entela Kondi, Spain

422.5 Knowledge improvement results of the European-mediterranean postgraduate program on organ donation and transplantation project (EMPODaT): A 3 years’ training project in Egypt, Lebanon and Morocco
Chloe Ballesté, Spain

422.6 Training and social awareness for increasing organ donation in the European union and neighbouring countries: EUDONORGAN
Martí Manyalich, Spain

422.7 Efficacy of at-home transplant education on transplant knowledge and pursuit in low-income and black dialysis patients with varying educational characteristics
Amy Waterman, United States

422.8 The impact on attitude toward organ donation of an educational intervention for teenagers involving the creation of short films
Javier Almela, Spain

422.9 Experiences and challenges in an NGO run organ donation helpline
Pallavi Kumar, India

09:45-11:15 Mini-Oral Abstract Session (Transplant Immunosuppression) N-112
423 - Novel Aspect of IS and VCA

Chairs: Vijay S. Gorantla, United States and TBA

423.1 Evaluation of immune responses following whole eye transplantation
Fatih Zor, United States

423.2 Application of mass cytometry for analysis of the alloimmune response in a model of vascularized composite allotransplantation
Sheri Krams, United States

423.3 The impact of topical immunosuppressive treatment on functional characterization of skin dendritic cell subpopulations in vascularized composite allotransplantation
Wensheng Zhang, United States

423.4 Burden of infectious complications after upper extremity allotransplantation: A matched cohort study
Anne Conrad, France

423.5 Ex vivo expanded regulatory T cells combined with short-term costimulation blockade prevent rejection of vascularized composite allografts
Giorgio Raimondi, United States

423.6 Monitoring of arterial vessels in upper extremity allotransplantation
Palmina Petruzzo, France

423.7 mTOR inhibitors maintain low levels of immune activation, immune senescence and EBV load in kidney transplant patients
Lucrezia Furian, Italy

423.8 Minocycline prolongs murine cardiac allograft survival through suppression of acute rejection
Karen L. Keung, Australia

423.9 Accumulated experience with sirolimus in pediatric intestinal transplantation
Alba Bueno, Spain

423.10 Development of post-transplant DSA in adult liver transplant patients from the ITN A-WISH trial
Vadim Jucaud, United States

Teresa Vazquez, Spain

423.12 The MADELEINE (coMbined tAcrolimus anD EveroLimus Early ImmuNosupprEssion) study: Pharmacokinetic evaluation
Thomas Jouve, France
09:45-11:15 Oral Abstract Session (Cellular and Regenerative Therapies)

424 - Cellular Therapies on the way to clinical application

N-115/116

424.1 “First-in-Human” clinical trial employing adoptive transfer of autologous thymus-derived Treg cells (thyTreg) to prevent graft rejection in heart-transplanted children

Rafael Correa-Rocha, Spain

424.2 NK cells differentiated from hematopoietic stem cells exert anti-HCC and anti-HCV activities similar to those of peripheral blood-propagated NK cells

Yuka Tanaka, Japan

424.3 Monocytic cells phagocytose therapeutic mesenchymal stem cells, which induces polarization, relocation and immune regulation

Jesus M. Sierra Parraga, Netherlands

424.4 The results of pilot study of the mesenchymal stem cells efficiency for induction of immunosuppressive therapy in the early postoperative period after kidney transplantation.

Sergey Korotkov, Belarus

424.5 Regulatory dendritic cell (DCreg) cell infusion in living donor liver transplantation

Angus W. Thomson, United States

424.6 Co-stimulatory modulation of human regulatory T cells for enhanced immunotherapy

Rebecca C. Arroyo Hornero, United Kingdom

424.7 Rapamycin-based expansion of natural CD8+Tregs for cell therapy

Séverine Bézie, France

424.8 A comparison of the transplant efficiency between intraportal and intrasplenic procedures in hepatocyte transplantation

Hiroyuki Ogasawara, Japan

424.9 A phase-i clinical trial of donor-derived MIC cell infusion for the induction of donor-specific hyporesponsiveness after living donor kidney transplantation (TOL-1 study)

Christian Morath, Germany

09:45-11:15 Oral Abstract Session (Histocompatibility)

425 - Antibodies and Allograft Outcomes

N-117/118

425.1 An increase in low-grade spot urine protein excretion during the first year after kidney transplantation associates with subclinical de-novo donor-specific antibodies and microvascular inflammation at 1-year surveillance biopsies

Gregor Milnišek, Slovenia

425.2 Antibody-mediated rejection with and without HLA donor-specific antibodies in kidney-transplantation

Marta Crespo Barrio, Spain

425.3 Correlation between pre-transplant bead-based screening of anti-HLA antibodies and single antigen arrays

Renaud Snanoudj, France

425.4 Unmasking uncertain results after anti-HLA antibody screening in patients on waiting list

David San Segundo, Spain

425.5 Broad HLA mismatches and epitope mismatches: Experience of the one transplantology centre

Aleksei B. Zulkarnaev, Russian Federation

425.6 Human neutrophil antibodies are associated with severe early rejection in kidney transplant recipients

Timothy Key, United Kingdom

425.7 False-positive flow-cytometric T cell crossmatch caused by blood type antigen expressed on lymphocytes in ABO incompatible kidney transplantation

Daiki Iwami, Japan

425.8 Shortened cold ischemia time and reduced incidence of delayed graft function for kidney transplants through enhanced tissue compatibility testing

Jouni Lauronen, Finland

425.9 Antibody analysis of 4176 candidates waiting for kidney transplantation discover the hierarchy of antibody-provoking HLA types that warrant matching in kidney transplantation

Raja Rajalingam, United States

11:15-11:45 Coffee Break / Poster Viewing / Visit Exhibitors

Hall 10 – Exhibition

11:15-11:45 Transplantation Direct

Hall 10 – TTS Innovative Studio in TTS booth

430.1 Edward K. Geissler, Germany
11:45-13:15  Plenary Session 2
435 - Future Developments in Transplantation - From Immunotherapy to Tissue Engineering

Facilitator: Marcelo Cantarovich, Canada

435.1  The development and function of Treg
Abul K. Abbas, United States

435.2  CAR T cells - lesson learned from cancer immunotherapy
Marcela V. Maus, United States

435.3  Designing natural and synthetic immune tissues
Jonathan S. Bromberg, United States

13:15-14:45  Lunch Break

13:30-14:30  Corporate Symposium
440 - Kidney & Liver Hypothermic Machine Perfusion: The Role of Oxygen
See page 29 for details.

13:30-14:15  Lunch and Learn (#LL2 search on WebApp) Retiro Room (NCC)
450 - Lunch and Learn 2 (registration required)

450.1  Xenograft tolerance
Megan Sykes, United States

450.2  Different strategies for beta cell replacement for the cure of Type 1 diabetes
Peter G. Stock, United States

450.3  Advocacy of pancreas and islet transplantation
Frantisek Saudek, Czech Republic

450.4  Meeting the demand for organ availability
Stefan G. Tullius, United States

450.5  Cellular therapies in the management of liver disease and liver transplantation
Anil Dhawan, United Kingdom

450.6  Blocking inflammation for cell and organ tolerance
Maria Koulmanda, United States

450.7  General adolescent issues
Miriam Kaufman, Canada

450.8  Measuring OPO performance – What’s the right denominator and parameters?
Howard M. Nathan, United States and Richard Hasz, United States

450.9  Preparation of children for renal transplantation
Stephen D. Marks, United Kingdom

450.10  Why commercialism is difficult to eradicate
Adibul Hasan Rizvi, Pakistan

450.11  Preservation by machine perfusion
Peter J. Friend, United Kingdom

450.12  Preparing your patient for transplant & prevention of infection after transplant: Antibiotics, antivirals, vaccines
Camille Kotton, United States

450.13  Toward HLA epitope matching in clinical transplantation
Frans HJ Claas, Netherlands

450.14  Robotic kidney transplantation: Current status, an update and future perspectives
Pranjal Modi, India

450.15  Immunosuppression in avoidance of recurrent malignancies after liver transplantation
John J. Fung, United States

450.16  Mentorship Roundtable
Hiroto Egawa, Japan

450.17  Mentorship Roundtable
Gabriel E. Gendollesi, Argentina

450.18  Manuscript Decisions
Transplantation Journal Editors

450.19  Immunobiogram® a novel precision medicine tool to help guidance of immunosuppression in renal transplantation. Results of “BH-Pilot” proof-of-concept clinical study
Isabel Portero, Spain and Julio Pascual, Spain
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:45</td>
<td>Plenary Speaker Interviews</td>
<td>Hall 10 – TTS Innovative Studio in TTS booth</td>
</tr>
<tr>
<td>13:45-14:00</td>
<td>Getting Motivated Post-Transplant (WTGF)</td>
<td>Hall 10 – TTS Innovative Studio in TTS booth</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>State-of-the-Art Session (Liver)</td>
<td>N-101</td>
</tr>
<tr>
<td></td>
<td>460 - Outcome Driven Liver Transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Hiroto Egawa, Japan and Johann Pratschke, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>460.1 In depth cardiac Pre-It investigation: A necessity to improve outcome</td>
<td>Samuel A. Irefin, United States</td>
</tr>
<tr>
<td></td>
<td>460.2 Sarcopenia and denutrition: How to tackle these major determinants of outcome</td>
<td>Toshimi Kaido, Japan</td>
</tr>
<tr>
<td></td>
<td>460.3 Pre-L-T antiviral treatment (HCV, HBV, and HIV): Improving outcomes with and/or without liver transplantation</td>
<td>Christian P. Strassburg, Germany</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>State-of-the-Art Session (Infectious Diseases)</td>
<td>N-102</td>
</tr>
<tr>
<td></td>
<td>461 - Improving Outcomes with Common Post-Transplant Infections</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Clarisse Machado, Brazil and Juan F. Delgado, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>461.1 Prevention and management of CMV: Current guidance</td>
<td>Camille Kotton, United States</td>
</tr>
<tr>
<td></td>
<td>461.2 Multi-drug resistant bacterial infections: Understanding epidemiology and management of challenging infections</td>
<td>Jose Maria Aguado, Spain</td>
</tr>
<tr>
<td></td>
<td>461.3 Infectious complications of thoracic transplantation: The challenge of ECMO, LVAD and thoracic transplantation</td>
<td>Silvia Vidal Campos, Brazil</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>State-of-the-Art Session (Kidney)</td>
<td>N-103</td>
</tr>
<tr>
<td></td>
<td>462 - Identifying the “At Risk” Renal Graft</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Christophe Legendre, France and Jose Maria Morales, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>462.1 The impact of disease recurrence on graft outcome</td>
<td>Germaine Wong, Australia</td>
</tr>
<tr>
<td></td>
<td>462.2 The development of DSA - who is at risk and what is the outcome</td>
<td>Alexandre Loupy, France</td>
</tr>
<tr>
<td></td>
<td>462.3 Histological predictors of premature graft loss</td>
<td>Brian J. Nankivell, Australia</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>State-of-the-Art Session (Basic Sciences and Translational Sciences)</td>
<td>N-104</td>
</tr>
<tr>
<td></td>
<td>463 - Engineering Immune System for Transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Shane T. Grey, Australia and Julien Zuber, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>463.1 Trained immunity in transplantation</td>
<td>Jordi Ochando, Spain</td>
</tr>
<tr>
<td></td>
<td>463.2 Antigen specific tregs - what is required for translation to the clinic</td>
<td>Megan Levings, Canada</td>
</tr>
<tr>
<td></td>
<td>463.3 Modulation of macrophage subsets to promote transplant survival</td>
<td>Xian C. Li, United States</td>
</tr>
</tbody>
</table>
14:45-16:15 State-of-the-Art Session (Pancreas & Islet) N-105

464 - Beta-Cell Replacement Therapy: Current Outcomes and Future Landscape

Chairs: Daniel Casanova, Spain and Thierry Berney, Switzerland

464.1 Islet transplantation alone vs. solitary pancreas transplantation: An outcome driven choice? Peter G. Stock, United States

464.2 SPK transplantation vs. living donor kidney transplantation alone: An outcome driven choice? Adam D. Barlow, United Kingdom

464.3 Future landscape: Defining a successful outcome using stem cells as a source of insulin producing cells Lorenzo Piemonti, Italy

14:45-16:15 State-of-the-Art Session (Transplant Immunosuppression) N-106

465 - Delivering Co-stimulation Blockade to the Clinic

Chairs: Lionel Rostaing, France and TBA

465.1 The role for inhibition of the CD40-CD154 pathway in coxtimulation blockade Flavio Vincenti, United States

465.2 New uses of Belatacept in kidney transplantation Oriol Bestard Matamoros, Spain

465.3 Selective Anti-CD28 blockade: Finally getting there? Lionel Rostaing, France

14:45-16:15 State-of-the-Art Session (Declaration of Istanbul) N-107/108

466 - A Multidisciplinary Approach in the Fight Against Organ Trafficking and Human Trafficking for Organ Removal

Chairs: Dominique E. Martin, Australia and Elmi Muller, South Africa

466.1 The role of clinicians in preventing and combatting organ trafficking Benita Padilla, Philippines

466.2 The role of prosecutors Gilad Erlich, Israel

466.3 The role of multinational organisations Marta López-Fraga, France

14:45-16:15 State-of-the-Art Session (Sex and Gender in Transplantation) N-111

467 - Why Does Sex Matter in Transplantation?

Chairs: Elaine F. Reed, United States and Ruth Sapir-Pichhadze, Canada

467.1 Sex on the bench Deborah J. Clegg, United States

467.2 Recipient sex related factors impacting transplant outcome Bethany Foster, Canada

467.3 Considering sex and gender in transplantation research and clinical care Christine S. Falk, Germany

14:45-16:15 State-of-the-Art Session (Transplantation Nursing) N-115/116

468 - Improving Transplant Outcomes: Assessing Transplant Candidates’ Risk

Chairs: Sandra A. Cupples, United States and Grainne M. Walsh, United Kingdom

468.1 Assessing transplant candidates’ risk: Frailty Mara Ann McAdams DeMarco, United States

468.2 Assessing transplant candidates’ risk: Nonadherence Miriam Kaufman, Canada

468.3 Assessing transplant candidates’ risk: Poor social support and health literacy Fabienne Dobbels, Belgium
14:45-16:15  State-of-the-Art Session (Anesthesia Management and Critical Care)  
469 - Perioperative Management: The Missing Link  

Chairs: Margaux N. Mustian, United States and Claus Niemann, United States

469.1 Bridging the failing recipient candidate in the ICU  
Catherine Paugam-Burtz, France

469.2 Back from the brink: Management of sepsis in the transplant recipient  
Karl K. Young, Hong Kong

469.3 Cardiac evaluation for abdominal organ transplant: Angiography for all or overrated?  
James Findlay, United States
16:30 to 17:30 - Campfire Sessions and Poster Session 2

16:30-17:30 Campfire Session (Kidney)

**C490 - Recipient Management**

**Chairs:** Germaine Wong, Australia and Flavio Vincenti, United States

- **C490.1** Impact of donor-specific anti-HLA antibodies on chronic-active antibody-mediated rejection histological phenotype and outcome is modulated by non-adherent behavior of kidney graft recipients
  
  **Jose Anjos Malheiro**, Portugal

- **C490.2** Differing opinions regarding diseased kidney allocation between patients and physicians and also among physician's specialties
  
  **Javier Dominguez**, Chile

- **C490.3** The Spanish prioritization system for highly sensitized patients: A successful tool
  
  **Maria Oliva Valentin**, Spain

- **C490.4** Modified DFPP eliminates ABO blood type IgG antibody with preserving fibrinogen before ABO-incompatible kidney transplantation
  
  **Daiki Iwami**, Japan

- **C490.5** Organ exchange programme based on virtual crossmatch increases access to kidney transplantation of highly sensitized patients in Andalusia. Andalusian work group for highly-sensitized patients
  
  **Antonia Alvarez Marquez**, Spain

16:30-17:30 Campfire Session (Ethics, Community, Economics)

**C491 - Ethical Challenges in Donation and Transplantation – Global Perspectives**

**Chairs:** Gabriel Danovitch, United States and Francis L. Delmonico, United States

- **C491.1** Transplantation tourism and recipients perspectives and experience
  
  **Issa Al Salmi**, Oman

- **C491.2** Ethical dilemmas in deceased organ donation and allocation – an emerging challenge in India
  
  **Sunil Shroff**, India

- **C491.3** Transplant volumes in China
  
  **David Matas**, Canada

- **C491.4** 10 years after Istanbul Declaration, achievements and failures
  
  **Mustafa S. A. Almousawi**, Kuwait

- **C491.5** Full body transplantation, is it allowed?
  
  **Kristoff Van Assche**, Canada

- **C491.6** Unique challenges in the deceased donation programme in India
  
  **Sunil Shroff**, India

16:30-17:30 Campfire Session (Complications)

**C492 - Infections and Malignancies**

**Chairs:** Richard D.M. Allen, Australia and TBA

- **C492.1** Underlying renal disease with increased infection risk is associated with inferior patient survival
  
  **Natalie Otto**, Germany

- **C492.2** The role of KIR2DS4 polymorphisms in BK virus and acute rejection following renal transplantation
  
  **Patrick B. Trotter**, United Kingdom

- **C492.3** Cancer incidence after kidney transplantation in Saudi Arabia
  
  **Hassan Ali Aleid**, Saudi Arabia

- **C492.4** Posttransplant malignancies in adult renal and hepatic transplant patients
  
  **Ebru H. Ayvazoglu Soy**, Turkey

- **C492.5** Outcomes of screening for BK viraemia and BK nephropathy in renal transplant recipients: a single centre cohort study
  
  **Kushani C. Jayasinghe**, Australia

- **C492.6** Primary central nervous system post-transplantation lymphoproliferative disorder: A case series of renal transplant recipients
  
  **Kushani C. Jayasinghe**, Australia
16:30-17:30  Campfire Session (Infectious Diseases)  
C493 - Viral Hepatitis and BK Post-Transplant  
Hall 10 – Exhibition  

Chairs: Hans H. Hirsch, Switzerland and Julián de la Torre Cisneros, Spain  

C493.1 Reducing immunosuppression preserves graft function in patients with BKVN - a single centre study  
Ejaz Ahmed, Pakistan  

C493.2 Staged screening of BK virus-associated nephropathy using urine cytology and serum quantitative polymerase chain reaction: Hong Kong experience  
Maggie K. M. Ma, Hong Kong  

C493.3 The use of sofosbuvir (SOF)-containing direct antiviral agents (DAA)-based regimens requires increase in tacrolimus (Tac) doses in kidney transplant (KT) recipients with hepatitis C virus (HCV) infection  
Natalia I. Polanco, Spain  

C493.4 Effectiveness of sofosbuvir and ribavirin for eradicating hepatitis C virus in renal transplant recipients in a resource constrained country  
Nasir Hassan Luck, Pakistan  

C493.5 Post transplant de novo hepatitis C virus infection in renal transplant recipients: Its impact on morbidity and mortality  
Nasir Hassan Luck, Pakistan  

C493.6 Clinical outcomes of sofosbuvir-based direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus  
Mohamad M. Alkadi, Qatar  

16:30-17:30  Campfire Session (Basic Sciences and Translational Sciences)  
C494 - Out-of-the-Box  
Hall 10 – Exhibition  

Chairs: Marina Berenguer, Spain and James A. Hutchinson, Germany  

C494.1 Synthetic immunomodulatory biomaterials to improve islet graft survival  
Maria M. Coronel, United States  

C494.2 Beneficial effects of human mesenchymal stromal cells on porcine hepatocyte viability and albumin secretion  
Elisa Montanari, Switzerland  

C494.3 Platelets stimulate liver sinusoidal endothelial cells to secrete interleukin-6 during the early phase of liver regeneration in mice  
Jeremy Meyer, Switzerland  

C494.4 Sex-specific dimorphism in cellular stress response upon mTOR inhibition revealed by podocyte specific RNA sequencing  
Angelika Kusch, Germany  

C494.5 Ex-vivo generation of alloantigen-specific immunomodulatory cells: Elucidating the mechanistical synergy of cell components  
Ming Han Yao, Sweden  

C494.6 Humanization and pre-clinical validation of an anti-HLA-A*02:01 chimeric antigen receptor for use with regulatory T cells to enhance transplant tolerance  
Nicholas AJ Dawson, Canada  

16:30-17:30  Campfire Session (Cellular and Regenerative Therapies)  
C495 - Preclinical Regenerative Medicine and Cellular Therapy  
Hall 10 – Exhibition  

Chairs: Frantisek Saudek, Czech Republic and Toshio Miki, United States  

C495.1 Effect of the isolation procedure and inflammatory cytokines on blood group antigen expression on human hepatocytes in preparation for investigating ABO-incompatible hepatocyte transplantation  
Kazuki Tokodai, Japan  

C495.2 Human urine-derived stem cells could protect renal function by releasing miR-129-5p which targets high-mobility group box-1 (HMGB1) in rat ischemia reperfusion injury model  
Longshan Liu, People's Republic of China  

C495.3 In vivo depletion of dividing donor cells using post-transplant cyclophosphamide can reduce the development of graft-versus-host disease in a humanised mouse model  
Sam R. Adhikary, Australia  

C495.4 Establishment of insulin-producing cells differentiated from human adipose-derived mesenchymal stem cells using a 3D-culture system with xeno-antigen free reagents  
Mitsuo Shimada, Japan  

C495.5 Comparison of continuous normothermic ex vivo kidney perfusion to dynamic and static hypothermic preservation techniques in porcine kidneys donated after cardiac death  
Matyas Hamar, Canada
### Campfire Session (Pancreas & Islet)
**C496 - Pancreas Transplantation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Session Chair(s)</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:30</td>
<td>Campfire Session (Pancreas &amp; Islet)</td>
<td>Lorenzo Piemonti, Italy and Thomas Kay, Australia</td>
<td>Franka Messner, Austria</td>
</tr>
<tr>
<td></td>
<td>Influence of donor and recipient sex on the outcome after pancreas transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Challenges in calcineurin inhibitor (CNI) withdrawal in conjunction with co-stimulation blockade in simultaneous pancreas and kidney transplant (SPK)</td>
<td>Casey J. Ward, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kidney failure is associated with worse pancreas graft survival in simultaneous pancreas and kidney transplantation</td>
<td>Peter Girman, Czech Republic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pseudocyst of pancreas transplant allograft, a rare complication</td>
<td>Jeffrey M. Stern, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kidney failure is associated with worse pancreas graft survival in simultaneous pancreas and kidney transplantation</td>
<td>Peter Girman, Czech Republic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duodenal leaks after pancreas transplantation. Incidence, management and outcome</td>
<td>Oana Anisa Nutu, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk factors for thrombosis in simultaneous pancreas-kidney transplants performed over ten years at westmead hospital</td>
<td>Sara Shahrestani, Australia</td>
<td></td>
</tr>
</tbody>
</table>

### Campfire Session (Donation & Procurement)
**C497 - Variety of Topics**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Session Chair(s)</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:30</td>
<td>Campfire Session (Donation &amp; Procurement)</td>
<td>Haibo Wang, People’s Republic of China and Eduardo Rocha, Brazil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Center variation in six-month post-donation follow-up of obese living kidney donors</td>
<td>Deirdre Sawinski, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cold preservation with a hyperbranched polyglycerol-based solution improves functional recovery of kidney transplants in a pig model</td>
<td>Caigan Du, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel organ transplantation technology for suturing vessels while perfusing organs</td>
<td>Syhei Yoshimoto, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opting out and offers of ‘Alibis’ for potential living kidney donors in US transplant centers</td>
<td>Renata Iskander, Canada</td>
<td></td>
</tr>
</tbody>
</table>

### Campfire Session (Paediatrics)
**C498 - Issues in Paediatric Kidney Transplantation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Session Chair(s)</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:30</td>
<td>Campfire Session (Paediatrics)</td>
<td>Stephen D. Marks, United Kingdom and Stephen Alexander, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Superior renal allograft function with male deceased donors for paediatric renal transplant recipients</td>
<td>Nadeesha L. Mudalige, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Improvement of cardiac functions after renal transplantation in patients with severe cardiac risk: Long term follow-up</td>
<td>Esra Baskin, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The rate of BK virus infection in pediatric renal transplant patients</td>
<td>Esra Baskin, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Living donor liver transplantation for hepatorenal fibrosystic disease in children</td>
<td>Rie Irie, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effects of early post-transplant blood transfusion on graft outcome in pediatric renal transplant recipients</td>
<td>Kaan Gullerooglu, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immune phenotype by flow cytometry of paediatric kidney transplant recipients and healthy adult controls</td>
<td>Elvira Jimenez Vera, Australia</td>
<td></td>
</tr>
</tbody>
</table>
16:30-17:30 Campfire Session (Liver)  
C499 - Liver Living Donor  
Hall 10 – Exhibition

Chairs: Toshimi Kaido, Japan and TBA

C499.1 Development of a mobile application for living liver donors to assist their understandings of a series of preoperative tests  
Noriyo Yamashiki, Japan

C499.2 Clinical outcomes of totally laparoscopic living donor right hepatectomy  
Youngseok Han, Korea

C499.3 The Efficacy of an Artificial Pancreas Device for Achieving Tight Perioperative Glycemic Control in Living Donor Liver Transplantation  
Tota Kugiyama, Japan

C499.4 Pegylated interferon-based versus direct-acting antiviral-based preemptive treatment of HCV after adult living donor liver transplantation  
Sang hyun Kang, Korea

C499.6 Is systemic heparinization necessary during living donor hepatectomy? Short-term and long-term outcomes  
Tae-Yoon Kim, Korea

16:30-17:30 Poster Session 2 - Even Poster Number Presentations  
Hall 10 – Exhibition

Detailed list of all the posters available on page 122
All poster presenters with even poster numbers shall be at their respective poster(s).
### 16:15 to 17:30 - Other Events

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:30</td>
<td>Corporate Symposium N-103 480 - Improving Management of Transplanted Patients with Viral Load Assays and Specific Cell-Mediated Immune Response Monitoring</td>
<td>See page 29 for details.</td>
</tr>
</tbody>
</table>
| 16:30-16:50   | SOTA Speaker Interviews Hall 10 – TTS Innovative Studio in TTS booth                      | 475.1  
                 Megan Levings, Canada  
                 Alexandre Loupy, France  
                 Camille Kotton, United States  
                 Lionel Rostaing, France |
| 16:50-17:05   | Case Competition Presentation 3 Hall 10 – TTS Innovative Studio in TTS booth              | 475.2  
                 The Great Pretender: when what you see, is not what you get. An unusual presentation of lung cancer on a post kidney transplant patient  
                 Bryan Christian Gaza Ilagan, Philippines |
| 17:30-19:00   | Women in Transplantation Networking Event (ticketed event) Colón Room (IFEMA, 2nd Floor) |         |
| 20:00-23:00   | Young Investigators Networking Event (ticketed event) Azotea del Círculo: C/Marqués de Casa Riera nº 2 |         |
DETAILED PROGRAM

Wednesday, July 4, 2018
08:30-09:30 Oral Abstract Session (Liver) N-101

**500 - Liver Recipient Selection and Malignancies**

**500.1** Delta PD-1 expressed m2 macrophages promote liver tumor recurrence after transplantation

_Wai Ho Oscar Yeung_, Hong Kong

**500.2** Serological tumor viability risk index comprising alpha-fetoprotein and C-reactive protein identifies eligible liver transplant patients with hepatocellular carcinoma beyond Milan and up-to-seven criteria

_Arno Kornberg_, Germany

**500.3** Proposal for a worldwide usable score for the prediction of recurrence and intention-to-treat survival after liver transplantation in patients with hepatocellular cancer: A West-East analysis on 1,903 patients

_Quirino Lai_, Italy

**500.4** Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis

_Quirino Lai_, Italy

**500.5** Utility of liquid biopsy (CTCs) after liver transplantation in cirrhotic patients with hepatocarcinoma

_David Ferreras_, Spain

**500.6** East vs West: Predictors of oncologic outcomes following DD and LD liver transplantation for HCC

_Varvara A. Kirchner_, United States

---

08:30-09:30 Oral Abstract Session (Kidney) N-102

**501 - Antibody-Mediated Rejection 2**

**501.1** Anti-angiotensin II type 1-receptor antibodies (AT1R-Ab) induce a specific phenotype of rejection distinct from HLA antibody-mediated rejection

_Carmen Lefaucheur_, France

**501.2** Banff survey on antibody mediated injury in kidney allografts: Diagnostic misclassification affects the treatment approach

_Carrie A. Schinstock_, United States

**501.3** Rearrangement of the endothelial cell cytoskeleton in glomerular and peritubular capillaries (PTCS) following antibody-mediated rejection (AMR): Its significance on the development of transplant glomerulopathy and interstitial fibrosis

_B. Handan Ozdemir_, Turkey

**501.4** Intimal arteritis associated with microvascular inflammation even in the absence of donor-specific antibodies might result into early chronic rejection

_Marek Novotny_, Czech Republic

**501.5** Do C1q-positive donor specific antibodies have prognostic effect in patients with resistant antibody-mediated rejection treated with bortezomib? Single-centre experience

_Janka Slatinska_, Czech Republic

---

08:30-09:30 Oral Abstract Session (Kidney) N-105

**502 - Recipients Issues**

**502.1** The role of proteinuria, paricalcitol and vitamin D in the development of post-transplant diabetes mellitus after kidney transplantation

_Ivana Dedinska_, Slovakia (Slovak Republic)

**502.2** A high abdominal aortic calcification score by dual x-ray absorptiometry (DXA) is associated with cardiovascular events after kidney transplantation

_Stan Benjamens_, Netherlands

**502.3** Significant difference between proteasome and immunoproteasome inhibition in acute kidney injury

_Feng Han_, People's Republic of China

**502.4** Mid-term outcome of donor specific antibody positive deceased donor kidney transplantation with peri-transplant desensitization

_Klara Osickova_, Czech Republic

**502.5** The clinical significance of pretransplant C1q assay status in positive crossmatch kidney transplantation

_Soo Jin Kim_, Korea

**502.6** Partial immunological tolerance induction with extracorporeal photopheresis

_Aleksei B. Zulkarnaev_, Russian Federation
WEDNESDAY, JULY 4, 2018

SCIENTIFIC PROGRAM

08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences) N-106
503 - Preclinical Studies

Chairs: Wayne J. Hawthorne, Australia and Lionel Rostaing, France

503.1 Induction of tolerance for long-term liver allograft survival without immunosuppression in cynomolgus monkeys
Erik Berglund, United States

503.2 Tomotherapy and hematopoietic stem cells for tolerance to kidney transplants in rhesus macaques
Dixon B. Kaufman, United States

503.3 Induction of tolerance to renal allografts in non human primates by concomitant donor-matched vascularized osteomyocutaneous allotransplantation
Xin Xiao Zheng, People’s Republic of China

503.4 Megadose bone marrow and regulatory t cells for the induction of immune tolerance in non-human primates through durable mixed hematopoietic chimerism across MHC-barriers
Paula Alonso Guallart, United States

503.5 Enhancement of intrinsic apoptosis via Bcl-2 inhibition promotes induction of robust mixed chimerism and renal allograft tolerance without myelosuppression in nonhuman primates
Tatsuo Kawai, United States

503.6 Long-term nonhuman primate renal allograft survival without ongoing immunosuppression in recipients of delayed donor bone marrow transplantation
Kiyohiko Hotta, Japan

08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences) N-107/108
504 - Kidney Biopsy

Chairs: Stefan G. Tullius, United States and Alexandre Loupy, France

504.1 Overexpression of BAX, NOL3, and XIAP poptotic genes participates in calcineurin inhibitors nephrotoxicity: New insights into chronic allograft dysfunction
Gloria Queipo, Mexico

504.2 Isolated V-lesion early after kidney transplantation may not truly represent a rejection
Mariana Wohlfahrtova, Czech Republic

504.3 In kidney allografts inflammation in scarred areas is not a reflection of chronic active T cell-mediated rejection
Philip F. Halloran, Canada

504.4 Transcriptional factor FOXP3 in renal allograft biopsies predicts tolerance in non-human primates
Masatoshi Matsunami, United States

504.5 Surveillance biopsy: Boon or bust?
Roslyn B. Mannon, United States

504.6 A molecular approach to chronic T-cell mediated rejection
Enver Akalin, United States

08:30-09:30 Morning Symposium (Anesthesia Management and Critical Care) N-111
505 - Organ Donor Management - Impact of Critical Care and Outcome

Chairs: Axel Rahmel, Germany and Claus Niemann, United States

505.1 Organ donation: Changing perspectives in critical care - donor management goals
Darren Malinoski, United States

505.2 Critical care training and education for donor coordinators
Sharon Swain, United States

505.3 Donation after cardiac death- the role of critical care
Martí Manyalich, Spain

08:30-09:30 Morning Symposium (Registries) N-112
506 - What is New in the World of Transplant Registries?

Chairs: Caner Süsal, Germany and Jongwon Ha, Korea

506.1 National Transplant Registry of India
Vivek Kute, India

506.2 China
Haibo Wang, People’s Republic of China

506.3 Korean Organ Transplant Registry (KOTRY)
Curie Ahn, Korea
08:30-09:30  Morning Symposium (Vascularized Composite Allotransplantation) N-113
507 - Innovation and Insights in VCA

Chairs: Benoit Lengele, Belgium and Vijay S. Gorantla, United States

507.1  Whole Eye Transplantation - Hope or Hype?
Fatih Zor, United States

507.2  Immunopathology of VCA Rejection - Knowns and Unknowns
Alice Koenig, France

Panel discussions

08:30-09:30  Morning Symposium (Ethics, Community, Economics) N-114
508 - A Discussion of Informed Consent with Living and Deceased Donation

Chairs: Francis L. Delmonico, United States and Peter G. Stock, United States

508.1  The discretionary living kidney donor
Gabriel Danovitch, United States

508.2  Marginal deceased donor
John S. Gill, Canada

508.3  High risk donors
Paolo A. Grossi, Italy

Panel discussions

08:30-09:30  Morning Symposium (Pancreas & Islet) N-115/116
509 - Beta Cell Replacement of the Future

Chairs: Peter J. Friend, United Kingdom and Thierry Berney, Switzerland

509.1  Will gene editing carry pig islets to the clinic
Marc Guell, United States

509.2  Advanced insulin delivery systems can they cure patients
Thomas Kay, Australia

509.3  Developing delivery approaches for stem cell transplantation
Shane T. Grey, Australia

08:30-09:30  Morning Symposium (Infectious Diseases) N-117/118
510 - Challenging Cases in Transplant Infectious Diseases: Pushing the Boundaries of Donor and Recipient Outcomes

Chairs: Nassim Kamar, France and Michael G. Ison, United States

510.1  Polyoma viruses (BK) - Case presenter
Diana Florescu, United States

510.2  Polyoma viruses (BK) - Case discussant
Hans H. Hirsch, Switzerland

510.3  Marginal donor - Case presenter
Hannah Kaminski, France

510.4  Marginal donor - Case discussant
Francisco M. Marty, United States

510.5  Nocardia - Case presenter
Edward A. Dominguez, United States

510.6  Nocardia - Case discussant
Cameron Wolfe, United States
09:45-10:45 Oral Abstract Session (Liver)  
515 - Allocation and Access  

**N-101**

**Chairs:** Valentín Cuervas-Mons, Spain and John P. Roberts, United States

**515.1** Survival benefit of liver transplantation in the MELD-Na era  
*Lucy C. Chau*, United States

**515.2** Introduction of share 35 interregional allocation for high MELD liver transplant waiting list patients in Australia and New Zealand  
*Micahel A. Fink*, Australia

**515.3** Hospitalization and life support before liver transplantation – easily available predictors for post-transplant patient survival  
*Leke Wiering*, Germany

**515.4** Trends in transplantation with older liver donors in the United States  
*Christine E. Haugen*, United States

**515.5** MELD based allocation deteriorates patient survival without improving waiting list mortality in a low donor area  
*Paul Viktor Ritschl*, Germany

**515.6** Ethnic and age disparities in outcomes among liver transplant waitlist candidates  
*Margaux N. Mustian*, United States

09:45-10:45 Oral Abstract Session (Kidney)  
516 - Chronic Kidney Dysfunction  

**N-102**

**Chairs:** Marcelo Cantarovich, Canada and Francesc Moreso Mateos, Spain

**516.1** Identifying the specific causes of kidney allograft loss: A population based study  
*Charlotte Loheac*, France

**516.2** Role of C1q-binding donor-specific anti-HLA antibodies in premature and accelerated kidney allograft interstitial fibrosis  
*Denis Glotz*, France

**516.3** Inflammation in fibrotic areas (i-IF/TA) identifies a T cell-mediated rejection component of IF/TA with poor kidney allograft outcome  
*Yassine Bouatou*, France

**516.4** Prediction of renal allograft chronic rejection using a model based on contrast enhanced ultrasonography  
*Cheng Yang*, People’s Republic of China

**516.5** Identifying the specific causes and the determinants of outcome in kidney recipients with transplant glomerulopathy: A multicenter study  
*Olivier Aubert*, France

**516.6** Potential novel proteomic biomarkers for acute T cell-mediated rejection in kidney transplant recipients  
*Jeong-Hoon Lim*, Korea

09:45-10:45 Oral Abstract Session (Kidney)  
517 - Immunosuppression 2  

**N-103**

**Chairs:** Julio Pascual, Spain and TBA

**517.1** The Athena Study: 12 months safety and efficacy data for everolimus combined with tacrolimus or cyclosporine compared to a standard tacrolimus-mycophenolate regimen in de novo kidney transplant patients  
*Bjorn Nashan*, Germany

**517.2** Different effects on transitional B lymphocytes after conversion to mTOR inhibitors or steroid withdrawal in renal transplant recipients  
*Laura Llinàs Mallol*, Spain

**517.3** Outcomes on allograft function after 12 months with everolimus plus either tacrolimus or cyclosporine compared to a standard tacrolimus-MPA regimen in de novo renal transplant recipients: The Athena Study  
*Peter Schenker*, Germany

**517.4** Long term exposure to high variability of tacrolimus trough levels and exposure to sub therapeutic drug levels predicts worse survival after kidney transplantation  
*Ruth Rahamimov*, Israel

**517.5** Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and their influence on tacrolimus pharmacokinetics in renal transplant recipients  
*Zijie Wang*, People's Republic of China

**517.6** Adherence to immunosuppressive medications in renal transplant recipients – different tools capture different patients  
*Marte Theie Gustavsen*, Norway
wednesday, july 4, 2018

09:45-10:45 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences) N-104
518 - Non-Classical Leucocytes

Chairs: Julien Zuber, France and Minnie M. Sarwal, United States

518.1 mTOR inhibitors enhance antitumor activity of liver resident NK cells
Jamilya Saparbay, Japan

518.2 NK cell recognition of peptides encoded by EBV latent cycle proteins
Berenice Mbiribindi, United States

518.3 Helper innate lymphoid cells (hILC) resist immunosuppressive therapy: An observation from kidney and liver transplantation
Elena Gómez Massa, Spain

518.4 Mast cells regulate CD4+ T Cell differentiation in absence of antigen presentation
Hector Rodriguez Cetina Biefer, Switzerland

518.5 Transplantation of tissue-resident lymphocytes
Amy C. Prosser, Australia

518.6 Dendritic cells as a non-invasive immunological biomarker of the late cellular rejection after kidney transplantation
Sergey Korotkov, Belarus

518.7 High levels of monocyte-myeloid-derived suppressor cell frequencies prior kidney transplantation are related with risk of acute rejection
María Iglesias Escudero, Spain

518.8 Dynamics of CD25 positive myeloid derived suppressor cells in solid organ transplanted patients and relationship with rejection
Alberto Utrero-Rico, Spain

09:45-10:45 Oral Abstract Session (Donation & Procurement) N-105

519 - Increasing Deceased Donation

Chairs: Helen I. Opdam, Australia and Darren Malinoski, United States

519.1 A systems-based approach to increasing organs transplanted: One organ procurement organization’s experience
Liz Lehr, United States

519.2 Risk factors of primary non-function using uncontrolled donors after cardiac arrest (uDCD)
Iago Justo, Spain

519.3 Family attitudes, actions, decisions and experiences following implementation of deemed consent and the human transplantation act (Wales) 2013
Leah Mc Laughlin, United Kingdom

519.4 Non-immunologic pairing of kidney transplant donors and recipients: How important is HLA match status?
Amanda J. Miller, Canada

519.5 Success of a “Multicultural Donation Education Program” to increase African-American organ donation in a donor service area with a high African-American population
Ruth D. Bell, United States

519.6 Hard-to-place kidney offers: System-level predictors of discard
Reinier Narvaez, United States
Mini-Oral Abstract Session (Basic Sciences and Translational Sciences)

520 - Regulation and Tolerance

Chairs: Megan Levings, Canada and Adrian E. Morelli, United States

520.1 Immunomodulation with SA-FasL-engineered microgels achieves long-term survival of allogeneic islet grafts
   Haval Shirwan, United States

520.2 CD48 blockade hindered tolerance induction in a Treg dependent allograft tolerance model
   Stephen Alexander, Australia

520.3 Use of splenocytes as stimulators for the ex vivo expansion of T regulatory cells using costimulatory blockade for adoptive
   transfer to solid organ transplant recipients
   Laura Contreras-Ruiz, United States

520.4 MHC-matched a-expressing blood cells induce ABO tolerance in infant and adult mice
   Ibrahim Adam, Canada

520.5 Leukocytes from lung transplant recipients with severe primary graft dysfunction adoptively transfer alloreactivity to vessel
   grafts trans vivo
   Ann-Kathrin Knoefel, Germany

520.6 Deletion of the M33 receptor gene in murine cytomegalovirus reduces levels of cardiac allograft vasculopathy in a murine
   aortic transplant model
   Christian Heim, Germany

520.8 Donor T cells undermine the protective effect of DST + Anti-CD 154 in transplant rejection
   Marcos Iglesias Lozano, United States

Oral Abstract Session (Paediatrics)

521 - Miscellaneous Issues in Paediatric Transplant

Chairs: Bethany Foster, Canada and Eduardo Miñambres, Spain

521.1 CDC high risk livers should be used more frequently in pediatric liver transplantation
   Christine S. Hwang, United States

521.2 Combined en-bloc heart liver transplantation in children with congenital heart disease complicated by cardiac cirrhosis
   Waldo Concepcion, United States

521.3 Results of kidney transplantation in small children
   Sigal Aizner, Israel

521.4 Large volume intraoperative fluid use in small (<20kg) renal transplant recipients is safe?
   Natasha Liow, United Kingdom

521.5 Bridge to heart transplant in pediatric patients. Successful mechanical cardiac support with ventricular assist devices (VAD)
   Gerardo Naiman, Argentina

521.6 Our experience of patients with juvenile nephronophthisis after renal transplantation
   Kaan Gulleroglu, Turkey

Oral Abstract Session (Intestine & Multivisceral Transplantation)

522 - Intestinal Failure, Rehabilitation and Transplant

Chairs: Martin Rumbo, Argentina and Rodrigo Vianna, United States

522.1 Paneth and intestinal stem cells are differentially affected during worsening of acute cellular rejection in small bowel
   transplantation compared to intestinal ischemia reperfusion injury and graft versus host disease
   Melissa E. Pucci Molineris, Argentina

522.2 The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome
   Georgios Bagias, Germany

522.3 Excellent outcomes of children with short bowel syndrome and intestinal failure associated liver disease (IFALD) at children's
   national health system (CNHS), Washington DC
   Clarivet Torres, United States

522.4 Intestinal transplantation: From rescue therapy to standard of care for intestinal failure?
   Emilio Canovai, Belgium

522.5 Ubiquitin ligase MARCH8 attenuates graft versus host disease via regulation of gut epithelial cell surface MHC II expression
   Katie E. Lineburg, Australia

522.6 Comparison of induction and maintenance immunosuppression regimens in intestinal and multivisceral transplant: An analysis
   of the UNOS registry
   Shunji Nagai, United States
**Oral Abstract Session (Cellular and Regenerative Therapies)**  
523 - Regenerative Medicine- New Approaches

**Chairs:** Eiji Kobayashi, Japan and Anil Dhawan, United States

- 523.1 Neonatal cardiovascular progenitor cell clones expressing islet-1 stimulate cardiovascular regeneration in vivo  
  Mary Kearns-Jonker, United States
- 523.2 The anti-inflammatory effect of alpha-1 antitrypsin in hepatocyte transplantation  
  Charlotte A. Lee, United Kingdom
- 523.3 Chimeric human liver reconstruction within the spleen of adult pigs  
  Eiji Kobayashi, Japan
- 523.4 The potential of repairing ischemically damaged human kidneys during acellular warm perfusion  
  Lauren Brasile, United States
- 523.5 Optimization of a polycaprolactone (PCL) scaffold for islet and cellular transplantation  
  Steven Wisel, United States
- 523.6 Evaluation of the efficiency of allogenic adipose tissue mesenchymal stem cells therapy for tacrolimus dose minimisation in patients with acute kidney injury after liver transplantation  
  Aliaksei Shcherba, Belarus

---

**Oral Abstract Session (Sex and Gender in Transplantation)**  
524 - Sex and Gender in Transplant Disparities and Outcomes

**Chairs:** Lori J. West, Canada and Karen Dwyer, Australia

- 524.1 Prospective trial on sexual dysfunction in male Chinese liver transplant recipients  
  Kenneth Siu Ho Chok, Hong Kong
- 524.2 Sexual dysfunction and risk factors in females patients on renal replacement therapy  
  Abdulmecit Yildiz, Turkey
- 524.3 Female Hispanic health disparities in orthotopic liver transplantation during ischemia-reperfusion injury  
  Rebecca A. Sosa, United States
- 524.4 Understanding race and gender disparities in living donor kidney transplant readiness, actions, knowledge, and socioeconomic barriers prior to transplant evaluation  
  Amy Waterman, United States
- 524.5 Gender and racial disparities in provision of transplant information in elderly dialysis patients  
  Silvi Shah, United States
- 524.6 Donor-recipient gender-mismatches correlate with survival outcome after lung transplantation  
  Johanna M. Kwakkel-van Erp, Netherlands

---

**Oral Abstract Session (Ethics, Community, Economics)**  
525 - Global Ethical Dilemmas in Donation and Transplantation

**Chairs:** Dominique E. Martin, Australia and Rudolf Garcia-Gallont, Guatemala

- 525.1 Assessing the impact of an online support group on the emotional health of transplant caregivers  
  Talia Giordano, United States
- 525.2 A first nation-wide survey of public attitudes towards socio-economic incentives to increase willingness to donate organs in Japan  
  Tomoko Asai, Japan
- 525.3 Decision making factors of commercial donors and recipients in live unrelated kidney transplantation in the Philippines  
  Campbell Fraser, Australia
- 525.4 Comprehensive study of an attitude of medical professionals towards organ donation in Russia  
  Oleg Reznik, Russian Federation
- 525.5 Accuracy of promis-57 depression and anxiety scales compared to legacy instruments among kidney transplant recipients  
  Aarushi Bansal, Kenya
- 525.6 Awareness of medical students in Sudan towards organ donation and its barriers, intellectual, cultural or ethical?  
  Alaa A.S.E Dafallah, Sudan
09:45-10:45 Oral Abstract Session (Xenotransplantation)  
526 - Xenotransplantation - Solid Organ  
N-115/116

Chairs: Léo Hans Bühler, Switzerland and Chung-Gyu Park, Korea

526.1 Study for comparison of CD40-mAb and CD40L-Ab costimulation blockade after life-supporting orthotopic cardiac xenotransplantation of multi-transgenic pig hearts into baboons with a worldwide first successful long-term survival  
Paolo Brenner, Germany

526.2 B-cell depletion prevents humoral sensitization after pig-to-baboon lung xenotransplantation  
Agnes Azimzadeh, United States

526.3 Transgenic expression of hCD47 on vessels in porcine GalTKO lung grafts in baboons may mitigate acute vascular rejection in baboons: Up to 13 days graft survival in baboons  
Hironosuke Watanabe, United States

526.4 Transgenic expression of hCD47 minimizes the development of proteinuria following pig-to-baboon kidney transplantation and reduces phagocytosis of porcine endothelial cells and podocytes  
Kazuhiko Yamada, United States

526.5 Insights into the development of a life-sustaining orthotopic cardiac xenotransplant model  
Laura DiChiacchio, United States

526.6 Reducing immunogenicity of porcine bioprosthetic heart valves via GGTA1/β4GalNT2/CMAH gene targeting  
Yifan Dai, People’s Republic of China

09:45-10:45 Oral Abstract Session (Complications)  
527 - Complications Infections & Malignancies  
N-117/118

Chairs: Oscar Len Abad, Spain and Olivia M. Martinez, United States

527.1 Natural history and determinants of Infectious complications after kidney transplantation: A nationwide prospective population based cohort  
Anne Scemla, France

527.2 Impact of complement fixing antibodies in murine cytomegalovirus infected renal allografts  
Masako Shimamura, United States

527.3 A ten year retrospective review of infections in the first 12 months post paediatric liver and liver-kidney transplantation at a single centre in Johannesburg, South Africa  
Eleanor M. Duncan, South Africa

527.4 Prospective analysis of EBV+ PTLD in a multi-center study of pediatric transplant recipients  
Olivia M. Martinez, United States

527.5 Delineation of the viral and host cell genomic alterations in EBV-positive PTLD  
Yarl Balachandran, United States

527.6 Clinical and immunological response to sublingual vaccination for the prevention of recurrent urinary tract infections in kidney transplant patients: Results after 1 year of follow-up  
Amir Shabaka, Spain

10:45-11:15 Coffee Break / Visit Exhibitors  
Hall 10 – Exhibition
11:15-13:15  535 - TTS President's Plenary and Awards  

- 535.1 Welcome from the Congress Chair and TTS President  
  Nancy Ascher, United States

- 535.2 Presidential Address  
  Nancy Ascher, United States
  Medawar Prize Lecture Presentation

- 535.3 The transformation of TTS by the DOI  
  Francis L. Delmonico, United States

- 535.4 The Spanish model on organ donation and transplantation, and its expansion to the world  
  Beatriz Dominguez-Gil, Spain

- 535.5 Presentation of TTS Young Investigator, TTS Recognition and WIT Awards  
  Nancy Ascher, United States

- 535.6 Introduction of Incoming TTS President (Mehmet Haberal) and Closing Remarks  
  Nancy Ascher, United States

13:15-14:30  Lunch Break / Last chance to visit Exhibitors

13:30-14:30  Corporate Symposium  

- 540 - The Molecular Microscope® Diagnostic System:  
  Insights into Disease Mechanisms Shared by all Organ Transplants
  
  See page 30 for details.
13:30-14:15  Lunch and Learn (#LL3 search on WebApp)  Retiro Room (NCC)

550 - Lunch and Learn 3 (registration required)

550.1 Promoting medication adherence in kidney transplant recipients  
Bethany Foster, Canada

550.2 Targeting metabolism to regulating immune responses  
Jonathan Powell, United States

550.3 Building a serious research career in transplant surgery  
Dorry Segev, United States

550.4 Pitfalls in Graft Survival Analysis (explaining the most frequently made mistakes in the statistical analysis of survival data in the field of kidney transplantation)  
Caner Süsäl, Germany and Christian Unterrainer, Germany

550.5 Tailoring the Pump for Bridge to Transplant Patients  
Simon Maltais, United States

550.6 How to use 50% of all lungs from the lung donor pool- without EVLP  
Gregory Snell, Australia

550.7 Pre-liver transplant cardiac evaluation – not just CAD  
James Findlay, United States

550.8 The Microbiome in Transplantation  
Jay Fishman, United States

550.9 Trained Immunity in Organ Transplantation  
Jordi Ochando, Spain

550.11 Living donor nephrectomy - donor or surgeon specific?  
Gabriel C. Oniscu, United Kingdom

550.12 Liver Transplantation for Hepatocellular Carcinoma (HCC)  
Daniel Cherqui, France

550.13 Mentorship Roundtable  
Marcelo Cantarovich, Canada

550.14 Perioperative management of Pulmonary Hypertension in Lung Transplantation  
Christopher Wigfield, United States

550.15 Islet auto-transplantation for non-pancreatitis indications  
Lorenzo Piemonti, Italy

550.16 Exploiting Immunometabolism to Sustain Immune Homeostasis  
Ping-Chih Ho, Switzerland

550.17 Manuscript Revisions  
Transplantation Journal Editors

13:30-14:00 Medawar Recipient Interview  Hall 10 – TTS Innovative Studio in TTS booth

545.1 Medawar Recipient Interview

14:00-14:30 ISN-TTS Sister Transplant Centers Program  Hall 10 – TTS Innovative Studio in TTS booth

545.2 Ehab H. Hammad, Saudi Arabia and Abdullah El-Kishawi, Palestinian Territory

14:30-16:00 State-of-the-Art Session (Liver)  N-101

560 - Adult LDLT: Long Term Outcome Problems

Chairs: Gabriel E. Gondolesi, Argentina and Jan Lerut, Belgium

560.1 Long term outcome of endovascular venous intragraft stents in LDLT  
Yu-Fan Cheng, Taiwan

560.2 Quality of life and lap donor hepatectomy  
Daniel Cherqui, France

560.3 Can the minimal invasive surgery using laparoscopic or robotic technique replace open surgery in living donor hepatectomy in near future?  
Kyung-Suk Suh, Korea
### Scientific Program

#### Wednesday, July 4, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Room</th>
<th>Chairs</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-16:00</td>
<td>State-of-the-Art Session (Transplant Immunosuppression)</td>
<td>N-102</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 561 - Personalized Immunosuppression in 2018: “Which Biomarkers in Solid Organ Transplantation Will Pay Off?” |                                                                                     |      | Chairs: Minnie M. Sarwal, United States and Helio S. Tedesco Jr, Brazil | 561.1 Biomarkers for acute rejection in clinic: Show time or no time? Manikkam Suthanthiran, United States  
561.2 Biomarkers for chronic allograft dysfunction: What mark are we aiming for? Barbara Murphy, United States  
561.3 CNI minimization: How to foretell a good versus bad outcome? Josep M. Cruzado, Spain |
| 14:30-16:00   | State-of-the-Art Session (Kidney)                                                    | N-103|                                                                           |                                                                            |
| 562 - Can We Solve the Discrepancy Between Demand and Supply |                                                                                     |      | Chairs: Robert A. Montgomery, United States and Amado Andres Belmonte, Spain | 562.1 Increased risk and hepatitis C positive organs donors for HCV positive and negative recipients Jay Fishman, United States  
562.2 The challenges of older donors and recipients Stefan G. Tullius, United States  
562.3 The strengths and weaknesses of KDRI Ron Shapiro, United States |
| 14:30-16:00   | State-of-the-Art Session (Basic Sciences and Translational Sciences)                | N-104|                                                                           |                                                                            |
| 563 - Metabolism in Transplantation |                                                                                     |      | Chairs: Anita Chong, United States and Marcos Lopez Hoyos, Spain         | 563.1 Preventing allograft rejection by targeting immune metabolism Jonathan Powell, United States  
563.2 Nutrient regulation of immune responses Ping-Chih Ho, Switzerland  
563.3 Manipulating macrophage responses in transplantation James A. Hutchinson, Germany |
| 14:30-16:00   | State-of-the-Art Session (Donation & Procurement)                                   | N-105|                                                                           |                                                                            |
| 564 - Best Use of Available Organs |                                                                                     |      | Chairs: Howard M. Nathan, United States and Eduardo Rocha, Brazil        | 564.1 DCD organs - what does the evidence say about outcomes? Eduardo Miñambres, Spain  
564.2 DCD perfusion techniques and outcomes Gabriel C. Oniscu, United Kingdom  
564.3 DCD lung donation and lung reconditioning Gregory Snell, Australia |
| 14:30-16:00   | State-of-the-Art Session (Complications)                                             | N-106|                                                                           |                                                                            |
| 565 - Obesity and Bone Disease – 21st Century Challenges for Transplantation |                                                                                     |      | Chairs: Peter J. Friend, United Kingdom and Mustafa S. A. Almousawi, Kuwait | 565.1 Features of postoperative bone complications specific to transplanted organs Meltem Zeytinoglu, United States  
565.2 Mechanisms of osteoporosis after organ transplantation and treatment Sara Jiménez, Spain  
565.3 Indication of bariatric surgery Timucin Taner, United States |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-16:00</td>
<td>State-of-the-Art Session (Xenotransplantation)</td>
<td><strong>566 - Clinical Xenotransplantation-How Close Are We?</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Megan Sykes, United States and Léo Hans Bühler, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>566.1 Kidney transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alfred J. Tector III, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>566.2 Islet transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wayne J. Hawthorne, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>566.3 Heart transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muhammad Mohiuddin, United States</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>State-of-the-Art Session (Registries)</td>
<td><strong>567 - The What, Who, When, Where and Why of Global Transplant Registries</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Jeremy R. Chapman, Australia and HaiBo Wang, People's Republic of China</td>
</tr>
<tr>
<td></td>
<td></td>
<td>567.1 The collaborative transplant study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caner Süssal, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>567.2 WHO Global Observatory managed by Organizacion Nacional de Trasplantes (ONT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beatriz Dominguez-Gil, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>567.3 The harmonisation of national registries to measure global outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stephen P. McDonald, Australia</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>State-of-the-Art Session</td>
<td><strong>568 - Joint TTS-AST-ASTS-ESOT: Advancing Transplant Therapeutics and Innovation</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Philip J. O'Connell, Australia and Randall E. Morris, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>568.1 The Transplant Therapeutics Consortium: Update on progress and goals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roslyn B. Mannon, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>568.2 Solidifying endpoints in clinical trials: SONG Tx Initiative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Allison Tong, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>568.3 Challenges involved in developing new endpoints for clinical trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stefan Schneeberger, Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panel discussion</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>State-of-the-Art Session (Heart and Lung)</td>
<td><strong>569 - ECMO in Thoracic Transplantation</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Anne Dipchand, Canada and Peter S. MacDonald, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>569.1 ECMO for heart and lung donors vs. ex vivo perfusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christopher Wigfield, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>569.2 ECMO intra- and postop in heart &amp; lung transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Olivier Bastien, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>569.3 Managing ECMO complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simon Maltais, United States</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>TTS Business Meeting</td>
<td></td>
</tr>
<tr>
<td>16:15-17:15</td>
<td>Corporate Symposium</td>
<td><strong>580 - Transforming Transplantation: From Large Scale Clinical Trials to Daily Practice</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>See page 30 for details.</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>
### Mini-Oral Abstract Session (Kidney) N-101

585 - Kidney Transplant Management

**Chairs:** Deirdre Sawinski, United States and Olivier Aubert, France

585.1 **Clinical outcomes of kidney transplant recipients with positive perfusion fluid cultures: A single centre retrospective study**
* Sally R. Black, United Kingdom

585.2 **Posttransplant lymphoproliferative disorders in Chinese kidney transplant recipients**
* Chi Yuen Simon Cheung, Hong Kong

585.3 **Prevalence of anal cytological abnormalities and human papilloma virus: A cohort study in kidney transplant recipients**
* Brenda M. Rosales, Australia

585.4 **Renal allograft biopsy findings in HLA identical renal transplant recipients**
* Muhammad Mubarak, Pakistan

585.5 **Comparison of recipients with early and later presentation polyomavirus nephropathy (PVN) with regard to histological findings and graft survival: What is the influence of CD4/CD8 ration on the presenting time of PVN**
* Nurhan Ozdemir, Turkey

585.6 **Immune profiling in highly sensitized kidney transplant recipients**
* Sarita Negi, Canada

585.7 **Comparison of the incidence, risk factors and types of acute rejection between indigenous and non-indigenous Australians with kidney transplant**
* Prue E. Howson, Australia

585.8 **The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies**
* Ziad Zaky, United States

585.9 **Renal transplantation of discolored kidneys from donors with rhabdomyolysis and acute kidney injury**
* Xiao-Peng Yuan, People's Republic of China

585.10 **SLPI expression on kidney biopsies correlates with better clinical outcomes**
* Eduardo Chuluyan, Argentina

17:00-18:30 Oral Abstract Session (Basic Sciences and Translational Sciences) N-102

586 - T Cell Biology 2

**Chairs:** Andreas Linkermann, Germany and Manuel Muro, Spain

586.1 **The mark of Zorro: IL35-coated exosomes cross-dress and exhaust recipient T & B cells during transplant tolerance**
* William J. Burlingham, United States

586.2 **Use of TGF-beta plus rapamycin to induce Foxp3, promote iTreg development and suppressive function, and induce long-term allograft survival**
* Liqing Wang, United States

586.3 **The immune monitoring for operationally tolerant recipients following a regulatory T cell-based cell therapy**
* Ryoichi Goto, Japan

586.4 **A novel mechanism of human regulatory T cell function in proinflammatory conditions**
* Joanna Hester, United Kingdom

586.5 **Human regulatory T cell potential for tissue repair via IL-33/ST2 and amphiregulin**
* Avery J. Lam, Canada

586.6 **Allogenic endothelial cells differentially modulate the expansion of anti-inflammatory FoxP3 high regulatory T lymphocytes according to their state of activation**
* Amy R. Cross, France

586.7 **High fibre diet induces donor specific tolerance of kidney allografts through SCFA induction of Tregs**
* Huiling Wu, Australia

586.8 **Gut microbiota determines graft survival outcome through regulation of anti-inflammatory and pro-inflammatory responses**
* Jonathan S. Bromberg, United States

586.9 **The efficacy of CMV specific immune reconstitution is highly dependent on donor/recipient serostatus and type of solid organ transplanted**
* Flavia Neri, Italy
587.1 Despite the growing impact of the American opioid epidemic on organ donation, a small percentage of drug intoxication deaths result in organ donation
Laura A. Hickman, United States

587.2 Machine perfusion preservation for porcine split liver graft
Hiroyuki Takahashi, Japan

587.3 Few gender differences in attitudes and experiences after live kidney donation, with minor changes over time
Shinji Yamamoto, Sweden

587.4 Risk factors for failure to complete post-donation follow-up among obese living kidney donors
Jayme E. Locke, United States

587.5 Comparison of pure laparo-endoscopic single-site surgery and mini-incision retroperitoneal surgery for the retrieval of a graft in living-donor kidney transplantation
Naoki Yokoyama, Japan

587.6 Total laparoscopic live donor nephrectomy: Comparison study between robotic arm assisted 3D laparoscopy and standard 2D laparoscopic donor nephrectomy
Lasantha L.N. Seneviratne, Sri Lanka

587.7 The use of kidneys from deceased donors over 80 years in kidney transplantation
Julio Pascual, Spain

587.8 Low utilization rate of hearts designated as PHS increased risk and presumed infected
Charles E. Wright, United States

587.9 Hepatitis B markers in tissue donors. National multicenter study. Preliminary results
Jacinto Sánchez Ibáñez, Spain

587.10 The in-hospital departments dedicated to expanding the organ donation and organ procurement in China have increased significantly the number of donors and transplants
Liugen Lan, People’s Republic of China

587.11 Pre-transplant histological assessment provides a useful predictor of subsequent kidney allograft function
Adam Brayne, United Kingdom

587.12 Experience of lung transplantation using voluntary organ donations after brain and cardiac death of citizens at Wuxí Center—report of 242 cases
Wenjun Mao Sr., People’s Republic of China
17:00-18:30 Mini-Oral Abstract Session (Kidney)  
588 - Miscellaneous Kidney Issues  

**588.1** Utility of preoperative non-contrast computed tomography (CT) to guide perioperative management for renal transplantation  
*Evan C. Werlin*, United States

**588.2** De novo or early conversion to Everolimus and cancer incidence in kidney transplant recipients: A trial-based ANZDATA linkage study  
*Wai Lim*, Australia

**588.3** Laparoscopic versus finger-assisted open nephrectomy techniques: A safe alternative  
*Nadey Hakim*, United Kingdom

**588.4** Comparison of IGL-1 versus UW ex vivo back table flush on early graft function after living donor kidney transplantation: Retrospective single center analysis  
*Laurie Massaad*, Belgium

**588.5** Transition from laparoscopy to retroperitoneoscopy for live donor nephrectomy - a case control study  
*Zi Qin Ng*, Australia

**588.6** The effect of donor-recipient weight mismatch on kidney graft function – demand defines supply  
*Andreja Figurek*, Switzerland

**588.7** Why in Spain the kidney altruistic donation rate is lower that of other countries of our environment?  
*Marta MG Garcia*, Spain

**588.8** Outcome of robotic assisted laparoscopic kidney transplantation with and without regional hypothermia  
*Joseph Kim*, Canada

**588.9** Utility of surveillance biopsies in kidney transplant recipients with delayed graft function under current immunosuppressive therapy  
*Roberto C. Manfro*, Brazil

17:00-18:30 Oral Abstract Session (Basic Sciences and Translational Sciences)  
589 - IRI Interventions & Tissue Repair

**589.1** Co-transplant of parathyroid gland and stem cell-derived insulin-producing cells enhances graft survival through release of pro-angiogenic and pro-survival factors  
*Gaetano Faleo*, United States

**589.2** Endothelial progenitor cell-derived extracellular vesicles inhibit kidney ischemia-reperfusion injury through the transfer of specific microrna and mrna coding for the transcription factor NRF2: relevance for delayed kidney graft function  
*Vincenzo Cantaluppi*, Italy

**589.3** Senolytic treatment attenuates mtDNA-mediated inflammatory injury in old donors and improves cardiac allograft survival  
*Koichiro Minami*, United States

**589.4** Impact of different dynamic preservation strategies on early renal function and physical machine perfusion parameters in a porcine DCD auto-transplant model  
*Tom Darius*, Belgium

**589.5** Histone deacetylase-6 inhibition is protective in liver ischemia-reperfusion injury and acetaminophen toxicity in a murine model  
*Seth J. Concors*, United States

**589.6** Inhalation of carbon monoxide protects liver against warm ischemia-reperfusion injury in CLAWN miniature swine  
*Hisashi Sahara*, Japan

**589.7** MicroRNAs in kidney hypothermic machine perfusion fluid as novel biomarkers for graft function. Have changes in normalization guidelines support previous results?  
*Victoria Gomez Dos Santos*, Spain

**589.8** A novel human myoblast chimeric cells therapy for restoration of muscle function  
*Maria Siemionow*, United States

**589.9** Blockade of the G-CSF receptor is protective in a mouse model of renal ischemia reperfusion injury  
*Jennifer L. McRae*, Australia
### 17:00-18:30 Mini-Oral Abstract Session (Infectious Diseases) N-111

**590 - The Challenges of Post-Transplant Infections**

<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>590.1</td>
<td>Incidence, prevalence and residual infection risk of HIV in increased risk groups presenting as potential organ donors in Australia; a systematic review and meta-analysis</td>
<td>Karen Waller, Australia</td>
</tr>
<tr>
<td>590.2</td>
<td>Cryptococcal infections in kidney transplant recipients. A single center experience</td>
<td>Marcelo V. Radisic, Argentina</td>
</tr>
<tr>
<td>590.3</td>
<td>Hepatitis C virus infected kidney wait list patients: Treat with DAA or delay?</td>
<td>Bryce A. Kibert, Canada</td>
</tr>
<tr>
<td>590.4</td>
<td>The choice of immunosuppressive regimen does not impact on the occurrence of primary CMV events</td>
<td>Kamilla Linhares-Silva, Brazil</td>
</tr>
<tr>
<td>590.5</td>
<td>Cytomegalovirus infection after transplantation in pediatric liver recipients</td>
<td>Olga Tsirulnikova, Russian Federation</td>
</tr>
<tr>
<td>590.6</td>
<td>IgG hypogammaglobulinemia is a risk factor of cytomegalovirus infection in a multicenter study in kidney transplantation</td>
<td>Ikram Ezzahouri, Spain</td>
</tr>
<tr>
<td>590.7</td>
<td>Lower rates of death in heart recipients with secondary antibody deficiency and severe infection after therapy with intravenous immunoglobulin</td>
<td>Javier Carbone, Spain</td>
</tr>
<tr>
<td>590.8</td>
<td>Pattern of antibiotic resistance in E. coli and klebsiella bacteremia in renal transplant recipients from developing country</td>
<td>Ejaz Ahmed, Pakistan</td>
</tr>
<tr>
<td>590.9</td>
<td>Deceased organ donor screening for Trypanosoma Cruzi in the UK - a strategy in a non-endemic country</td>
<td>Ines Ushiro-Lumb, United Kingdom</td>
</tr>
<tr>
<td>590.10</td>
<td>Screening coccidioides serology in kidney transplant recipients: A 10-year cross-sectional analysis</td>
<td>Korntip Phonphok, Thailand</td>
</tr>
<tr>
<td>590.11</td>
<td>Risk factors for mortality among kidney transplant recipients with Pneumocystis jirovecii infection</td>
<td>Maristela P. Freire, Brazil</td>
</tr>
<tr>
<td>590.12</td>
<td>A single center experience with post transplant tuberculosis in a developing country</td>
<td>Deepesh B. Kenwar, India</td>
</tr>
</tbody>
</table>

### 17:00-18:30 Oral Abstract Session (Transplant Immunosuppression) N-112

**591 - Minimization/ Optimization**

<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>591.1</td>
<td>MANDELA study results at 18 months after heart transplantation: Superior renal function with cni-free everolimus over standard CNI-based regimen: A randomized, multi-center trial in de novo heart transplant recipients.</td>
<td>Markus J. Barten, Germany</td>
</tr>
<tr>
<td>591.2</td>
<td>Renal function outcomes in de novo kidney transplant recipients receiving everolimus with reduced-exposure calcineurin inhibitor versus mycophenolate with standard-exposure calcineurin inhibitor: Results from the TRANSFORM study</td>
<td>Federico Oppenheimer, Spain</td>
</tr>
<tr>
<td>591.3</td>
<td>Everolimus failure to counteract the cytotoxic response mediated by CD8+ T and NK cells in heart-transplant patients</td>
<td>Beatriz Suarez-Alvarez, Spain</td>
</tr>
<tr>
<td>591.4</td>
<td>High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney</td>
<td>Erlend J. Egeland, Norway</td>
</tr>
<tr>
<td>591.5</td>
<td>The feasibility of organ-specific immunosuppression</td>
<td>Lauren Brasile, United States</td>
</tr>
<tr>
<td>591.6</td>
<td>CD40 inhibition with CFZ533 - A new, fully human, non-depleting, Fc silent mAb - improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in de-novo CNI-Free kidney transplant recipients</td>
<td>Bjoern Nashan, Germany</td>
</tr>
<tr>
<td>591.7</td>
<td>Targeting the CD40-ostimulation pathway by CFZ533 prevents the cross--talk between follicular T helper cells and B cells</td>
<td>Martijn W.F. van den Hoogen, Netherlands</td>
</tr>
<tr>
<td>591.8</td>
<td>Costimulatory blockade with CTLA4-Ig abrogates prolonged graft survival in old recipients</td>
<td>Yeqi Nian, United States</td>
</tr>
<tr>
<td>591.9</td>
<td>Efficacy and safety of everolimus with reduced-dose calcineurin inhibitor in de novo kidney transplant recipients: Results from the TRANSFORM study</td>
<td>Julio Pascual, Spain</td>
</tr>
</tbody>
</table>
**Wednesday, July 4, 2018**

**SCIENTIFIC PROGRAM**

**17:00-18:30 Oral Abstract Session (Pancreas & Islet) N-113**

**592 - Islet Transplantation**

**Chairs:** Marc Guell, United States and Peter G. Stock, United States

592.1 Reversal of diabetes and preservation of pancreatic islet grafts in the extrahepatic space with novel parathyroid gland co-transplantation

*Casey J. Ward,* United States

592.2 Prevention of islet inflammatory stress with JAK1/JAK2 inhibitors

*Helen Thomas,* Australia

592.3 Local attenuation of immunoreaction in xenogeneic islet transplantation by controlled release of a low-dose FK506 using polydopamine-coated polymeric microspheres immobilized on pancreatic islet surface

*Tung Thanh Pham,* Korea

592.4 Islet heterospheroids generated from islet cells and amniotic epithelial cells reverse diabetes after marginal mass transplantation in a murine model

*Ekaterine Berishvili,* Switzerland

592.5 Prevascularization of the subcutaneous space improves survival of transplanted mouse islets

*Nicole Conkling,* United States

592.6 A simple and promising strategy for pancreatic islet preconditioning to reduce immunogenicity and improve islet graft longevity

*Takayuki Anazawa,* Japan

**17:00-18:30 Mini-Oral Abstract Session (Donation & Procurement) N-115/116**

**593 - Preservation and Increasing Donation**

**Chairs:** Gabriel C. Oniscu, United Kingdom and Faissal Shaheen, Saudi Arabia

593.1 Longitudinal molecular assessment of renal allograft and short-term outcome: Markers of injury and recovery

*Daniel G. Maluf,* United States

593.2 First series of brain death organ donors in united United Arab Emirates - SEUSA Program implementation

*Ali A. Alobaidli,* United Arab Emirates

593.3 Normothermic ex-vivo kidney perfusion improves function of marginal renal grafts that were subjected to prolonged ischemia prior to preservation

*Peter Urbanellis,* Canada

593.4 Effects of static subnormothermic preservation on extended warm ischemic porcine kidneys assessed by normothermic machine perfusion and renal transplantation

*Mitsuhiro Sekijima,* Japan

593.5 Project of support to controlled donation after circulatory death through a normothermal regional perfusion mobile equipment for hospitals of the community of Madrid, Spain. Start-up and preliminary result.

*Marina Pérez Redondo,* Spain

593.6 A national registry analysis of aortic versus dual in situ perfusion for retrieval of the DBD liver

*Ahmer M. Hameed,* Australia

593.7 Histidine-Tryptophan-Ketoglutarate (HTK) versus celsior in the association with heart transplant outcomes

*Dewei Ren,* United States

593.8 Superior outcomes using normothermic regional perfusion in CDCD liver transplantation

*Elisabeth Coll,* Spain

593.9 The customized design of hospital-level deceased organ donation quality system in china for continuous improvement

*Wenshi Jiang,* People's Republic of China

593.10 Spanish non standard risk donor project (period 2013-June 2017)

*Beatriz Mahillo,* Spain

593.11 In house oxygen persufflation of cold stored livers versus simple cold storage in extended criteria liver grafts: 5-year results of a randomized controlled clinical trial

*Anja Gallinat,* Germany

593.12 Current status of organ donation for transplantation in Vietnam

*Richard D.M. Allen,* Australia
17:00-18:30  Oral Abstract Session (Liver)  

594 - Immunosuppression and Rejection

Chairs: Valentín Cuervas-Mons, Spain and Stephan Busque, United States

594.1 ABO-incompatible liver transplantation using only rituximab for patients with low anti-ABO antibody titer  
Boram Lee, Korea

594.2 Donor specific antibodies are associated with more inflammation, more fibrosis and higher expression of rejection associated transcripts in subclinically rejected liver allografts  
Richard Taubert, Germany

594.3 Prospective evaluation of noninvasive cell death marker and donor specific antibodies as predictors of subclinical graft inflammation and graft fibrosis  
Richard Taubert, Germany

594.4 Are only pre-transplant rituximab and plasma exchange sufficient for pre-transplantation desensitization protocol of ABO incompatible LDLT? Single institute experience  
Youngseok Han, Korea

594.5 Ab initio everolimus-based vs. standard CNI immunosuppression-regimen in liver transplant recipients  
Tommaso Maria Manzia, Italy

594.6 Hepatic estrogen receptor expression prevents liver fibrosis through decreasing the risk of early activation of hepatic stellate cells  
Gonca Ozugun, Turkey

594.7 Tacrolimus (TAC) and single intra-operative high-dose of r-ATG induction vs. tacrolimus monotherapy as immunosuppression (IS) in adult liver transplantation (LT): one-year results of an investigator-driven, prospective, randomized, controlled trial (RCT)  
Samuele Iesari, Italy

594.8 Immunological impact of portal hypertension and splenectomy in living donor liver transplantation  
Kazuhiro Taguchi, Japan

20:00-23:00  Congress Networking Event  

Palacete de los Duques de Pastrana  
Paseo de la Habana, 208

Tickets are available for purchase at $75 US must be purchased in advance.  
No ticket sales at the door.
THURSDAY, JULY 5, 2018

08:30-09:30  Morning Symposium (Kidney) N-102
600 - Recurrent Disease after Transplantation

Chairs: Josep M. Grinyo, Spain and Daniel Seron, Spain

600.1 FSGS
Guillaume Canaud, France

600.2 aHUS
Christophe Legendre, France

600.3 C3 GN
John S. Gill, Canada

08:30-09:30  Morning Symposium (Liver) N-105
601 - When the Liver Transplant Surgeons Need Help...

Chairs: Jan Lerut, Belgium and Valentín Cuervas-Mons, Spain

601.1 The role of interventional endoscopist
Magdy El-Serafy, Egypt

601.2 The role of the interventional radiologist
Pierre Goffette, Belgium

601.3 The role of the liver transplant pathologist
Laura Rubbia-Brandt, Switzerland

08:30-09:30  Morning Symposium (Basic Sciences and Translational Sciences) N-106
602 - Modern Reinterpretation of Classical Concepts in Transplant Immunology

Chairs: Adrian E. Morelli, United States and TBA

602.1 Die another day: Apoptosis, necroptosis and immune activation
Andreas Linkermann, Germany

602.2 Tricky ways of allorecognition: Exosomes and antigen
Adrian E. Morelli, United States

602.3 Are we getting there? Novel mechanistic aspects of tolerance induction
Julien Zuber, France

08:30-09:30  Oral Abstract Session (Donation & Procurement) N-107/108
603 - Donation after Circulatory Death

Chairs: Gabriel C. Oniscu, United Kingdom and María García-Conde Delgado, Spain

603.1 Donation after circulatory death: An updated description of the European landscape
Maria del Mar Lomero, France

603.2 Long-term outcomes using uncontrolled donors after circulatory death (uDCD) for liver transplantation. A 10-year single center experience
Iago Justo, Spain

603.3 Liver transplantation from donor after cardiac death (DCD) Maastricht type IIA: Comparative study of outcomes during the initial five years and on
María García-Conde Delgado, Spain

603.4 A systematic review and meta-analysis of outcomes for islet transplantation in donation after circulatory death (DCD) compared with donation after brain death (DBD)
Yi Vee Chew, Australia

603.5 A new technique for cannulation and external ‘clamping’ in the difficult DCD donor
Joshua F. Hollingshead, United States

603.6 Should donation after cardiac death donor organs be used in the pediatric patient population?
Christine S. Hwang, United States
### 08:30-09:30 Morning Symposium (Histocompatibility) **N-111**

**604 - Kidney Paired Exchange. Success Stories, Ongoing Challenges and What We Can Learn from Others**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>604.1</td>
<td>Kidney paired exchange in Canada. What works and what challenges remain. A national approach to KPD</td>
<td><strong>Kathryn Tinckam</strong>, Canada</td>
</tr>
<tr>
<td>604.2</td>
<td>Kidney paired exchange in Saudi Arabia. Success and lessons</td>
<td><strong>Khalid AlMeshari</strong>, Saudi Arabia</td>
</tr>
<tr>
<td>604.3</td>
<td>The National Kidney Registry approach to paired exchange</td>
<td><strong>J. Michael Cecka</strong>, United States</td>
</tr>
</tbody>
</table>

### 08:30-09:30 Oral Abstract Session (Xenotransplantation) **N-112**

**605 - Xenotransplantation: Cell/Tissue and Immune Regulation**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>605.1</td>
<td>Long-term function of genetically modified porcine neonatal islet xenografts in baboons</td>
<td><strong>Wayne J. Hawthorne</strong>, Australia</td>
</tr>
<tr>
<td>605.2</td>
<td>Correlation between islet number in the small biopsy liver and blood glucose level after pig to non-human primate islet xenotransplantation model</td>
<td><strong>Byoung-Hoon Min</strong>, Korea</td>
</tr>
<tr>
<td>605.3</td>
<td>Effects of several genetic engineering in the graft survival of pig-to-monkey lamellar corneal xenotransplantation with minimal immunosuppression</td>
<td><strong>Ki Cheul Shin</strong>, Korea</td>
</tr>
<tr>
<td>605.4</td>
<td>Durable macrochimerism (&gt;8 weeks) and pig-specific T and B Cell unresponsiveness following hCD47+ transgenic GalTKO pig intra-bone bone marrow transplantation in baboons</td>
<td><strong>Hironosuke Watanabe</strong>, United States</td>
</tr>
<tr>
<td>605.5</td>
<td>Human HLA-DR+CD27+ memory-type regulatory T cells show potent xenoantigen-specific suppression in vitro</td>
<td><strong>Lu Cao</strong>, Australia</td>
</tr>
<tr>
<td>605.6</td>
<td>Isolation of human xenospecific regulatory t cells with high suppressive function</td>
<td><strong>Elmar Jaeckel</strong>, Germany</td>
</tr>
</tbody>
</table>

### 08:30-09:30 Morning Symposium **N-113**

**606 - Pearls of Wisdom – A Roadmap to Developing a Successful Career in Transplantation**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>606.1</td>
<td>Your first real job - making yourself marketable and finding a clinical niche</td>
<td><strong>Barbara Murphy</strong>, United States</td>
</tr>
<tr>
<td>606.2</td>
<td>The “How to Guide” for the aspiring physician/surgeon-scientist: Funding and publications</td>
<td><strong>Jeremy R. Chapman</strong>, Australia</td>
</tr>
<tr>
<td>606.3</td>
<td>The “Holy Grail of Work-Life Balance”: Mindfulness, emotional intelligence and well-being</td>
<td><strong>Nancy Ascher</strong>, United States</td>
</tr>
<tr>
<td>606.4</td>
<td>How to find a research focus – and funding – as a trainee</td>
<td><strong>Jayme E. Locke</strong>, United States</td>
</tr>
</tbody>
</table>

### 08:30-09:30 Morning Symposium **N-115/116**

**607 - Tackling the Challenges Posed by Donor Intervention Research**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>607.1</td>
<td>Why is it difficult to conduct trials testing novel interventions in deceased donors?</td>
<td><strong>Claus Niemann</strong>, United States</td>
</tr>
<tr>
<td>607.2</td>
<td>Guidance delineated in the National Academies of Medicine Donor Intervention Report</td>
<td><strong>Sandy Feng</strong>, United States</td>
</tr>
<tr>
<td>607.3</td>
<td>Conducting donor intervention trials in my country – an international panel discussion</td>
<td><strong>Claus Niemann</strong>, United States, <strong>Axel Rahmel</strong>, Germany, <strong>Christopher J. E. Watson</strong>, United Kingdom, <strong>Elisabeth Coll</strong>, Spain, <strong>Helen I. Opdam</strong>, Australia</td>
</tr>
</tbody>
</table>
08:30-09:30 Oral Abstract Session (Transplant Immunosuppression)  
608 - Tolerance  

Chairs: Stephan Busque, United States and Suzanne T. Ildstad, United States  

608.1 Relationship between mixed chimerism and acceptance of HLA-matched and -mismatched kidney transplants after withdrawal of immunosuppressive drugs  
Stephan Busque, United States  

608.2 Renal allograft tolerance for end-stage renal disease patients with hematologic malignancies  
Megan Sykes, United States  

608.3 In-vivo costimulation-blockade induced Foxp3 Tregs from DEREG mice with neonatal islet cell cluster tolerant xenografts exist memory Tregs phenotype  
Yuanfei Zhao, Australia  

608.4 Long-term follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients  
David Tollerud, United States  

608.5 Non-myeloablative conditioning with low-dose total body irradiation in place of cyclophosphamide induces mixed chimerism and long-term immunosuppression free allograft survival without acute kidney injury in HLA mismatched kidney transplantation.  
Tatsuo Kawai, United States  

608.6 Does the end justify the means? An analysis of outcomes in recipients of combined kidney/hematopoietic stem cell (HSC) transplants and comparison to standard of care (SOC) patients  
Suzanne T. Ildstad, United States  

09:45-11:00 Oral Abstract Session (Donation & Procurement)  
615 - Organ Preservation and Utilization  

Chairs: Francisco Del Rio, Spain and Richard S. Mangus, United States  

615.1 Ex-vivo lung perfusion - 10 year follow-up of the first performed double LTX with marginal donor lungs evaluated using EVLP  
Mohammed Fakhro, Sweden  

615.2 Extending the human liver preservation time for transplantation by supercooling  
Reinier J. de Vries, United States  

615.3 Normothermic ex-vivo kidney perfusion restores the genetic profile of marginal kidney grafts subjected to warm ischemia  
Peter Urbanellis, Canada  

615.4 Use of tissue plasminogen activator (tPA) and histidine-tryptophan-ketoglutarate solution (HTK) in donation after circulatory death (dcd) liver transplant prevents ischemic cholangiopathy  
Richard S. Mangus, United States  

615.5 Efficacy and quality of flush-out prior to cold storage of liver and kidney in donation after circulatory death  
Catherine Boffa, United Kingdom  

615.6 Expedited evaluation for liver transplantation: Does patient acuity influence processes or outcomes?  
Hillary J. Braun, United States  

615.7 Explant biopsy and remuzzi scoring outperforms kidney donor profile index (KDPI) in selection of extended criteria donor kidneys for single implant  
Hersharan K. Sran, Singapore  

09:45-11:00 Oral Abstract Session (Kidney)  
616 - Immunosuppression 3  

Chairs: Francesc Moreso Mateos, Spain and TBA  

616.1 Thymoglobulin induction decreases risk of ABMR and death in kidney recipients  
Charlotte Loheac, France  

616.2 Pretransplant immunologic predictors of rejection in patients treated with belatacept  
Jun Shoji, United States  

616.3 Steroid withdrawal promotes B lymphocyte phenotypes of operational tolerance predisposition in renal allograft recipients  
Laura Llinás Mallol, Spain  

616.4 Predicting mycophenolic acid area under the curve with mycophenolic acid trough in de novo renal transplantation  
Shiong Shiong Yew, Malaysia  

616.5 MRP2 24 CT is associated with an increased risk of cytomegalovirus infection among renal transplant recipients  
Beatriz Rodriguez-Cubillo, Spain  

616.6 Subclinical inflammation in early surveillance biopsies is associated with immunosuppression exposure and HLA-DR mismatch  
Francesc Moreso Mateos, Spain  

616.7 M-CSF and TNF-α Induce human MDSCs that attenuate GVHD  
Puxun Tian, People's Republic of China
09:45-11:00 Oral Abstract Session (Kidney)  
617 - Deceased Donor Issues & Others

617.1 Survival analysis of kidney transplants with grafts from uncontrolled DCD donors under normothermic preservation prior to organ retrieval related to DBD: Data from our 300 transplants series  
Felix Guerrero-Ramos, Spain

617.2 A new risk stratification score for deceased donor kidneys in Korea  
Tai Yeon Koo, Korea

617.3 Beneficial effect of ABO incompatibility on de novo DSA production after kidney transplantation  
Takaaki Kobayashi, Japan

617.4 Evaluation of a deceased donor kidney allocation score. The Catalan experience  
Jordi Comas, Spain

617.5 Inflammatory frailty index and mortality after kidney transplantation  
Christine E. Haugen, United States

617.6 Impact of the new kidney allocation system A2/A2B—> B policy on access to transplantation among minority candidates  
Margaux N. Mustian, United States

617.7 Kidney transplantation from uncontrolled donation after circulatory death, our outcomes compared to donation after brain death after very long time  
Esther González Monte Sr, Spain

09:45-11:00 Oral Abstract Session (Liver)  
618 - Liver Complications

618.1 Better graft survival with no ischemic cholangiopathy in DCD liver transplantation in the UK using normothermic regional perfusion (nrp)  
Gabriel C. Oniscu, United Kingdom

618.2 Hazard ratio trends among deceased liver transplant recipients in the United States, 2011-2016: A propensity score-matched study  
Shunji Nagai, United States

618.3 The AKI-predict-score: A new prediction model for acute kidney injury after liver transplantation  
Marit Kalisvaart, United Kingdom

618.4 Pharmacotherapy before or after liver transplantation in familial amyloidotic polyneuropathy (FAP) and domino recipients – early report from the familial amyloidotic world transplant registry (FAPWTR) and the domino liver transplant registry (DLTR).  
Bo-Göran Ericzon, Sweden

618.5 Revascularization techniques in liver transplantation for portal vein thrombosis and stenosis: Single center experience  
Aliaksei Shcherba, Belarus

618.6 Predictors for post transplant survival in patients with acute-on-chronic liver failure  
Martina Sterneck, Germany

618.7 Severe injury of common bile ducts in donation after circulatory death liver transplantation: Histological and immunohistochemical evaluation  
Francesca Tinti, Italy
09:45-11:00 Oral Abstract Session (Basic Sciences and Translational Sciences)  N-106

619 - Chimerism and GvHD

Chairs: Jordi Ochando, Spain and Andreas Linkermann, Germany

619.1 Durable donor hematopoietic stem cell chimerism is associated with protection from native renal disease recurrence in recipients of combined stem cell/kidney transplants
Suzanne T. Ildstad, United States

619.2 Donor's graft ex vivo t cell depletion with fludarabine reduces GvHD signs and improves survival after intestine transplantation
Maria Vela, Spain

619.3 Role of graft-derived graft-versus-host t cells in facilitating multilineage blood chimerism after human intestinal transplantation
Jiating Fu, United States

619.4 Clonal and functional analysis reveals the capacity of allograft t cells to join the circulating pool after human intestinal transplantation
Jiating Fu, United States

619.5 Bone marrow graft-versus-host disease in reduced intensity conditioned major histocompatibility complex matched murine allogeneic hematopoietic cell transplantation
Pablo A. Silveira, Australia

619.6 Recipient t regulatory cells enhance chimerism and prolong galt-KO pig skin graft survival in baboons
Nathaly P. Llore, United States

619.7 Donor conditioning with recipient-derived PD-L1/PD-L2-expressing B cells prevents lethal acute GVHD in a fully allogeneic mouse model
Asuka Tanaka, Japan

09:45-11:00 Oral Abstract Session (Complications)  N-107/108

620 - Cardio-Vascular & Metabolic Complications

Chairs: Juan F. Delgado, Spain and TBA

620.1 Stroke mortality in kidney transplant recipients: A retrospective population-based cohort study using data linkage
Nicole L. De La Mata, Australia

620.2 Concentric left ventricular hypertrophy geometry predicts cardiovascular events after renal transplantation
Edoardo Melilli, Spain

620.3 Prevalence and predictors of hypertension among heart transplant recipients: An analysis of Russian National Medical Research Centre of Transplantology and Artificial Organs Registry
Alex O. Shevchenko, Russian Federation

620.4 Pulse wave velocity and augmentation index in renal transplant recipients - 4.6 years follow up
Jan Alatiti, Slovenia

620.5 Influence of immunosuppression on metabolic outcomes one year after kidney transplantation: The role of mycophenolate and mTOR inhibitors on lipid metabolism and glycemic control
David Cucchiari, Spain

620.6 Tacrolimus activated bmp signaling acts in synergy with stress-activated FOXO1 to induce loss of beta-cell function and identity
Aiko PJ de Vries, Netherlands

620.7 Influence of hypomagnesemia on new-onset diabetes after kidney transplantation
Korntip Phonphok, Thailand
THURSDAY, JULY 5, 2018

SCIENTIFIC PROGRAM

09:45-11:00 Oral Abstract Session (Heart and Lung) N-111
621 - Lung Transplantation

Chairs: Gregory Snell, Australia and Irene Bello, Spain

621.1 Ultrastructural changes in lung allografts: Endothelial changes correlate with donor specific antibody and antibody-mediated rejection
Mariam P. Alexander, United States

621.2 Induction of tolerance to fully allogeneic pulmonary allograft by adenosine A2A receptor agonist in MHC-defined CLAWN miniature swine
Hisashi Sahara, Japan

621.4 Obliterative bronchiolitis syndrome and outcomes of unplanned ICU readmission following lung transplantation
Christopher C. Mazo Torre Sr., Spain

621.5 Is the lung allocate score associated with the decrease of the primary graft dysfunction in lung transplantation?
Irene Bello, Spain

621.6 Clinical benefit of lung transplantation after ECMO support
Alessandro Bertani, Italy

621.7 Impact of allograft ischemic time on short- and long-term survival in lung transplantation
Mohammed Fakhro, Sweden

09:45-11:00 Oral Abstract Session (Vascularized Composite Allotransplantation) N-112
622 - VCA

Chairs: Jelena M. Janjic, United States and David W. Mathes, United States

622.1 Mayo clinic’s first face transplant: One year outcome
Hatem Amer, United States

622.2 A clinically relevant protocol induces tolerance to a vascularized composite allograft across major histocompatibility barrier in a large animal model
David W. Mathes, United States

622.3 End stage renal disease as a complication of face transplant
Nicole M. Shockcor, United States

622.4 Mechanisms of vascularized bone marrow graft protection of vascularized composite allografts
Nicole M. Shockcor, United States

622.5 Quadruple therapy tacrolimus-sparing belatacept-based maintenance immunosuppression after an arm transplant
Luis Landin, Spain

622.6 Functional reconstruction of urogenital tissue defects using vascularized composite allotransplantation: A novel microsurgical penis transplant model and clinical & histological rejection classification
Giorgio Raimondi, United States

622.7 Optimization of an ex-vivo limb perfusion protocol for vascularized composite allograft transplantation
Kavit Amin, United Kingdom

09:45-11:00 Oral Abstract Session (Education) N-113
623 - Innovations in Transplant Education II

Chairs: Marcelo Cantarovich, Canada and Medhat Askar, United States

623.1 Integration of a massive open online course on clinical kidney, pancreas and islet transplantation into a regular medical science curriculum
Marlies E.J. Reinders, Netherlands

623.2 Knowledge transfer and leadership in organ donation from Europe to China: keTLOD
Chloe Ballesté, Spain

623.3 Kidney transplant education using the explore transplant Ontario package: Increasing transplant knowledge in patients on maintenance dialysis and addressing ethnic disparities in transplant education
Dmitri Belenko, Canada

623.4 Effect of TV advertisement on donor card registration
Katayoun Najafizadeh, Iran (Islamic Republic of)

623.5 Increasing demand on Master Education for transplantation
Alicia Molina, Spain

623.6 Donors after circulatory death - theme of present or a future? The research of west pomeranian province in Poland
Marek Ostrowski, Poland

623.7 Minimizing risks in organ transplantation: Notify project new developments
Aurora Navarro, Spain
09:45-11:00 Oral Abstract Session (Anesthesia Management and Critical Care) N-114
624 - Anesthesia and Critical Care Issues

Chairs: Darren Malinoski, United States and TBA

624.1 Intraoperative cytokine hemoadsorption treatment may prevent vasoplegic syndrome during orthotopic heart transplantation
Endre Nemeth, Hungary

624.2 Effect of the surgical intervention of laparoscopic donor nephrectomy on proteomic changes in living kidney donors using either propofol or sevoflurane anaesthesia
Honglei Huang, United Kingdom

624.3 Evaluation of clonidine as an adjuvant to bupivacaine in wound infiltration for providing postoperative analgesia after laparoscopic donor nephrectomy
Bina Butala, India

624.4 PiCCO monitoring during liver transplantation for pediatric patients
Zeynep Ersoy, Turkey

624.5 Evaluate the efficacy of epidural dexmedetomidine as postoperative analgesic in live donor renal allograft recipients for open renal transplantation surgical approach
Geeta P. Parikh, India

624.6 Clinical significance of lactate clearance for the development of early allograft dysfunction and short-term prognosis in deceased donor liver transplantation
Sung Hoon Kim, Korea

624.7 Hierarchical model to predict length of stay and ICU outcome according to post-operative respiratory failure after liver transplantation
Alfonso W. Avolio, Italy

09:45-11:00 Oral Abstract Session (Pancreas & Islet) N-115/116
625 - Pancreas Transplantation

Chairs: Wayne J. Hawthorne, Australia and Peter J. Friend, United Kingdom

625.1 Allograft duodenal cuff biopsy as surrogate in evaluation of pancreatic transplant rejection – a multicenter data effort
Danni G. Holanda, United States

625.2 New tool helping differentiation between rejection and graft pancreatitis
Malwina Bialobrzecka, Germany

625.3 Antibody monitoring in pancreas transplantation: When should we do protocol biopsies?
Pablo D. Uva, Argentina

625.4 Pancreas graft outcomes in living versus deceased kidney donor in pancreas after kidney transplant recipients
Pedro Ventura-Aguirar, Spain

625.5 Outcomes from brain death donors with cardiac arrest accepted for pancreas transplantation
Pedro Ventura-Aguirar, Spain

625.6 Post-transplant survival in Type 1 diabetics in Australia and New Zealand
Patrick Kelly, Australia

09:45-11:00 Oral Abstract Session (Basic Sciences and Translational Sciences) N-117/118
626 - Innovative Approaches

Chairs: Estela Paz-Artal, Spain and Manuel Muro, Spain

626.1 Anti-TIRC7 antibody treatment prevents rejection of mice cardiac allografts while immune competency to viral and bacterial antigens remain normal
Stefan G. Tullius, United States

626.2 Blockade of tyrosine kinases as preventive strategy against cardiac allograft vasculopathy in a murine aortic transplant model
Christian Heim, Germany

626.3 Targeting lymphotixin receptor classical NFkB signaling facilitates inflammation resolution
Jonathan S. Bromberg, United States

626.4 Transient antibody targeting of CD45RC to prevent the development of graft versus host diseases in rat and NSG mice
Laetitia Boucault, France, Metropolitan

626.5 In vivo perfusion of porcine kidney scaffolds re-endothelialized with human umbilical vein endothelial cells
Ron Shapiro, United States

626.6 Low dose IL-2 and rapamycin leads topProlongation of human islet allograft Survival by inhibition of IFN-gamma+ T cells and expansion of FOXP3+CD25+ Tregs in a humanized islet transplant mouse model
Min Hu, Australia

626.7 The transient display of a chimeric PD-L1 protein on pancreatic islets promotes indefinite survival in allogeneic recipients
Esma S. Yolcu, United States
09:45-11:00 Oral Abstract Session (Paediatrics) Retiro Room (NCC)

627 - Long Term Outcomes in Paediatric Transplantation

Chairs: Stephen D. Marks, United Kingdom and Douglas G. Farmer, United States

627.1 The impact of donor/recipient age difference and HLA matching on graft outcome in pediatric kidney transplantation
Steven McTaggart, Australia

627.2 Successful ABO and HLA incompatible renal transplantation in children in the United Kingdom over the last decade
Stephen D. Marks, United Kingdom

627.3 Liver transplantation in children with hepatoblastoma: A single-center 30 year experience examining prognostic factors for survival and recurrence
Douglas G. Farmer, United States

627.4 Poorer long-term survival associated with monomorphic post-transplant lymphoproliferative disorder after solid organ transplantation in children
Fang Kuan Chiou, Singapore

627.5 Septic complications and graft outcome after post-transplant lymphoproliferative disorder in paediatric solid organ transplant patients in the rituximab era
Fang Kuan Chiou, Singapore

627.6 Improved renal allograft survival for pre-emptive paediatric renal transplant recipients in the United Kingdom
Matko Marlais, United Kingdom

627.7 Impact of a dedicated young adult service on risk of non-adherence and non-engagement in pediatric-adult transition transplant recipients and in young adult patients presenting directly to adult care for transplantation
Paul N. Harden, United Kingdom

11:00-11:30 Coffee Break Foyer Area (NCC)

11:30-12:30 Plenary Session 3 N-103/104

630 - How Will Big Data Transform Medicine and Transplantation

Facilitator: Philip O’Connell, Australia

630.1 How can we use large data in medicine
Atul Butte, United States

630.2 What does large data tell us in transplantation
Dorry Segev, United States

Closing Ceremony - 12:30 to 13:30

12:30-13:30 Closing Plenary N-103/104

635 - Over the Horizon Summary: What Is The Future for Transplantation?

Facilitator: Nancy Ascher, United States

635.1 Basic Science Summary
Stefan G. Tullius, United States

635.2 Clinical Science Summary
Elmi Muller, South Africas

635.3 Closing Remarks
Nancy Ascher, United States

635.4 Presentation of TTS 2020 Congress
Kyung Suk Suh, Korea
All poster presenters with **odd poster numbers** shall be at their respective poster(s) on July 2, 2018 from 16:30 to 17:30.

All poster presenters with **even poster numbers** shall be at their respective poster(s) on July 3, 2018 from 16:30 to 17:30.

---

**Kidney Posters – P.001 to P.245**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.001</td>
<td>Incidence of contrast-induced nephropathy in kidney transplant patients</td>
<td>María Ovidia López-Oliva, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P.002</td>
<td>Impact of delayed graft function without dialysis needed</td>
<td>Carlos Arias-Cabral, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P.003</td>
<td>Delayed graft function in kidney transplant: A pair analysis</td>
<td>Fernanda Salomao Gorayeb-Polacchini, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>P.004</td>
<td>Perioperative hemoglobin and delayed graft function in kidney transplant recipients</td>
<td>Shaifali Sandal, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>P.005</td>
<td>Systemic free heme increases the risk for acute kidney injury (AKI) after solid organ transplantation</td>
<td>Julian Doric, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>P.006</td>
<td>Clinical analysis of impact of intraoperative hepatic blood inflow on acute kidney injury following allogeneic liver transplantation</td>
<td>Jiain Zhang, People’s Republic of China</td>
<td>China</td>
</tr>
<tr>
<td>P.007</td>
<td>Efficacy and safety of early mammalian target of rapamycin inhibitors with minimization of calcineurin inhibitors in kidney transplant recipients</td>
<td>Yuki Nakamura, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>P.008</td>
<td>Analysis of uric acid and other factors affecting renal function in the monitoring of renal transplant recipients</td>
<td>Verushka Reddy, South Africa</td>
<td>Africa</td>
</tr>
<tr>
<td>P.009</td>
<td>Prognostic significance of microvascular injury in kidney transplant recipients</td>
<td>Ksenija Vučur, Croatia</td>
<td>Croatia</td>
</tr>
<tr>
<td>P.010</td>
<td>Use of electron microscopy (EM) to detect transplant glomerulopathy (TG) in patients with late-indication allograft biopsy</td>
<td>Rafael A. Maldonado, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td>P.011</td>
<td>The profile of kidney transplantation in Dr. Kariadi Hospital Semarang, Indonesia: A single centre experience</td>
<td>Eriawan Agung Nugroho, Indonesia</td>
<td>Indonesia</td>
</tr>
<tr>
<td>P.012</td>
<td>Is the donor age a real limitation to the use of very extended criteria donors in kidney transplantation?</td>
<td>Asuncion Sancho Calabuig, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P.013</td>
<td>Kidney transplantation in recipients older than 70 years old: A good option for our patients</td>
<td>Asuncion Sancho Calabuig, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P.014</td>
<td>Risk factors of graft loss in renal transplant recipients including histopathological changes present in implanted kidney</td>
<td>Joanna Pazik, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>P.016</td>
<td>Kidney allograft survival in oldest donors</td>
<td>Ester Castillas Sagrado, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>P.017</td>
<td>Distribution of anti-ABO immunoglobulin G subclass and C1q antibody in ABO incompatible kidney transplantation</td>
<td>Jeong-Hoon Lim, Korea</td>
<td>Korea</td>
</tr>
<tr>
<td>P.018</td>
<td>ABO incompatibility does not have an influence on kidney graft survival in living related donor transplantation</td>
<td>Agne Laucyte-Cibulskiene, Lithuania</td>
<td>Lithuania</td>
</tr>
<tr>
<td>P.019</td>
<td>The outcome of kidney transplant recipients who had combined ABO incompatibility and performed antibody against donor HLA antigen</td>
<td>In Sung Moon, Korea</td>
<td>Korea</td>
</tr>
<tr>
<td>P.020</td>
<td>Long-term outcomes of ABO-incompatible living donor kidney transplantation compared with ABO-compatible grafts: A single-center experience in Korea</td>
<td>Ji Il Kim, Korea</td>
<td>Korea</td>
</tr>
<tr>
<td>P.021</td>
<td>Is it really necessary to remove anti-A/B antibodies in ABO-incompatible kidney transplantation?</td>
<td>Yuki Nakagawa, Japan</td>
<td>Japan</td>
</tr>
</tbody>
</table>
Transplant Immunosuppression Posters – P.250 to P.266

P.250  Hyperkalemia in the early post renal transplant period
Emily Christie, Canada

P.251  Influence of tacrolimus metabolism rate on kidney graft survival
Bernd Döbler, Germany

P.252  Determination of tacrolimus concentration and protein expression of P-glycoprotein in single human renal core biopsies
Erlend J. Egeland, Norway

P.253  Bone marrow derived myeloid suppressor cell (BM-MDSCs) prolongs the graft survival in murine heart transplantation
Keiichi Fujimoto, Japan

P.254  High-dose fish oil supplementation increase tacrolimus exposure in stable renal transplant recipients
Marte Thele Gustavsen, Norway

P.255  Drug-induced CYP-induction as therapy for tacrolimus intoxication
John M. Hoppe, Germany

P.256  Inter-individual variability of tacrolimus trough level may be due to differential p-glycoprotein expression on PBMCs in renal transplant recipient
Akhilesh Kumar Jaiswal, India

P.257  Comparative study of human and cynomolgus t-cell depletion with rabbit anti-thymocyte globulin (rATG) treatment - dose adjustment in a non-human primate transplantation model
Sungjoo Kim, Korea

P.258  Safety of induction immunosuppression in kidney transplantation: Focus on 1-year hospitalizations for infection and development of post-transplant neoplasia
Alicia Molina, Spain

P.259  Rifampin drug interactions with tacrolimus in solid organ transplant
Alaa A. Mously, Saudi Arabia

P.260  A retrospective study on effectiveness and safety of the novel once-daily melt-dose tacrolimus in a Spanish cohort of stable kidney transplant recipients converted from once or twice-daily formulations: Reconoce study
Juan Carlos Ruiz, Spain

P.261  Characterization of the new immune suppressive anti human CD83 monoclonal antibody 3C12C in non-human primates
Pablo A. Silveira, Australia

P.262  The ratio of CTLA4 to perforin and granzyme b as a potential biomarker of tolerance in chimeric renal transplant patients
David Tollerud, United States

P.263  Posttransplant lymphoproliferative disorder in liver transplant recipients
Ying Liu, People’s Republic of China

P.264  Eculizumab and intravenous immunoglobulins for the treatment of acute antibody-mediated rejection after lung and liver transplantation
Julien Vionnet, Switzerland

P.265  Tolerance induction by delayed non-myeloablative irradiation in a large animal lung transplantation model
Karolin Hacker, Germany

P.266  Analysis of CCR4high CD4+ in kidney graft blood after steroid withdrawal: A prospective, randomized, controlled, parallel group study. Preliminary results
Teresa Vazquez, Spain

Ethics, Community, Economics Posters – P.270 to P.288

P.270  Developing stronger team dynamics to improve communication internally and externally
Deborah Adey, United States

P.271  Attitudes and factors affecting organ donation in family members of kidney transplant recipients. A single centre survey
Atul Bagul, United Kingdom

P.272  Health related quality of life in post renal transplant patients: A single center study
Manish Ramesh Baliwani, India

P.273  Fit for life, thanks for life donor
Won-Hyun Cho, Korea

P.274  Argentine integral protection system for transplanted persons and on the wait list: First specific legislation in Latin America
Eugenia Ferreira Centeno, Argentina

P.275  Beneficial impact of group psychotherapy on depression and quality of life in cirrhotic patients on the liver transplant waiting list
Beatriz B. Gómez, Spain

P.276  Deceased directed donation: Considering the ethical permissibility in a multi-cultural setting
Rebecca Greenberg, Canada

P.277  Physician practice patterns and barriers to counselling on physical activity in solid organ transplant recipients: A Canadian survey
Tanja Janaudis-Ferreira, Canada

P.278  Psychosocial long-term impact of donation on kidney living donors - a comparative study of two major European transplant centres
Entela Kondi, Spain

P.279  Current status of overseas transplantation in Korea
Oh Jung Kwon, Korea

P.280  The great recession and the importance of Donation After Circulatory Determination of Death (DCDD)
Paula Y. Lawrence, United States

P.281  Pediatric liver transplantation outcomes: insured vs. uninsured children
Helen Dayan Pava Acosta, Colombia

P.282  Raising awareness of the importance of exercise training in solid organ transplant: Description of a Canadian knowledge dissemination project
Sunita Mathur, Canada

P.283  Ethical issues of using ECMO in organ donation
Oleg Reznik, Russian Federation

P.284  Health related quality of life (HRQOL) after donating a kidney: do kidney donors feel the same as those who lose a pathological kidney
Lasantha L.N. Senewiratne, Sri Lanka

P.285  Assessing the impact of a hospital house on the mental and physical health of transplant patients
Jan L. Weinstock, United States

P.286  Social aspects of long-term kidney transplant outcomes
Viktor Denisov, Ukraine

P.287  Should transplant recipients participating in the World Transplant Games have cardiac stress testing before being able to participate
Paul N. Harden, United Kingdom

P.288  Adherence and alexithymia in adolescent renal transplant recipients
Ruben O. Schiavelli, Argentina
Histocompatibility Posters – P.290 to P.308

P.290 Renal transplantation in highly sensitized patients: SIUT experience
Khawar Abbas, Pakistan

P.291 Detection of HLA donor-specific antibodies with screening and/or specificity kits and antibody-mediated rejection in kidney transplant recipients
Carla Burballa, Spain

P.292 Single center experience of desensitization for preformed HLA-related donor specific antibody in living donor liver transplantation
Hiroto Egawa, Japan

P.293 Renal transplant with positive virtual crossmatch in patients with high immunological risk
Sandra Elias, Spain

P.294 C4d deposition – an independent predictor of graft failure following liver transplantation
Speranta Iacob, Romania

P.295 Number of BAFF-receptor molecules on plasma cells prior kidney transplantation identify patients at risk of antibody-mediated rejection
Juan Iruire-Ventura, Spain

P.296 The relative immunogenicity of HLA mismatches in adult liver transplant patients from the ITN A-WISH Trial
Vadim Jucaud, United States

P.297 Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry crossmatches
Jee Yeon Kim, Korea

P.298 Formalin fixed paraffin embedded tissue-based gene expression and immune cell profiling as a tool for monitoring immune response in kidney biopsies with low grade inflammation
Henrik H. Junger, United States

P.299 Comparison of new OneLambda Flow DSA-XM with conventional flow crossmatch
Pamela M. Kimball, United States

P.300 Repeated freezing and thawing does not affect HLA antibody titer
Myoung Hee Park, Korea

P.301 A method for determining based on the frequencies of HLA alleles of HLA antibodies that are often observed with single antigen bead assay
Younhee Park, Korea

P.302 High prevalence of post-transplant donor specific HLA-DQ antibody in live related renal transplantation
Mirza Naqi Zafar, Pakistan

P.303 Humoral rejection in lung transplantation: more than Anti-HLA antibodies
David San Segundo, Spain

P.304 AT1R antibody assessment: How should we interpret positive results?
Lori J. West, Canada

P.305 Pretransplant discordant sera with a negative bead-based screening test and a positive single antigen test may reveal the presence of antibodies against denatured HLA antigens
Renaud Snaonoud, France

P.307 Non-HLA antibodies in highly sensitized renal transplant candidates
Angeliki Vittoraki, Greece

P.308 Risk Factors of De Novo Sensitization and DSA in Long-Term Renal Transplant Patients with Stable Graft Function
Efstratios Kasimatis, Greece

Complications Posters – P.310 to P.378

P.310 Surgical treatment for ureteral obstruction after kidney transplantation
Aydincan Akdur, Turkey

P.311 Recurrent glomerulonephritis after kidney transplantation in Saudi Arabia, single center retrospective study
Ehab H. Hammad, Saudi Arabia

P.312 Skin involvement in kidney allograft patients
Fabio Ruben Acosta, Argentina

P.313 Endovascular management of arterial complications following renal transplant biopsy
Cuneyt Aytekin, Turkey

P.314 Medical complications in living donor kidney transplant recipients in the developing world
Mukunda Prasad Kafle, Nepal

P.315 Juxta-anastomotic transplant renal artery pseudoaneurysm. A graft preserving option
Adam D. Barlow, United Kingdom

P.316 Importance of the dental treatment in renal-transplant recipients
Koichi Kozaki, Japan

P.317 Medical complications associated with renal transplantation, monitoring one year
Jose Medina-Polo, Spain

P.318 Complications into urinary tract following renal transplantation: Influence of bladder anastomosis technique and urinary catheters (double J Stent and urethral catheterization)
Jose Medina-Polo, Spain

P.319 Trends of mortality among renal transplant patients in Bahrain
Amgad E, El-Agroody, Bahrain

P.320 Kidney transplantation with grafts from old donors: Is there a difference in term of urological complications?
Jose Medina-Polo, Spain

P.321 Course and outcome of renal transplant recipients admitted to the intensive care unit (ICU): long term follow-up
Amgad E, El-Agroody, Bahrain

P.322 Intraoperative retrograde intrarenal surgery (RIRS) as a good management option for large ureteropelvic impacted stone of transplanted kidney
Giuseppe Latino, Italy

P.324 A proposed classification system and therapeutic strategy for chyle leak after laparoscopic live donor nephrectomy: A single-centre experience and review of literature
Zi Qin Ng, Australia

P.325 The incidence and clinical significance of isolated distal deep vein thrombosis in kidney transplant recipient
Ji Il Kim, Korea

P.326 Treatment of refractory small bowel bleeding with thalidomide after living donor kidney transplantation
Hyung Sub Park, Korea

P.327 Brain computed tomography and magnetic resonance imaging in neurological complications of liver and kidney transplantation
Feride Kural Rahatlı, Turkey

P.328 Long-term results of percutaneous balloon dilatation of ureteral stricture after kidney transplantation
Ruth Rahaimov, Israel

P.330 Treatment of persistent hyperparathyroidism after renal transplant: Single center experience
Gabriel G. Rivelli, Brazil

P.331 Acute rejection in kidney transplantation and early beginning of tacrolimus
Sergio Salcedo, Colombia
P.332 Combination therapy with BCAA intake and physical therapy improved leg strength in Japanese elderly kidney transplant recipients diagnosed as sarcopenia
Hitomi Sasaki, Japan

P.334 Contamination of preservation fluid in cadaveric renal transplantation
Ruben O. Schiavelli, Argentina

P.336 The coefficient of variability is the same in the mTOR-inhibitors?
Rosalia Valero, Spain

P.340 Non melanoma skin cancers in solid organ transplant recipients: A single center experience
Cagri A. Uysal, Turkey

P.341 Lung malignancy in solid organ transplant recipients: A case series
Sule Akcay, Turkey

P.342 A case of urinary bladder squamous cell carcinoma post renal transplant with a previous history of Bilharziasis
Ashraf Ali Attia, Saudi Arabia

P.344 High serum fibroblast growth factor 23 level is associated with metabolic syndrome in kidney transplantation patients
Ming-Chie Lee, Taiwan

P.345 Incidence and risk factors of post transplant diabetes mellitus in kidney transplant recipients in Qatar
Mohamad M. Alkadi, Qatar

P.346 Use of emaprilat in renal transplant recipients with post transplantation diabetes mellitus: Short term safety
Thea A. S. Halden, Norway

P.347 The effect of diabetes on serum magnesium levels after kidney transplantation
Gabriel Danovitch, United States

P.348 Correlation of pretransplant glucose metabolism and nonalcoholic fatty liver disease with the development of post transplantation diabetes mellitus
Sahil Bagai, India

P.349 Post-transplant lymphoproliferative disorders (PTLDs) after heart transplantation? Single center experience in Japan
Norhide Fukushima, Japan

P.350 Post-transplant lymphoproliferative Disorder (PTLD): a descriptive cross sectional study describing the presence of associated factors for PTLD in a cohort of first year post renal transplant patients in Sri Lanka
Adhyana IK Mahanama, Sri Lanka

P.351 A cross-sectional prospective study of low serum L-carnitine level associated with peripheral arterial stiffness in renal transplant recipients
Bang-Gee Hsu, Taiwan

P.352 Cardiovascular disease in kidney transplant recipients: Japan academic consortium of kidney transplantation (JACK) cohort study
Masayoshi Okumi, Japan

P.353 Development of recommendations for a core outcome set for clinical trials of physical rehabilitation in adults across the continuum of solid organ transplantation: a Canadian Delphi consensus study
Sunita Mathur, Canada

P.354 Early treatment with NPH insulin in renal transplantation and diabetes mellitus
Marfa del Carmen de Gracia Guindo, Spain

P.355 Cyclosporin a aggravates the calcification of vascular smooth muscle cells under high glucose conditions with a calcifying medium
Sang Youb Han, Korea

P.357 The assessment of cardiovascular risk in renal transplant recipients
Zbigniew Heleniak, Poland

P.358 The schedule of treatment and control of hypertension in hemodialysis patients and renal transplant recipients in 2006 and 2014/2016.
Zbigniew Heleniak, Poland

P.361 Changes in vitamin D levels after kidney transplantation
Gabriel Danovitch, United States

P.362 The impact of immunosuppression on mineral metabolism one year after kidney transplantation: differences between a mycophenolate-based regimen versus an mTOR inhibitor-based one
David Cucchiari, Spain

P.363 Worsening lumbar spin bone disease among steroid maintenance kidney allograft recipients in Qatar
Omar Mahjoub Flituri, Qatar

P.364 Early-onset and late-onset bacteremias after liver transplantation
Sang Il Kim, Korea

P.365 Occult hepatitis C virus in recipients of kidney transplantation: Prevalence and clinical implications
Carlos Jiménez, Spain

P.366 Incidence of viral infections after kidney transplantation in a single pediatric center
Majed Aloufi, Saudi Arabia

P.367 Prevalence of BK viraemia among post kidney transplant patients in Sri Lanka - a single center experience
Buddhista S. Mahanama, Sri Lanka

P.368 Infections by carbapenemase producing klebsiella pneumoniae bacteria in solid organ transplant recipients
Victoria E. Garcia, Spain

P.369 Adenovirus nephritis followed by visceral leishmaniasis in a renal transplant recipient
Helen K. Zanetti, Brazil

P.370 The examination of hepatitis E after renal transplantation
Yuki Nakagawa, Japan

P.371 How reliable is the management of cytomegalovirus by preemptive therapy after renal transplantation?
Helen K. Zanetti, Brazil

P.372 Dengue in the renal transplant population - a single center experience
Navdeep Singh, India

P.373 Tuberculosis in living donor kidney transplant recipients
Mukunda Prasad Kafe, Nepal

P.374 Acute graft-versus-host disease after liver transplantation: A case report and literature review
Yuichi Miura, Japan

P.376 Epidemiology of infectious complications in renal recipients in the first year after transplantation
Lilla Ben Fatma, Tunisia

P.378 Regular surveillance of BK viruria allows early detection of BK infection in kidney allograft and alleviates BK nephropathy
Ping Chin Lai, Taiwan
Infectious Disease Posters – P.380 to P.398

P.380 Mucormycosis in Turkey
Hande Arslan, Turkey

P.381 Urinary tract infections after kidney transplantation in fourteen medical centers in Turkey
Hande Arslan, Turkey

P.382 Clinical utility of a modified qRT-PCR for Trypanosoma cruzi detection in transplant patients
Florenzia Bonisconti, Argentina

P.383 Clinical efficacy of pretransplant vaccination for preventing herpes zoster after living donor liver transplantation in recipients aged 50 years and older
Chan Woo Cho, Korea

P.384 Adenovirus infection of the urinary tract after kidney transplantation
Kyung Chul Chung, Korea

P.385 Epidemiologic study and genotyping in renal transplant recipients BK virus
Marisa M. Cobos, Argentina

P.386 Activation of the calcium sensing receptor (CASR) prevents secretagogue-induced diarrhea in the rat small intestine
Michele Finotti, United States

P.387 Elimination of chronic hepatitis B in a kidney transplantation recipient via monotherapy: A case report
Mun Jang, Korea

P.388 Candidaemia among adult solid organ transplant recipients
Ozlem Kurt Azap, Turkey

P.389 Screening of recipients prior to liver and heart transplantation
Ozlem Kurt Azap, Turkey

P.390 The selective prophylaxis does not increase the risk of pneumocystis jirovecii pneumonia (PJP) after renal transplantation.
Ho Lee, Korea

P.391 Extensive cutaneous necrosis in kidney transplant. a rare case of mucormycosis
Dayana Sampaio De Almeida, Brazil

P.392 Efficacy of direct acting antiviral agents in dialysis patients with chronic hepatitis C virus infection on the kidney transplant waiting list: a single center experience
Abdulmedet Yildiz, Turkey

P.393 Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant recipients: Risk factors and spectrum of infectious complications
Igor Stoma, Belarus

P.394 A novel generative mycobacterium tuberculosis-specific T cells method for adoptive cellular therapy
Juan Zhang, People’s Republic of China

P.395 New strategy for deceased organ donor serology testing following two serious adverse occurrences
Aura Navarro, Spain

P.397 Incidence of Mycobacterium Tuberculosis disease following renal transplant, in a tertiary care hospital in South India
Satish Balan, India

P.398 Hospital course after TAH implantation, Nebraska experience
Diana Florescu, United States

Basic and Translational Sciences Posters – P.400 to P.489

P.400 Anti MICA antibody (major histocompatibility complex class i related chain a) whether to treat or avoid?
Pankaj R. Shah, India

P.401 Detection of donor-specific antibodies both in serum and cardiac allograft biopsy in heart transplant patients: Tissue DSA is more predictive than serum DSA
Bilkay Baturk, Turkey

P.402 Investigation of miRNA and anti HLA antibodies correlation in patients with kidney transplant
Bilkay Baturk, Turkey

P.403 Clinical importance of type 1 angiotensin II receptor (ATR1) y anti-endothelin-1 type a (ETAR) antibodies plus HLA antibodies in kidney transplantation.
Manuel Muro, Spain

P.404 Toll-like receptor 9 -1486C/T genetic polymorphism is associated with hepatocarcinoma recurrence after liver transplantation
Maria Jesus Citores Sanchez, Spain

P.405 A composite of urinary biomarkers to differentiate between tubulointerstitial inflammation and fibrosis in kidney allografts
Sung Shin, Korea

P.406 Predicting early viral control under DAA therapy for chronic HCV using pretreatment immunological markers
Akinbami R. Adenugba, Germany

P.407 Complement regulator CD46 transcripts are associated with progression of chronic antibody mediated rejection and recurrent IgA nephropathy
Aneta Plekova, Czech Republic

P.408 CD8 T effector memory t cells as predictive biomarker of severe acute rejection in lung transplantation
Maria Iglesias Escudero, Spain

P.409 Plasma inhibition of activation of lymphocyte from kidney transplants on various immunosuppressive drugs: Possible role of plasma exchange in anti-rejection therapy?
Alain G. Assounga, South Africa

P.410 Hypoxia induced ANKRD37 promotes angiogenesis and reprograms glucose metabolism in hepatocellular carcinoma following liver transplantation
Chuanhui Peng, People’s Republic of China

P.411 What’s normal? Using standardized flow cytometry immunophenotyping to create comprehensive pediatric reference ranges
Lori J. West, Canada

P.412 Ex vivo lung perfusion using the portable OCS maintains endothelial integrity in the context of reduced severe PGD rates
Christine S. Falk, Germany

P.413 The synthesis of coagulation factors during normothermic machine perfusion of livers is impaired by ischemia in pigs and might predict graft viability
Nicholas Gilbo, Belgium

P.414 Presence of pre-existing HLA antibodies in renal transplant patients and its impact during the first year post transplant
Mariana A. Selja II, Uruguay

P.415 Identification of plasma protein biomarkers of acute renal allograft rejection
Elaine F. Reed, United States

P.416 Defining secondary antibody deficiency after heart transplantation
Elizabeth Sarmiento, Spain

P.418 Mannose binding lectin (mbl2) genotype frequencies in solid organ transplant patients
Ikram Ezzahouri, Spain
The study of relationship between serum levels of soluble VEGF receptor-1 and soluble Fibrinogen-like protein 2 with delayed graft function after kidney transplantation

Hassan Nikoueinejad, Iran (Islamic Republic of)

Donor-derived cell-free DNA as minimally invasive tool to diagnose acute rejection after kidney transplantation

Carla C. Baan, Netherlands

Differential expression of metallothioneins and slc family genes in accommodation and subclinical antibody mediated rejection

Petra Hruba, Czech Republic

VDJ gene usage among B-Cell Receptors in ABO-incompatible kidney transplantation determined by RNA-seq transcriptomic analysis

Hee Jung Jeon, Korea

Genomic changes in pediatric renal transplant patients detected by aCGH

Feride I. Sahin, Turkey

Developing a rationale for an appropriate immunosuppressive regimen in lung vs kidney transplant recipients.

Paloma Leticia Martin Moreno, Spain

Soluble fibrinogen-like protein 2 regulates myeloid-derived suppressor cells differentiation and enhances its immunosuppressive function of in allograft immunity

Cheng Yang, People's Republic of China

Association of increased peripheral transitional B cells and plasmablasts with long-term kidney graft survival

Aneta Pletkova, Czech Republic

Immune modulatory effect of thalidomide and dexamethasone co-treatment on immune cells

Joon Ye Kim, Korea

Targeting trained immunity promotes organ transplant acceptance

Patricia Conde-San Román, Spain

NKT cells in the liver are important for peripheral tolerance induction

Wei Li, People's Republic of China

NK cells regulate CD8 t cell-mediated allogeneic rejection in immunocompetent recipients across an MHC class i mismatched barrier

Jose Ignacio Rodriguez-Barbaso, Spain

Standard induction immunosuppression interferes with the role of vascularized bone marrow in vascularized composite allograft protection

Josue Alvarez-Casas, United States

The effect of bisphosphonates on dendritic cells

Yuri Cho, Korea

Effect of native spleen preservation in an experimental model of modified multiorgan transplantation

Martin Rumbo, Argentina

Ischaemic tolerance and the effect of ageing using a rodent model after circulatory death (DCD) model

Hong Chee Chew, Australia

Underlying protective mechanisms of cortisol against the deleterious effects of brain death in both steatotic and non-steatotic liver transplantation

Mónica B. Jiménez-Castro, Spain

The protective effect of ischemic preconditioning and HMGB1 in steatotic liver grafts from brain-dead donors submitted to transplant

Maria Eugenia Comide Petronio, Spain

Effects of cortisol-induced acetylcholine accumulation on tissue damage and regeneration in steatotic livers in the context of partial hepatectomy under vascular occlusion

Maria Eugenia Comide Petronio, Spain

Astataxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice

Shaowei Li, Japan

Impact of diabetes on renal ischemia-reperfusion injury in a non-human primate model

Kyo Won Lee, Korea

Intra-renal delivery of drugs targeting ischemia-reperfusion injury of the kidney using normothermic machine perfusion

Ahmer M. Hameed, Australia

High oxygen pressure during continuous hypothermic machine perfusion is associated with a better ex vivo renal blood flow and early graft function in a porcine DCD auto-transplant model

Tom Darius, Belgium

Potential limitation for the use of cyclosporine as a cardioprotective agent during donor heart retrieval and storage

Ling Gao, Australia

Protective role of m-TOR system in fatty liver grafts preserved in IGL-1 and HTK solutions.

Arnau Panselló Rosello, Spain

Stereotyped molecular response during liver and kidney ischemia/reperfusion injury

Daniel G. Maluf, United States

Role of ubiquitin proteasome activation in fatty liver damage and regeneration in steatotic livers in the context of modified multivisceral transplantation

Perelman, Czech Republic

Histone deacetylase-11 gene deletion is protective in renal ischemia-reperfusion injury

Seth J. Concors, United States

Immune-mechanistic insights into improved lung preservation using the organ care system in a porcine transplantation model in comparison to the INSPIRE trial

Ann-Kathrin Knoefel, Germany

Effects of ulinastatin on liver warm ischemia reperfusion injury in mice

We Li, People's Republic of China

The polymer pro-drug APP-103 mitigates i/r injury and improves graft function in a pre-clinical renal transplant model

Koichiro Minami, United States

Prevention of ischemia-reperfusion injury and chronic rejection in a porcine vascularized composite allotransplantation model

Nicholas L. Robbins, United States

CD137L signaling is an inflammation checkpoint in renal inflammation

Jong Soo Lee, Korea

Addition of different oxygen concentrations during long-term hypothermic machine perfusion in a clinically relevant porcine donation after circulatory death model

Leonie H. Venema, Netherlands

Activation of autophagy by everolimus confers hepatoprotection against ischemia–reperfusion injury

Kee-Hwan Kim, Korea

In vivo and in vitro PPAR-y activation decreases m1-macrophage polarization and improves liver ischemia reperfusion injury

Matyas Hamar, Canada

Prevention of ischemic injury in colon and small intestine in an ex vivo perfusion animal model: The role of l-arginine and nutraceutical nanoparticles

Maria J. Barahona, United States

Recombinant thrombomodulin alpha protects kidney graft from damage after long cold ischemia time in a rat kidney transplant model

Kazunobu Shinoda, Japan

Ischemia reperfusion injury (IRI) causes local release of free heme which aggravates inflammation and contributes to delayed graft function

Falkah Gueler, Germany
The prognostic implications of renal function recovery and delayed graft function in kidney transplantation

Shafiley Sandal, Canada

Changes of glyocalyx in steatotic liver graft preservation with UW, HTK and IGL-1 solutions

Alexandre Lopez, France

Protective effect of ulvan (sulfated polysaccharide) pretreatment against hepatic ischemia-reperfusion injury in mice

Hyuk Jai Jang, Korea

Targeting innate immune cells and regulated cell death in early hepatic ischemia reperfusion injury

Elke Eggenhofer, Germany

Ex-vivo hyperbaric normothermic perfusion for 24 hours mitigates reperfusion injury in porcine vascular composite allotransplantation (VCA)

Matthew Wordsworth, United States

High throughput proteomic exploration of hypothermic preservation reveals dynamic processes within the cell interconnected to cold ischemia time

Thierry Hauet, France, Metropolitan

Dietary omega-3 food supplementation to attenuate renal ischemia reperfusion injury

Julian Doricic, Germany

B-cell activating factor BAFF reflects patients’ immunological risk profile after kidney transplantation

Antonia M. Schuster, Germany

Anti-CD40 antibodies do not cause thromboembolism as demonstrated by in vitro and in vivo studies

Tina Rubic-Schneider, Switzerland

Development of organized intra-graft lymphocyte clusters – role of b cell activating factor BAFF

Louisa Kühne, Germany

Human CD49dhighCD4+ T Cells have characteristics of innate-memory t cells and can help immunoglobulin production of B1 cells

Jae-Ghi Lee, Korea

CD137-CD137L interactions regulate B-cell autoimmunity during alloimmune responses

Jong Soo Lee, Korea

High intragenic methylation of SERPINB9, a regulator of cytotoxicity, in T cells as a marker for skin cancer after kidney transplantation

Fleur S. Peters, Netherlands

FK506 accelerates CoCl2-induced cytotoxicity via endoplasmic reticulum stress pathway in HepG2 cells

Sang Young Chung, Korea

The new role of HIF-1 in the development of renal fibrosis in mouse UUO model

Kazuya Kabei, Japan

Renal intra-arterial delivery of MSC to ischemic porcine kidneys: Retention, localization and survival

Jesus M. Sierra Parraga, Netherlands

Characterization of ex vivo created human multi-chimeric cells - a novel approach for tolerance induction in vascularized composite allotransplantation

Maria Siemionow, United States

Sarcoclemmal complement membrane attack complex deposits during acute rejection of myofibers in nonhuman primates

Daniel Skuk, Canada

Impact of MMP2, MMP9 and TIMP2 gene polymorphisms on allograft rejection in pediatric renal transplant recipients

Selin Akad, Turkey

Differences in the colon microbiome between patients with and without recurrence of primary sclerosing cholangitis

Thijmen Visseren, Netherlands
Cellular and Regenerative Therapies Posters – P.501 to P.518

P501  Effects of adipose-derived stem cell application on everolimus immunosuppressed rats on colon anastomosis: An experimental study  
Aydincan Akdur, Turkey

P502  Adipose-derived regenerative cells: therapeutic potential in IRI  
Ryan Ghita, United Kingdom

P504  Hepatocyte transplantation with magnet sorting after large hepatocyte for cholangiocellular carcinoma  
Masahiro Ito, Japan

P505  Gender based transcriptome expression in induced hepatocyte like cells (miHep)  
Sun A. Ock, Korea

P506  The optimization of the hepatocyte surface modification procedures in terms of heparin and apyrase for improving hepatocyte engraftment  
Hiroyuki Ogasawara, Japan

P507  Establishment of effective differentiation protocols for insulin-producing cells using a new 3D culture system from adipose-tissue derived mesenchymal stem cell  
Yu Saito, Japan

P508  Modifying renal gene expression by anti-sense oligonucleotide delivery during normothermic machine perfusion  
Avinash Sewpaul, United Kingdom

P509  Effect of SOX9 on ductular reaction and fibrogenesis  
Keita Shimata, Japan

P510  Dna demethylation agents promote pancreatic endodermal differentiation of mesenchymal stem cells  
Kisha N. Sivanathan, Australia

P511  Development of young porcine islet maturation in vitro through helper dependent adenovirus carrying INS-venus  
Yuzumi Sugahara, Japan

P512  Dynamics of glucagon-like Peptide -1 in patients with Type 1 diabetes mellitus after autologous hematopoietic stem cell transplantation  
Olga Ulyanova, Kazakhstan

P513  Role of adipose tissue-derived mesenchymal stromal cells in preventing rejection in rat intestinal transplantation  
Ane M. Andres, Spain

P517  Structural modification of alginate microbeads containing human hepatocyte and mesenchymal stromal cells as a potential way to improve hepatic functions for cell transplantation in acute liver failure  
Charlotte A. Lee, United Kingdom

P518  Adoptive transfer of HVEG signal induced alloreactive regulatory T cell protect rejection in allogeneic murine cardiac transplantation model  
Koichiro Uchida, Japan

Xenotransplantation Posters – P.520 to P.539

P520  Partial xenotransplantation from the porcine trachea to the dog trachea  
Seok-Hwa Choi, Korea

P521  Structural and expression analyses of porcine tumor necrosis factor receptor 2 variants  
Cristina Costa, Spain

P522  Genetic engineering in xenotransplantation: What human transgenes should the GTKO.hCD46 pig lung donor additionally express?  
Lars Burdorf, United States

P523  Re-endothelialization of liver xenografts utilizing human endothelial cells  
Laura DiChiacchio. United States

P524  Multivisceral xenotransplantation: The effect of different species combination  
Flavio H F Galvao, Brazil

P525  Combining enhancement of inhibitory signals and blockade of co-stimulation to modulate human anti-pig immune responses  
Rabea Hein, Germany

P526  Glycoproteomic characterization of α-1,3-galactosyltransferase and isoglucosylceramide synthase double knock-out cells  
Seongsoo Hwang, Korea

P527  South Korean student opinions about xenotransplantation  
Kyeonghee Jang. United States

P528  Inflammatory responses in α,3—galactosyltransferase gene-knockout (GTKO) porcine vascular retransplantation to cynomolgus monkeys  
Eun Mi Lee, Korea

P529  Porcine neonatal islet-like cell clusters cultured with EGM2 medium enhance their resistance to apoptosis in islet xenotransplantation  
Xiaoqian Ma, People’s Republic of China

P529a  Human CD31 suppress macrophage-mediated xenogeneic rejection  
Akira Maeda, Japan

P531  PQA-18, a novel immunosuppressant, suppresses macrophage differentiation and macrophage-mediated xenogeneic cytotoxicity  
Akira Maeda, Japan

P532  Attitude of the chronic kidney disease patients toward xenotransplantation of organs  
Mohan Patel, India

P533  Transplantation outcome after pig to mouse intra-portal islet transplantation  
Jun-Seop Shin, Korea

P534  Real time high-resolution imaging of porcine endothelial glycocalyx shedding by human serum in an in vitro microfluidic model of pig-to-human xenotransplantation  
Riccardo Sfriso, Switzerland

P535  Expression of human thrombomodulin on GTKO.CD46 donor pigs and costimulation blockade by anti CD40 antibody is critical for extending cardiac xenograft survival in non-human primates  
Ameesh Singh, United States

P536  Composite tissue xenopreservation  
Fath Zor, United States

P538  Operational tolerance in xenotransplantation by use of regulatory T cells with a SLA-specific chimeric antigen receptor  
Elmar Jaeckel, Germany

P539  Additive expression of hTBM on hCD46 stable cell line has synergistic effect on complement regulation  
Hwajung Kim, Korea
Use of norepinephrine in pancreas donors and its influence on
alloresponse and outcome in type 1 diabetes islet transplantation recipients

Min Hu, Australia

Quercetin enhanced the function of mouse islets

Hyuk Jai Jang, Korea

Australian experience of total pancreatectomy and islet auto transplant (TPIAT) utilizing a remote isolation center

Chris J. Droegemueller, Australia

Pre-clinical results of islet allo-transplantation using JAK inhibitor as replacement for tacrolimus widely used immunosuppressive drug in islet transplantation in cynomolgus monkeys

Jong-Min Kim, Korea

Development of a highly effective protocol using local immune suppression strategy in pancreatic islet transplantation

Shiva Pathak, Korea

Construction of EMSC-islet co-localizing composites for xenogeneic porcine islet transplantation

Jung-Sik Kim, Korea

Improvement of metabolic function after intra-portal allogeneic islet transplantation using induction treatment of the non-hematopoetic erythropoietin analogue cibinetide in a mouse model

Ming Han Yao, Sweden

Islet identity in patients with pancreatitis

Omaima M. Sabek, United States

The effect of steroid maintenance in recipients with pancreas transplant alone: A single center experience

Ji Yoon Chol, Korea

A fatal course after combined pancreas kidney transplantation from a donor with HELLP-syndrome

Malwina Bialobrzecka, Germany

Antibody mediated rejection due to de-novo DSA causing venous thrombosis of pancreas allograft – a case report

Kunal Yadav, United States

Use of norepinephrine in pancreas donors and its influence on patient and graft survival

Alberto A. Marcucuzzy Quinto, Spain

Preserved insulin sensitivity and kidney function one year after successful pancreas transplantation

Espen Nordheim, Norway

Results of pancreas transplantation in the twenty-one century: A single center experience in Spain

Jaime López, Spain

Endoscopic intervention can prevent reoperation in patients after pancreas transplantation – the advantage of the duodenoduodenal anastomosis

Marek Dunlik, Poland

Complications after pancreas transplantation

Lea Berger, Germany

Update on clinical trial EMA – SPK: Everolimus verus mycophenolic acid in simultaneous pancreas and kidney transplantation to evaluate the differences in retinal neovascularisation in patients with diabetic retinopathy

Barbara Voglova, Czech Republic

De novo glomerulonephritis in simultaneous pancreas-kidney transplantation: A single center experience

Christian Margreiter, Austria

Impact of peritoneal dialysis on SPK results

Agnieszka Surowiecka-Pastewka, Poland

Pre-operative predictors of health-related quality of life for pancreas transplant recipients

Irene Mosca, United Kingdom

Pancreas and Islet Posters – P.545 to P.569

Pancreas graftectomy predicting markers

Agnieszka Surowiecka-Pastewka, Poland

Enteric leaks following simultaneous pancreas and kidney transplantation: Associated risk factors and management in the Westmead Hospital Transplantation Program

Amy Hort, Australia

Delayed pancreas graft function – a challenge for clinicians

Marta Matejak-Górská, Poland

Causes and risk factors of pancreas graft loss: A single center study

Ichiro Koyama, Japan

Role of intravascular interventions in simultaneous pancreas and kidney transplantation - almost 15 years of experience

Marta Matejak-Górská, Poland

Results of pancreas transplantation in the twenty-one century: A single center experience in Spain

Jaime López, Spain

Endoscopic intervention can prevent reoperation in patients after pancreas transplantation – the advantage of the duodenoduodenal anastomosis

Marek Dunlik, Poland

Complications after pancreas transplantation

Lea Berger, Germany

Update on clinical trial EMA – SPK: Everolimus verus mycophenolic acid in simultaneous pancreas and kidney transplantation to evaluate the differences in retinal neovascularisation in patients with diabetic retinopathy

Barbara Voglova, Czech Republic

De novo glomerulonephritis in simultaneous pancreas-kidney transplantation: A single center experience

Christian Margreiter, Austria

Impact of peritoneal dialysis on SPK results

Agnieszka Surowiecka-Pastewka, Poland

Pre-operative predictors of health-related quality of life for pancreas transplant recipients

Irene Mosca, United Kingdom

Pancreas and Islet Posters – P.545 to P.569

Pancreas graftectomy predicting markers

Agnieszka Surowiecka-Pastewka, Poland

Enteric leaks following simultaneous pancreas and kidney transplantation: Associated risk factors and management in the Westmead Hospital Transplantation Program

Amy Hort, Australia

Delayed pancreas graft function – a challenge for clinicians

Marta Matejak-Górská, Poland

Causes and risk factors of pancreas graft loss: A single center study

Ichiro Koyama, Japan

Role of intravascular interventions in simultaneous pancreas and kidney transplantation - almost 15 years of experience

Marta Matejak-Górská, Poland

Results of pancreas transplantation in the twenty-one century: A single center experience in Spain

Jaime López, Spain

Endoscopic intervention can prevent reoperation in patients after pancreas transplantation – the advantage of the duodenoduodenal anastomosis

Marek Dunlik, Poland

Complications after pancreas transplantation

Lea Berger, Germany

Update on clinical trial EMA – SPK: Everolimus verus mycophenolic acid in simultaneous pancreas and kidney transplantation to evaluate the differences in retinal neovascularisation in patients with diabetic retinopathy

Barbara Voglova, Czech Republic

De novo glomerulonephritis in simultaneous pancreas-kidney transplantation: A single center experience

Christian Margreiter, Austria

Impact of peritoneal dialysis on SPK results

Agnieszka Surowiecka-Pastewka, Poland

Pre-operative predictors of health-related quality of life for pancreas transplant recipients

Irene Mosca, United Kingdom
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.575</td>
<td>Impact of donor with positive bacterial infections in deceased donor liver transplantation</td>
<td>Kun-Ming Chan, Taiwan</td>
</tr>
<tr>
<td>P.576</td>
<td>Influences on a culture that supports organ donation after circulatory death</td>
<td>Luke Milross, Australia</td>
</tr>
<tr>
<td>P.577</td>
<td>Increased serum sodium values in a brain-dead donor do not influence the long-term kidney function</td>
<td>Mamoru Kusaka, Japan</td>
</tr>
<tr>
<td>P.578</td>
<td>Impact of in situ cold perfusion of kidney grafts during vascular anastomosis</td>
<td>Shinji Tora, Japan</td>
</tr>
<tr>
<td>P.579</td>
<td>Causes of rejection for organ donation by family of deceased donor</td>
<td>Jinwoo Seo, Korea</td>
</tr>
<tr>
<td>P.580</td>
<td>Long term management of a deceased organ donor- an organ donor coordinator's point of view</td>
<td>Nina Seng, Australia</td>
</tr>
<tr>
<td>P.581</td>
<td>Donor brain death alters plasma protein levels and is dependent of cause of death</td>
<td>Jan Lukac, Finland</td>
</tr>
<tr>
<td>P.582</td>
<td>Opportunities to increase organ availability from neonatal donors. The United States experience</td>
<td>Thomas A. Nakagawa, United States</td>
</tr>
<tr>
<td>P.583</td>
<td>Analysis of the reasons donor families donate organs for organ transplantation</td>
<td>Eunji Lee, Korea</td>
</tr>
<tr>
<td>P.584</td>
<td>Effects of phased education on attitudes toward organ donation and willingness to donate after brain death in an Asian country</td>
<td>Young-Nam Roh, Korea</td>
</tr>
<tr>
<td>P.585</td>
<td>Role of body mass index in determining outcomes after renal transplantation: A retrospective single-centre observational study</td>
<td>Binay Gurung, United Kingdom</td>
</tr>
<tr>
<td>P.586</td>
<td>Analysis of family interviews in uncontrolled DCD in the community of Madrid</td>
<td>Alonso Mateos Rodriguez, Spain</td>
</tr>
<tr>
<td>P.587</td>
<td>Survival analysis of deceased donor organ transplantation in a third world country</td>
<td>Noble Gracioux Sr., India</td>
</tr>
<tr>
<td>P.588</td>
<td>Optimal hemodynamic monitoring in deceased donor</td>
<td>Sang Youb Han, Korea</td>
</tr>
<tr>
<td>P.589</td>
<td>Impact of extraction time during organ procurement on kidney function after transplantation</td>
<td>Erika Rademaker, Netherlands</td>
</tr>
<tr>
<td>P.590</td>
<td>A kidney with type II damage to be transplanted into a patient undergoing treatment with antiplatelet and anticoagulant medications</td>
<td>Shunri Taniguchi, Japan</td>
</tr>
<tr>
<td>P.591</td>
<td>Donor body mass index as a risk factor for delayed onset of graft function</td>
<td>Juraj Miklušíčka, Slovakia (Slovak Republic)</td>
</tr>
<tr>
<td>P.592</td>
<td>The preliminary experience of deceased organ transplantation in local hospital</td>
<td>Shin Do Suh, Korea</td>
</tr>
<tr>
<td>P.593</td>
<td>Experience with hypothermic machine perfusion in extended criteria donors. Functional outcomes</td>
<td>Mercedes M. Ruiz Hernández, Spain</td>
</tr>
<tr>
<td>P.594</td>
<td>Implementation of a quality management system on organ donation in the Kingdom of Saudi Arabia (KSA)</td>
<td>Besher Al-Attar, Saudi Arabia</td>
</tr>
<tr>
<td>P.595</td>
<td>Impact of logistics with the cold ischemia time of utilized deceased organs in KSA; years 2015-2016</td>
<td>Besher Al-Attar, Saudi Arabia</td>
</tr>
<tr>
<td>P.596</td>
<td>Attitudes and knowledge about donation in Catalonia</td>
<td>Jaume Tort Bartolet, Spain</td>
</tr>
<tr>
<td>P.597</td>
<td>Use of the capnometry as a renal graft evolution predictor in uncontrolled cardiac arrest death donors</td>
<td>Alicia Villar-Arias, Spain</td>
</tr>
<tr>
<td>P.598</td>
<td>PDSA cycles show improvements in key indicators in deceased donation: The Spanish experience</td>
<td>Christel Terron, Spain</td>
</tr>
<tr>
<td>P.599</td>
<td>Features of deceased kidney transplantation in KSA; 2014-2016</td>
<td>Faisal Shaheen, Saudi Arabia</td>
</tr>
<tr>
<td>P.600</td>
<td>Survival analysis after kidney-pancreas and kidney transplant in Argentina</td>
<td>Liliana Bisigniano IV, Argentina</td>
</tr>
<tr>
<td>P.601</td>
<td>Survival analysis in uncontrolled DCD in the Kingdom of Saudi Arabia (KSA)</td>
<td>Besher Al-Attar, Saudi Arabia</td>
</tr>
<tr>
<td>P.602</td>
<td>Standard vs modified technique of laparoscopic living donor nephrectomy: First experience in Lithuania</td>
<td>Agne Laucyte-Cibulskiene, Lithuania</td>
</tr>
<tr>
<td>P.603</td>
<td>The early effects of kidney donation in living kidney donors</td>
<td>Palash Mitra, Bangladesh</td>
</tr>
<tr>
<td>P.604</td>
<td>Long-term risks for living kidney donors</td>
<td>Solon Castillo, Spain</td>
</tr>
<tr>
<td>P.605</td>
<td>Which Spanish living kidney donors fear post donation kidney failure?</td>
<td>Xavier Torres, Spain</td>
</tr>
<tr>
<td>P.606</td>
<td>Challenges of renal transplantation in Asia</td>
<td>Anwar Naqvi, Pakistan</td>
</tr>
<tr>
<td>P.607</td>
<td>Health information management for clinical monitoring, research, and quality assurance in living kidney donor evaluation: The comprehensive living kidney donor database</td>
<td>Olusegun Famure, Canada</td>
</tr>
<tr>
<td>P.608</td>
<td>Crossed transplant: A strategy that maximizes benefits and minimizes risks</td>
<td>Carlos E Pregno, Argentina</td>
</tr>
<tr>
<td>P.609</td>
<td>The role of teenage living donor in Korean transplantation activity</td>
<td>Jeehye Chung, Korea</td>
</tr>
<tr>
<td>P.610</td>
<td>Living unrelated kidney transplantation: Does it prevent deceased donor kidney transplantation growth?</td>
<td>Mohammad Nadjafi-Semnani, Iran (Islamic Republic of)</td>
</tr>
<tr>
<td>P.611</td>
<td>Kidney transplantation from living donor allograft with small renal cell cancer after laparoscopic partial nephrectomy: A case report</td>
<td>Young Hwa Kim, Korea</td>
</tr>
<tr>
<td>P.612</td>
<td>Comparison of formulas estimating GFR with scintigraphy-measured GFR in living kidney donor candidates</td>
<td>Julia Mróz, Poland</td>
</tr>
<tr>
<td>P.613</td>
<td>Usefulness of serum uromodulin and beta trace protein (BTP) in evaluation of glomerular filtration rate in living kidney donor candidates</td>
<td>Łukasz Białek, Poland</td>
</tr>
</tbody>
</table>
Preclinical modeling of DCD class iii donation and evaluation of the most adapted preservation protocol: Paving the way for the increased use of this challenging donor type
Thierry Haue, France, Metropolitan

Organ utilization following drug overdose death is variable by region in the United States
Laura A. Hickman, United States

Renal allografts from brain dead donors following cerebral gunshot wounds
Carlos Jiménez, Spain

The relationship between marginal and non-marginal kidney transplants
Erzin Elgin, Turkey

The use of donor with renal failure in cadaver and one-year outcome
Erzin Elgin, Turkey

Analysis of the lung donors in the Chinese mainland
Qianli Ma, People's Republic of China

The role of clinical and morphological factors in evaluation of donor liver suitability for transplantation
Marina Minina, Russian Federation

International Registry in Organ Donation and Transplantation (iRODAT) - 2016 worldwide data
Maria Paula Gómez, Spain

Self-sufficiency in organ donation and transplantation
Maria Paula Gómez, Spain

Needs for a paediatric organ and tissue donation protocol: An overview of the literature
Alicja Vleito, Netherlands

Analysis of reasons for rejection and discontinuance of tissue donation in Korea
Ohhyuk Yun, Korea

Analysis of improving effect of organ donation culture by world transplant game in Korea
Ik Jin Yun, Korea

Evolution of donation and transplantation after circulatory death activities (2012-2016): review of the newsletter Transplant of the Council of Europe
Jaime Marco, Spain

Organ donation programs and the definition of success: A scoping review preliminary results
Vanessa Silva e Silva, Canada

Understanding the influence of inter-professional relational networks within organ donation programs in Ontario: A research protocol and preliminary results
Vanessa Silva e Silva, Canada

Knowledge and attitude towards organ donation among medical residents. Lima-Peru
Ana Cecilia Pastor Ludênia II, Peru

Analysis of the incidence of brain death per ventilator in the intensive care units of a general hospital
Hernando Trujillo, Spain

Change the hospital culture - make donation routine
Rosemary O'Meeghan, United States

Experience with cadaveric arterial conduits as hemodialysis access
Deepesh B. Kenwar, India

The factors affecting the awareness about transplantation and decision of organ donation in Istanbul, Turkey
Ali Çevik, Turkey

Open data on donation and transplantation in Buenos Aires City
Luis D. Rojas, Argentina

Follow-up on donor family
Luis D. Rojas, Argentina
Continuous training of critical care professional to increase organ donation rates in Yunnan province and Guangxi autonomous region in China

Chao Li, People's Republic of China

Donor risk index could be a predictor of "resistant to flow" liver grafts

Pablo Lozano, Spain

Solvable mortality in Latin America related with lack of organ for transplantation

Francisco Gonzalez-Martinez, Uruguay

Law and increasing kidney donation in Australia: Is the law complicating increasing living kidney donation?

Mayowa Oyeniyi Ajigboye, Australia

Criminal liability of medical professionals who engage in organ trafficking and human trafficking for the purpose of organ removal, and their obligations to assist in preventing and curbing these crimes

Sylwia Gawronska, Poland

Attitude toward living liver donation after an audiovisual educational intervention on teenagers

Javier Almela, Spain

Knowledge regarding brain death and organ donation laws among medical students

Manish Ramesh Baiwani, India

Impact on teenagers of completing a questionnaire about organ donation and transplantation

Beatriz B. Gómez, Spain

Factors affecting compliance to calcineurin inhibitors among solid organ transplant recipients

Chi Yuen Simon Cheung, Hong Kong

A joint effect to train over 1,200 Chinese medical professionals for organ donation in 5 years in China to boost up the organ donation rate

Wenshi Jiang, People's Republic of China

Impact of training volunteers for creating awareness on organ donation

Pallavi Kumar, India

Effect on each step strategy of donation by DIP in Korea

Jyoun Kwon, Korea

Seeding life: Cooperation for innovation and exchange of good practices in education in organ donation and transplantation

Marí Manyalich, Spain

Knowledge, attitude and perception about kidney disease and renal transplantation among care givers of CKD patients

Masud M. Iqbal, Bangladesh

Using informatic education strategy to break through the dilemma of teaching transplantation in medical institutions – multidisciplinary medical team perspectives

Ming Hsin Hsieh, Taiwan

Using informatic education strategy to break through the dilemma of teaching transplantation in medical institutions – compare medical and administrative informatic team perspectives

Ming Hsin Hsieh, Taiwan

Trends in organ transplantation. DCD in West Pomeranian in Poland.

Marek Ostrowski, Poland
Transplantation Nursing Posters – P.695 to P.697

P.695 Fatigue one to five years after lung transplantation - A significant problem
Anna Forsberg, Sweden

P.697 Postoperative nursing and nutrition support in non-human primate recipients of combined donor-matched vascularized osteomyocutaneous and renal allografts
Xin Xiao Zheng, People's Republic of China

Vascularized Composite Allotransplantation Posters – P.700 to P.707

P.700 Results of combined penetrating keratoplasty and implantation of posterior chamber intraocular lenses
Leyla Asena, Turkey

P.701 Visual rehabilitation after penetrating keratoplasty
Leyla Asena, Turkey

P.702 Descemet's membrane endothelial keratoplasty (DMEK): 6-month clinical outcomes
Dilek Dursun Altinors, Turkey

P.703 Customizing illumination by the operating microscope aids the visualization of DMEK grafts
Dilek Dursun Altinors, Turkey

P.704 Effect of cold-preservation on the vessels of vascularized composite allografts in rats
Luis Landin, Spain

P.705 Surgical technique for pelvic floor transplantation
Flavio HF Galvao, Brazil

P.706 Foxp3+ Treg cells resident within donor bone marrow are essential for costimulation blockade-induced long-term survival of murine limb transplants
Liqing Wang, United States

P.707 Aesthetic surgery in transplantation patients: A single center experience
Cagri A. Uysal, Turkey

Heart and Lung Posters – P.710 to P.732

P.710 Thyroid disorders in recipients after heart transplantation
Maria M. Simonenko, Russian Federation

P.711 Thirty-year dynamics of survival among heart recipients: A single center Russian experience
Alex O. Shevchenko, Russian Federation

P.712 Relationship between glycemic control and survival in heart transplant recipients.
Jose Manuel Sobrino-Marquez, Spain

P.713 IgM-enriched human intravenous immunoglobulin for treatment of early antibody mediated rejection after heart transplantation
Markus J. Barten, Germany

P.714 Early adjunctive treatment with human cytomegaly virus (CMV) immunoglobulin increased CMV-free survival after heart transplantation
Carolin Neumaier, Germany

P.715 Posterior reversible encephalopathy syndrome after pediatric heart transplantation
Ilkay Erdogan, Turkey

P.716 Results of endomycocardial biopsy in children with heart transplantation
Ilkay Erdogan, Turkey

P.717 What should be the treatment approach in patients with cardiac allograft vasculopathy?
Ozgur Esoy, Turkey

P.718 Left ventricular assist device management strategy
Atilla Sezgin, Turkey

P.719 Impact of renal injury on survival following left ventricular assist device
Atilla Sezgin, Turkey

P.720 High cardiac output immediately after heart transplantation is an independent risk factor of seizure early posttransplant
Keiichiro Iwasaki, Japan

P.721 Extracorporeal photopheresis (ECP) and calcineurin inhibitor (CNI) delay after heart transplantation
Johannes Goekler, Austria

P.722 Lung related complications in heart transplant recipients: results of a single center experience
Sule Akay, Turkey

P.723 The pathological analysis of underlying diseases of explanted hearts and outcome of recipients: a single center 100 cases experience
Hatsue Ishibashi-Ueda, Japan

P.724 A man of many devices. A 15 year old boy with exclusively myocardial mitochondrial disease received a LVAD, TAH, an orthotopic heart transplant and ECMO in one inpatient episode
Aaraby Ragavan, United Kingdom

P.725 Immune monitoring of regulatory CD4 T cells in heart recipients using one-single dose versus two-dose basiliximab induction
Elizabeth Sarmiento, Spain

P.726 Immunological factors associated with health status of heart transplant recipients long-term after transplantation
Javier Carbone, Spain

P.727 Is tricuspid annular plane systolic excursion (TAPSE) predictor for out patients with Ivd right ventricular failure in Ivd patients with preoperative low value (TAPSE) on mild-term follow up
Umit Kervan, Turkey

P.728 How long can we safely follow transplant patients with ineffective anticoagulation after left ventricular assist device implantation
Umit Kervan, Turkey

P.729 Lower post-transplant 1 month tacrolimus level less than 10 ng/mL was associated with poor patient survival in lung transplant patients
Junghwa Ryu, Korea
P.730  Aspergillus infections in patients received lung transplantation
Wenhui Chen, People's Republic of China

P.731  Infection from lung allograft donors in lung transplantation
Wenhui Chen, People's Republic of China

Wenjun Mao Sr, People's Republic of China

Paediatrics Posters – P.735 to P.757

P.735  Azathioprine versus mycophenolate mofetil in combination with tacrolimus and steroids maintenance in pediatric kidney transplantation
Sahar M. Al-Mowainia, Saudi Arabia

P.736  Meaning of positive anti-HLA antibodies in simultaneous liver-kidney transplantation
Ángel Alonso Melgar, Spain

P.737  Clinical findings and explant liver histology in Crigler Najjar disease
Zeren Baris, Turkey

P.738  Experience of post-transplant lymphoproliferative disorder (PTLD) after pediatric liver transplant: Incidence, outcomes and association with food allergy
Zeren Baris, Turkey

P.739  Cardiac function in children after kidney transplantation
Kenan Caliskan, Turkey

P.740  Catch-up growth evaluation after liver transplant...experience in Fundación Valle del Lílí
Luis Caicedo, Colombia

P.741  Whole deceased donor liver transplantation in pediatric recipients less than 10 kg. retrospective analysis of outcome and surgical complications
Ivan Capobianco, Germany

P.742  The value of working together: Organ transplantation in a highly specialized pediatric transplantation center
Luis García-Guerrera, Spain

P.743  Transplantchild, an European Strategy to Attend “The Secondary Rare Disease” Induced by Pediatric Transplantation
Francisco Hernandez, Spain

P.744  Transplantation and resection of the liver for multimodal treatment of hepatoblastoma
Oleg Kotenko, Ukraine

P.745  Increasing obesity prevalence in the United States pediatric end-stage renal disease population
Jayme E. Locke, United States

P.746  The effects of graft weight on allograft outcomes in pediatric patients
Gokhan Moray, Turkey

P.747  Renal blood flow measurements by magnetic resonance imaging using arterial spin labelling as a novel non-invasive biomarker in paediatric renal transplant recipients
Stephen D. Marks, United Kingdom

P.748  Postoperative platelet count can predict splenic volume expansion after living donor liver transplantation in pediatric patients with biliary atresia
Yuki Noguchi, Japan

P.749  Clinical features, laboratory findings and prognosis in Fulminant Wilson’s disease
Figen Ozciay, Turkey

P.750  Incidence, clinical features and prognosis of food allergy in children who underwent liver transplantation
Figen Ozciay, Turkey

P.751  Development of a pediatric liver transplant program in a developing country: From deceased to living donors. 10-year experience
Jairo Eduardo Rivera Baquero Sr, Colombia

P.752  Double heterozygous mutation causing PFIC2 with synchronic hepatocellular carcinomas before two years of age
Julio J. Trentadue, Argentina

P.753  Impact of Kasai portoenterostomy on liver transplantation in patients with a history of biliary atresia at the Fundacion Cardioinfantil
Jairo Eduardo Rivera Baquero Sr, Colombia
Intestine & Multivisceral Transplantation Posters – P.761 to P.769

P.761  Multivisceral transplantation for diffuse portomesenteric thrombosis: A case series
Emilio Canovali, Belgium

P.763  Implication of the spleen in pediatric multivisceral transplantation
Inmaculada Hidalgo Montes, Spain

P.765  Grafting’s function in patients with liver intestinal and multivisceral transplantation
Inmaculada Hidalgo Montes, Spain

P.767  Postoperative infections following intestinal transplantation
Barbara Kern, Germany

P.769  Long term outcomes after intestinal transplantation from a single South American center, lessons learned
Julio J. Trentadue, Argentina

Anesthesia Management and Critical Care Posters – P.775 to P.783

P.775  Validating the McCluskey index for the necessity for hemoderivative transfusion in our liver transplant serie
Pilar Del Pozo, Spain

P.776  Hemoderivates transfusion differences between recipients of liver grafts from donors after uncontrolled cardiac death (uDCD) and brain death donors (DBD)
Pilar Del Pozo, Spain

P.777  Incidence of acute kidney injury following liver transplantation
Zeynep Ersoy, Turkey

P.778  Anesthesiologic management for multivisceral transplant: A case report
Aida Fernández García, Spain

P.779  Anesthetic management of renal and liver transplantation recipients during cesarean section
Zeynep Kayhan, Turkey

P.780  Perioperative predictors of acute kidney injury after liver transplantation and its impact on postoperative outcome
Cristina J. Lisboa, Spain

P.781  Determinants of one-year mortality in lung transplants recipients readmitted to intensive care unit
Judit Sacanel, Spain

P.782  Early postoperative acute kidney injury among pediatric liver transplant recipients
Pinar Zeyneloglu, Turkey

P.783  Renal replacement therapy for renal transplant recipients during ICU stay
Adnan Torgay, Turkey
Liver Posters – P.800 to P.904

P.800 Postoperative tracheal extubation after pediatric liver transplantation
   Adnan Torgay, Turkey

P.801 Successful living donor liver transplantation in a case of mean pulmonary arterial pressure of 52 mmHg
   Yang Won Yang Nah, Korea

P.802 Do we still need a veno-venous bypass service in liver transplantation? A survey of UK practice
   Vivienne N. Hannon, United Kingdom

P.803 Preemptive chest tube in liver transplantation – an unconventional way to reduce morbidity
   Leke Wiering, Germany

P.804 Effect of meal intake for evaluating hepatic artery by doppler ultrasonography in liver transplantation patients: Does fasting matter for screening hepatic artery due to hemodynamic changes in splanchnic circulation?
   Nihal Uslu, Turkey

P.805 Impact of the donor age and comorbidities on graft survival after liver transplant due to hepatocellular carcinoma. Experience in 100 consecutive cases
   Luis Alberto Martinez Insfran, Spain

P.807 Risk factors for graft steatosis after liver transplantation using controlled attenuation parameter measurements
   James Fung, Hong Kong

P.809 Association between liver perfusate natural killer cellular subset from deceased brain donors and acute cellular rejection after liver transplantation procedure: Single center analysis.
   Calogero Ricotta, Italy

P.810 Liver transplantation as a feasible and definitive treatment for advanced polycystic liver disease: Our experience and outcomes
   Cristina Cobo, Spain

P.810a Implications of doppler alterations on outcomes after liver transplantation. Our experience in the last seven years
   Cristina Cobo, Spain

P.811 Percutaneous transhepatic tips for Budd-Chiari syndrome: Direct simultaneous puncture of portal vein and inferior vena cava
   Fatih Boyvat, Turkey

P.812 Post-liver transplant (LT) early allograft dysfunction (EAD) is associated with lack of post-LT renal recovery
   Hani M. Wadei, United States

P.813 Sarcopenia no longer impacts survival after LDLT managed with early enteral feeding protocols but its postoperative prevalence is still significant
   Riccardo Pravisani, Italy

P.814 Liver abcesses after liver transplantation
   Isabel Lechuga Alonso, Spain

P.815 The influence of AbgA antibodies as a vascular complication marker in liver transplantation
   Isabel Lechuga Alonso, Spain

P.816 Clinical course of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation
   Didem Ozer Etil, Turkey

P.817 Malnutrition is associated with poor outcomes after liver transplantation: A promising target for pre-transplantation nutritional intervention
   Su Kah Goh, Australia

P.818 Hepatic venous outflow obstruction after living-donor liver transplantation using right lateral sector graft
   Rihito Nagata, Japan

P.820 Report of two cases of acute pancreatitis after liver transplantation for HCC
   Qinfen Xie, People's Republic of China

P.821 C-reactive protein before liver transplantation is predictive of post-transplant mortality
   Robert M. Jones, Australia

P.822 Successful treatment of a case of complex bile duct stones and gastrointestinal bleeding with liver transplantation and interventional radiology
   Qinfen Xie, People's Republic of China

P.823 The experience of pseudoaneurysm rupture of the hepatic artery after living donor liver transplantation
   Masashi Kadohisa, Japan

P.824 Percutaneous transhepatic portal vein angioplasty for portal vein stricture after living donor liver transplantation
   Atsuyoshi Mita, Japan

P.825 Single center experience on the clinical course of hepatic artery thrombosis after living donor liver transplantation using right lobe
   Ho Joong Choi, Korea

P.826 Comparable levels of inflammatory mediators in portal venous blood collected from organ donors donating after circulatory death and those donating after brain death
   Janske Reiling, Australia

P.827 Long-term follow-up of patients with primary sclerosing cholangitis undergoing liver transplantation with duct-to-duct biliary
   Bijan Eghtesad, United States

P.828 Comparison between cadaveric whole liver and live donor partial liver transplantation in high risk patients with MELD score more than 40
   Chul Soo Ahn, Korea

P.829 Post liver transplant biliary complications and management in local university hospital
   Tae-Seok Kim, Korea

P.830 A hundred experiences of liver transplantation in local university hospital
   Tae-Seok Kim, Korea

P.831 Liver transplantation in patients with pre-existing portal vein thrombosis: Results of a single center
   Sedat Yildirim, Turkey

P.832 Adherence of immunosuppression therapy and donor-specific anti-HLA antibodies in the pediatric liver transplant recipients
   Atsushi Yoshizawa, Japan

P.833 The risk factors of post-transplant bacteremia in living donor liver transplantation
   Masahiko Kubo, Japan

P.835 Influence of graft steatosis on the outcome of liver transplantation
   Oana Anisa Nutu, Spain

P.836 Liver transplantation due to fulminant liver failure by heat stroke
   Felipe Alconchel, Spain

P.837 Liver transplantation due to fulminant liver failure secondary to acute submassive necrosis in a patient treated with orlistat
   Felipe Alconchel, Spain

P.838 Is hepatic flow a predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation? An observational cohort study
   Pablo Lozano, Spain

P.839 Long-term outcomes after stent insertion in patients with early and late hepatic vein outflow obstruction after living donor liver transplantation
   Kyeong Sik Kim, Korea

P.843 The risk factors for portal vein thrombosis after living donor liver transplantation in adults
   Shigeo Miyagi, Japan
P.844  MELD score predicts survival in patients treated with transjugular intrahepatic portosystemic shunt after liver transplantation

Donor wound satisfaction after living donor liver transplantation

Magdalena Salcedo, Spain

P.845  Donor specific antibody negative acute antibody-mediated rejection under the low anti-ABO antibody titer after ABO incompatible liver transplantation: A case report

Boram Lee, Korea

P.846  Higher risk of post-transplant graft failure in male recipients of female donor grafts is not due to anastomosis mismatch

Kyo Won Lee, Korea

P.847  Liver transplantation outcomes after acute liver failure: Still some questions to be asked

Marina Pérez-Flecha González, Spain

P.847a  Risk factors and consequences of ischemic cholangiopathy in liver transplantation from DCD Maastricht IIA

Marina Pérez-Flecha González, Spain

P.848  Propensity score matching analysis of post-transplant outcomes in living donor liver transplantation for obese recipients (BMI > 30)

Chan Woo Cho, Korea

P.849  Liver transplantation as curative treatment in severe pulmonary hypertension due to hepatic vascular malformations in Rendu-Osler-Weber disease

Javier Martínez Caballero, Spain

P.850  Molecular adsorbent recirculating system support followed by liver transplantation for multiorgan failure from exertional heatstroke

Nicole M. Shockcor, United States

P.852  Actual outcomes and technical feasibility of living donor-related liver re-transplantation

Wan-Joon Kim, Korea

P.854  Liver transplantation in the adult following Kasai operation in infancy

Undine Gerlach, Germany

P.855  Incidence of biliary and arterial complications using liver grafts from 70 to 94 years old

Carlos M. Muñoz-Arce, Spain

P.855a  Liver Transplantation Using Nonagenarian Liver Grafts

Carlos M. Muñoz-Arce, Spain

P.856  Liver transplantation in the treatment of neuroendocrine metastatic tumors: Our experience

Gabriel E. Gondolesi, Argentina

P.857  Applicability of liver transplantation for patients with acute on chronic liver failure

Valeria Descazi, Argentina

P.858  DRL-MELD: A new concept to predict graft survival after liver transplantation with aged donors

Carlos Jimenez, Spain

P.859  Morbidly obese patients awaiting liver transplantation. Sleeve gastrectomy: Safety and efficacy from a liver transplant unit experience

Alberto A. Marcacuzzo Quinto, Spain

P.860  The analysis of pathological and serological findings in the long-term pediatric liver transplantation: The achievement of clinical operational tolerance

Atsushi Yoshizawa, Japan

P.861  Donor wound satisfaction after living donor liver transplantation in the era of pure laparoscopic donor hepatectomy

Jeong-Moo Lee, Korea

P.862  Comparative study of pure laparoscopic donor right hemihepatectomy and open donor right hemihepatectomy in patients with separate right anterior and right posterior portal veins

Jeong-Moo Lee, Korea

P.863  Volumetric reevaluation of liver left lateral segment donors, which had previously been incompatible with intraoperative weight findings

 Mehmet Coskun, Turkey

P.865  Manual computed tomography liver volumetry: Can it be done faster?

 Mehmet Coskun, Turkey

P.866  Outcome of left lobe living-donor liver transplantation in Tokushima

Satoru Imura, Japan

P.867  The impact of minimally-invasive open donor hepatectomy on outcomes in adult living donor liver transplantation

Yui Soejima, Japan

P.868  The anterior sector venous outflow reconstruction using recipient's superficial femoral vein in adult right lobe living donor liver transplantation

Shigeyuki Kawachi, Japan

P.869  Simultaneous splenectomy is not recommended in living-donor liver transplantation

Nobuwa Aka, Japan

P.870  The result of weight reduction program and the risk factors for failed weight reduction in patient with fatty liver during living donor liver transplantation work up

Mira Jung, Korea

P.871  A comparison of hepatic artery reconstruction using a surgical loupe and operating microscope during living donor liver transplantation

Tae-Yoon Kim, Korea

P.872  The first case of pure 3D laparoscopic living donor hepatectomy in Kazakhstan

Yermakhan Assikhanuly, Kazakhstan

P.873  Potential effect of using ABO-compatible living-donor liver transplantation

Eleazar Calb, Brazil

P.874  Laparoscopic approach for living donor to paediatric liver transplantation. Experience of the first 7 cases in Spain

Irene Gomez-Luque, Spain

P.877  Right extended living donor hepatectomy for double portal vein graft (type D): A case report

Doojin Kim, Korea

P.878  Outcomes of ABO compatible and DSA positive living donor liver transplantation

Masahiro Shinoda, Japan

P.880  Anastomosis bile duct and portal anomaly in living donor liver transplantation

Kwangsik Chun, Korea

P.881  ABOI live donor liver transplantation for patients with single lymph node metastasis of hepatocellular carcinoma after hepatectomy

Geun Hong, Korea

P.882  Percutaneous biopsy of hepatocellular cancer using coaxial needle system and track catherization to prevent bleeding and seeding

Fatih Boyvat, Turkey

P.883  Baskent University expanded criteria for hepatocellular carcinoma: The importance of the histopathological features as a part of the evaluation criteria for liver transplantation

Onca Ozgun, Turkey

P.884  Advantage of early liver transplantation whenever hepatocellular carcinoma recurrence after primary liver resection

Kun-Ming Chan, Taiwan

P.885  Living-donor liver transplantation for hepatic epithelioid hemangioendothelioma with early recurrence in an adult: A case report

Kee-Hwan Kim, Korea
P.886 Blood transfusion as an independent risk factor for recurrence after hepatocellular carcinoma resection
Dongdo You, Korea

P.887 Preoperative prognostic nutritional index as independent predictor of overall survival on hepatocellular carcinoma after liver transplantation
Maria García-Conde Delgado, Spain

P.888 Analysis of differentially expressed proteins in hepatocellular carcinoma
Angeles Baquerizo, United States

P.889 Can biliary papillomatosis recur after liver transplantation in the absence of infiltrative carcinoma?
Carlos Jimenez, Spain

P.892 Impact of basiliximab induction on adult recipient survival at 60 months after liver retransplantation procedure: Single center experience
Calogero Ricotta, Italy

P.894 Liver biopsy results in potential donor evaluation in living related liver transplantation
Fatih Hilmioğlu, Turkey

P.895 Successful treatment with direct-acting antiviral agents of hepatitis C in the setting of end-stage renal disease
Digdem Ozer Etik, Turkey

P.896 Efficacy and tolerability of direct-acting antiviral agents for hepatitis C virus infection in kidney transplant recipients
Fatih Hilmioğlu, Turkey

P.897 Results from a long term histological follow up of de novo HBV-infection in liver transplant patients unrelated to HBV-reinfection and HBV-reactivation
Christine Hofer, Germany

P.898 Sofosbuvir plus velpatasvir combination therapy for recurrent hepatitis C infection after sofosbuvir plus ribavirin combination therapy in a liver transplant recipient
Yang Won Yang Nah, Korea

P.899 Surgical aspects of split liver transplantation
Sergey Gautier, Russian Federation

P.900 Successfully in situ right-left split liver transplantation: First report of in Argentina
Andres Fraile, Argentina

P.901 Pyloric artery to segment 4 artery vascular reconstruction, a novel surgical technique developed for donor safety after LLS hepatectomy, and now proposed for extended right lobe split grafts
Andres Fraile, Argentina

P.902 The changes of pediatric liver transplantation in Seoul National University Hospital according to the changes of allocation system
Ok-Kyung Kim, Korea

P.903 Establishing a porcine model of “Small for Flow Syndrome”
Maitane I. Orue-Echebarria, Spain

P.904 Performing a right hemihepatectomy sequentially after DDLT–The solution for a large-for-size graft during liver transplantation: Case report
Sung Eun Park, Korea
Abbas, Abul K..................................................435.1, 445.1
Abbud-Filho, Mario M.................................419.9
Abrams, Peter I .....................................................252.1
Acosta, Fabio Ruben .............................................P.312
Adam, Ibrahim ....................................................316.6, 520.4
Adenugba, Akinbami R .................................394.5, P.406
Adey, Deborah ..........................................................133.3, P.270
Adhikary, Sam R ....................................................495.3
Agbor-Enoh, Sean ..................................................201.2
Aguado, Jose Maria ...........................................322.8, 461.2
Agung Nugroho, Eriawan ..................................P.011
Ahmed, Ejaz ..........................................................493.1, 590.8
Ahn, Chul Soo ....................................................P.828
Aizner, Sigal ..........................................................521.3, P.152
Akandoye, Mayowa Oyeniyi ..................................P.676
Akad, Selina ..........................................................P.485
Akalin, Enver .....................................................418.7, 504.6
Akamatsu, Nobuhisa ...........................................P.869
Akay, Sule ...............................................................P.341, P.722
Akdur, Aydincan ....................................................P.310, P.501
Akimoto, Shuji .....................................................326.2
Akioka, Kiyo kazu .....................................................P.068
Akutsu, Naotake ....................................................P.080, P.639
Al Salmi, Isaa .....................................................393.6, 491.1
Al-Attar, Besher .....................................................P.594, P.595
Al-Mousawi, Mustafa S. A .....................................491.4
Al-Mowaihat, Sahar M ...........................................P.735
Altait, Jan .................................................................620.4
Alcongel, Felipe .....................................................P.836, P.837
Aleid, Hassan Ali ....................................................492.3, P.611
Alexander, Mariam P ...........................................621.1
Ali, Abeara ...............................................................P.071, P.072
Alkadi, Mohamad M .............................................493.6, P.345
Alkendi, Fatima ......................................................P.237
Allen, Richard D.M .................................................593.12
Almel, Javier ...........................................................422.8, P.680
AllMeshari, Khalid Kam .......................................604.2
Alobaoidi, Ali A ......................................................593.2
Alonso Guallart, Paula ..........................................503.4
Alonso Melgar, Ángel .............................................P.736
Aloufi, Majed .......................................................P.266
Alqasimi, Khalid .....................................................P.079
Alrukhaimi, Mona ....................................................232.2, 235.6
Alvarez Marquez, Antonio .....................................490.5, P.205
Alvarez-Casas, Josue .............................................415.7, P.433
Alvarez, Cristian M ....................................................P.128
Amer, Hatem ..........................................................622.1
Amin, Kavit .............................................................622.7
Andrade, Larissa Guedes da Fonte .................................P.644
Andres, Ane M ..........................................................P.513
Anjos Malheiro, Jorge .............................................490.1
Arillas-Cabales, Carlos ..........................................322.3, P.002, P.207
Aroervo Hornero, Rebeca C ....................................P.424.6
Arslan, Hande .........................................................P.380, P.381
Arvelakis, Antonios ..............................................P.047a
Asai, Tomoko ..........................................................525.2
Ásberg, Anders .....................................................326.9, 391.1
Ascher, Nancy .........................................................234.6, 535.1, 535.2,
                                                                                   335.5, 335.6, 575, 606.3, 635.3
Asena, Leyla ..........................................................P.700, P.701
Ashwin, Monika ......................................................417.9, P.133
Askar, Medhat .........................................................100.1, 100.2, 308.3, 328.1
Assoungua, Alain G .................................................P.230, P.409
Assylhanuliy, Yermakhan .....................................P.872
Attiya, Ashraf Ali .....................................................P.342
Aubert, Olivier .......................................................362.2, 419.2, 516.5
Auñón, Pilar .............................................................302.2, P.119
Avolio, Alfonzo W ....................................................624.7
Aytekin, Cumeys .....................................................P.106, P.313
Ayazoglu Soy, Ebru H .............................................415.3, 492.4
Azimzadeh, Agnes ..................................................526.2
Aziz, Feroz ...............................................................P.027
Baan, Carla C .........................................................140.3, 330.1, 403.2, P.420
Babel, Nina ...............................................................204.4
Bachul, Piotr J ..........................................................325.3
Bagai, Sahil .............................................................P.338
Bagias, Georgios ....................................................P.522
Bagul, Atul ...............................................................P.136, P.271
Balachandran, Yash .................................................392.4, 527.5
Balan, Satish ...........................................................P.397
Ballesté, Chloé .........................................................422.5, 623.2
Balwani, Manish Ramesh .......................................P.272, P.681
Banas, Bernhard ......................................................321.2
Bansal, Aarushi ......................................................525.5
Baquerizo, Angeles ...............................................P.888
Barahona, Maria J ....................................................P.462
Baris, Zeren ..............................................................P.737, P.738
Barlow, Adam D ......................................................464.2, P.410, P.315
Barten, Mark J .........................................................591.1, P.713
Baskin, Esper ..........................................................498.2, 498.3
Bastien, Olivier OB ...................................................P.569.2
Basturk, Bilay ..........................................................P.401, P.402
Benet, Dimitri .........................................................623.3, P.126
Bell, Ruth D .............................................................519.5
Bellini, Maria Irene ....................................................133.1
Bello, Irene ...............................................................621.5
Bellón, Teresa ..........................................................321.4
Belmar Vega, Lara ....................................................P.127
Ben Abdallah, Taieb ...............................................P.219
Ben Fatma, Lila ...........................................................P.377
Benjamin, Stan .........................................................325.11, 502.2
Berenguer, Marina ...................................................360.2
Berger, Lea ...............................................................P.560
Berglund, Erik ..........................................................503.1
Beirishvili, Ekaterine .................................................592.4
Bertani, Alessandro ...............................................621.6
Bestard Matamoros, Oriol .......................................465.2
Bézie, Séverine .........................................................424.7
Bialek, Lukasz .........................................................P.621a
Bialobrzeska, Malwina ..........................................625.2, P.554
Bisigniano IV, Liliana .................................................397.5, P.604
Bitterer, Florian .......................................................304.5
Black, John T ...........................................................393.2, P.138
Black, Sally R ..........................................................585.1, P.641
Boffa, Catherine .....................................................615.5
Bonisconti, Florencia .................................................P.382
Borkar-Tripati, Minal ..............................................316.4, 316.8
Borrás-Serres, Francesc E .......................................322.4
Bottino, Rita ............................................................407.2
Bouatou, Yassin ....................................................301.1, 516.3
Boucault, Laetitia ....................................................624.4
Boyyat, Fatih ..........................................................P.811, P.882
Brasil, Laurence ......................................................523.4, 591.5
Braun, Hillary J .........................................................315.5, 615.6
Brayman, Kenneth ....................................................318.4
Brayne, Adam ..........................................................587.11
Brenner, Paolo .........................................................526.1
Bromberg, Jonathan S ..............................................101.4, 320.9, 435.3, 586.8
Brousseau, Carole .....................................................303.2
Bruintjes, Moira H ....................................................319.4, P.065
Buchholz, Bettina .....................................................300.1, 393.3
Buchko, Max T .........................................................P.638
Bueno, Antonio .........................................................P.204
Bueno, Alba ...............................................................423.9
Bugeja, Anna ...........................................................P.087
Bühler, Léo Hans .......................................................241.2
Bul, Kim .................................................................P.242, P.242a
Burballa, Carla ..........................................................P.291
Burdorf, Lars ............................................................395.2, P.522
Burguete, Daniel .......................................................301.4
Burlingham, William J .............................................586.1
Busque, Stephan ......................................................608.1
Butala, Bina .............................................................624.3
Butte, Atul ............................................................... 630.1
Caicedo, Luís ......................................................... P.740
Cakiroglu, Ahmet .................................................... P.608
Caliskan, Kenan ..................................................... P.112, P.739
Calle MFalla, Oscar A ............................................. 326.10, 400.6
Calvo Romero Sr., Natividad N .................................................. 317.7, 317.8
Canaud, Guillaume .................................................. 600.1
Canovai, Emilio .......................................................... 522.4, P.764
Cantalluppi, Vincenzo .............................................. 402.6, 589.2
Cantarovich, Diego ...................................................... 325.9
Cao, Lu ........................................................................... 605.5
Capobianco, Ivan .......................................................... P.741
Capron, Alexander M ........................................... 233.4, 234.5, 305.2
Carbone, Javier .......................................................... 326.7, 590.7, P.726
Carmona Jr., Marco Antonio .............................................. 404.2, P.034
Carrillo Cobarro, María ............................................. 393.3
Casillas Sagrado, Ester .............................................. P.016, P.167
Castillo, Solon ............................................................. P.610
Cecka, J. Michael .......................................................... P.741
Čevik, Ali ....................................................................... P.669
Chaib, Eleazar .............................................................. P.873
Chan, Kun-Ming ............................................................ P.575, P.884
Chanta, Gabriel E ....................................................... P.171
Chapman, Jeremy R .................................................. 100.3, 234.2, 308.6, 606.2
Chau, Ka Foan ............................................................. P.171
Chen, Cheng ................................................................. 418.5
Cheng, Yu Fan ............................................................. 560.1
Cherqui, Daniel ............................................................. 550.12, 560.2
Cherukuri, Aravind ..................................................... 318.1
Cheung, Chi Yuen Simon .............................................. 585.2, P.683
Chew, Hong Chee ........................................................ 323.5, P.440
Chinhong, Peter V ........................................................ 321.6
Chiou, Fang Kuan ......................................................... 627.4, 627.5
Chittka, Dominik .......................................................... 316.1, 318.9
Cho, Chan Woo ........................................................... P.383, P.848
Choi, Ho Joong ............................................................ P.825
Chok, Kenneth Siu Ho ................................................... 524.1
Chong, Anita ................................................................. 132.2
Christie, Emily ............................................................ P.250
Chu, Simon N ............................................................... 403.3
Chuluyan, Eduardo ...................................................... 585.10
Chun, Kwangslik ............................................................ P.880
Chung, Jeehye ............................................................... P.618
Citoros Sanchez, Maria Jesus ........................................... 322.2, P.404
Citterio, Franco ............................................................ 391.6
Claas, Frans HJ ............................................................. 362.3, 375.1, 450.13
Clatworthy, Menna R .................................................. 363.1
Clegg, Deborah J .......................................................... 350.9, 467.1
Cobo, Cristina .............................................................. P.810, P.810a
Cobos, Marisa M .......................................................... P.385
Coll, Elisabeth ............................................................... 593.8, 607.1
Comas, Jordi ................................................................. 617.4
Conception, Waldio ...................................................... 521.2
Concors, Seth J ............................................................. 589.5, P.452
Conde -San Román, Patricia .............................................. P.430
Conkling, Nicole ........................................................... 592.5
Conrad, Anne ................................................................. 423.4
Contreras-Ruiz, Laura ................................................... 520.3
Cooper, David K.C ......................................................... 240.1
Comide Petronio, Maria Eugenia ......................................... P.442, P.443
Coroel, Maria M ........................................................... 494.1
Correa-Rocha, Rafael ..................................................... 404.1, 424.1
Coskun, Mehmet ......................................................... P.863, P.865
Costa, Cristina .............................................................. P.521
Cozzi, Emanuele E ........................................................ 407.1
Crespo Barrio, Marta .................................................... 425.2
Crome, Sarah ................................................................. P.103.3
Cross, Amy R ................................................................. 318.8, 586.6
Cruz Santiago, Jose ....................................................... P.244, P.317
Cruzado, Josep M .......................................................... 561.3
Cucchiari, David ........................................................... 620.5, P.362
Dafallah, Alaa A.S ........................................................ 525.6
Dai, Helong ................................................................. 418.9, 421.2
Danovitch, Gabriel ...................................................... 233.2, 235.7, 508.1, P.347, P.361
Darius, Tom ................................................................. 589.4, P.447
Dawson, Nicholas AJ .................................................... 494.6
de Fijter, Johan W ......................................................... 420.5
de Gracia Guindo, Maria del Carmen ................................... P.354
De La Mata, Nicole L ..................................................... 602.1
de Leur, Kitty ................................................................. 404.6
De Simone, Paolo ......................................................... 307.2
De Teresa Alguacil, Javier ........................................... P.164, P.165
de Vries, Alko PJ ........................................................... 620.6
Dedinska, Ivana ............................................................ 502.1, P.157
Deeb, Maya ................................................................. P.155
Del Pozo, Pilar ............................................................... P.775, P.776
Delmonico, Francis L ..................................................... 535.3
Deng, Shaoping ............................................................ 241.3
Dennisov, Viktor .......................................................... P.286
Dascalvi, Valeria ........................................................... P.857
Dhawan, Anil ............................................................... 202.2, 365.1, 450.5
DeChiacchio, Laura ...................................................... 526.5, P.523
Dipchand, Anne ............................................................ 272.1
Dittmer, Ian D ............................................................... P.231.3
Dobbels, Fabienne ....................................................... 468.3, P.181
Dohler, Bernd .............................................................. P.251
Dominguez-Gil, Beatriz ........................................... 231.5, 234.3, 535.4, 567.2
Dominguez, Edward A .................................................. 225.1, 510.5
Dorician, Julian ............................................................ P.005, P.472
Drachenberg, Cintia B ................................................... P.214
Dragun, Duska .............................................................. 401.2
Drogemuller, Chris J ...................................................... P.547
Du Toit,inus ................................................................. P.058
Du, Caigan ................................................................. 497.2
Duncan, Eleanor M ....................................................... 620.2
Durlik, Marek ............................................................... P.559
Dursun Altimors, Dilek ................................................ 702,703
Dzwoñkowska, Sandra ................................................... P.086
Eagawa, Hiroto ............................................................ 450.16, P.292
Egeland, Erlend J .......................................................... 591.4, P.252
Eggerhofer, Elke .......................................................... P.468
Eghesad, Bijan ............................................................. P.827
El-Agroody, Amgad E .................................................... P.319, P.321
El-Kishawi, Abdullah .................................................... 545.2
El-Sarafy, Magdy .......................................................... 601.1
Elgin, Ervin ................................................................. P.649, P.650
Elias, Sandra ............................................................... P.293
Ellis, Eva ................................................................. 151.2
Empson, Katja ............................................................. 410.1
Emre, Sukru H ............................................................. 250.2, 253.2
Entwistle, Timothy R ..................................................... 323.7
Erdogan, Ilkay ............................................................... P.715, P.716
Erichson, Bo-Goran ...................................................... 618.4
Erlis, Gilad ................................................................. 466.2
Ersoy, Ozgur ............................................................... 323.3, P.717
Eszquivel, Carlos O ....................................................... 350.1, 361.2
Ezzahouri, Ikram .......................................................... 590.6, 5418
Fadhil Al Noaman, Riadh A.S .......................................... 233.3
Fakhr, Mohammad ......................................................... 615.1, 621.7
Faleo, Gaetano ............................................................. 589.1
Falk, Christine S ......................................................... 418.4, 467.3, P.412
Falletta, Calogero .......................................................... 326.3, 398.3
Famure, Olusegun ......................................................... 390.2, P.616
Fame, Douglas G ........................................................... 627.3
Farouk, Samira ............................................................ P.041
Feng, Sanyd ............................................................... 607.2
Fernández García, Aída .................................................. P.778
Fernández, Ernesto J .................................................... P.226
Ferreira Centeno, Eugenia ............................................. P.274
Ferrerás, David ............................................................. 500.5
Figuer, Andreja ............................................................. 588.6
Filldlay, James ............................................................. 469.3, 550.7
Fink, Michael A ........................................................... 415.3, 515.2
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trujillo, Hernando</td>
<td>416.9, P665</td>
</tr>
<tr>
<td>Tsirulnikova, Olga</td>
<td>590.5</td>
</tr>
<tr>
<td>Tullius, Stefan G.</td>
<td>132.3, 418.3, 450.4, 562.2, 626.1, 635.1</td>
</tr>
<tr>
<td>Twombley, Katherine</td>
<td>P754</td>
</tr>
<tr>
<td>Uchida, Junji</td>
<td>P235</td>
</tr>
<tr>
<td>Uematsu, Satomi Suzuki</td>
<td>325.1</td>
</tr>
<tr>
<td>Ueno, Takehisa</td>
<td>315.6, 399.2</td>
</tr>
<tr>
<td>Ulu Öztürk, Funda</td>
<td>415.2, P096</td>
</tr>
<tr>
<td>Ulyanova, Olga</td>
<td>P512</td>
</tr>
<tr>
<td>Unterrainer, Christian</td>
<td>302.6, 550.4</td>
</tr>
<tr>
<td>Urbanellis, Peter</td>
<td>593.3, 615.3</td>
</tr>
<tr>
<td>Ushiro-Lumb, Ines</td>
<td>393.4, 590.9</td>
</tr>
<tr>
<td>Uslu, Nihal</td>
<td>P107, P804</td>
</tr>
<tr>
<td>Ussif, Amin M</td>
<td>326.6</td>
</tr>
<tr>
<td>Utrero-Rico, Alberto</td>
<td>518.8</td>
</tr>
<tr>
<td>Uva, Pablo D</td>
<td>625.3</td>
</tr>
<tr>
<td>Uwechue, Raphael</td>
<td>402.7</td>
</tr>
<tr>
<td>Uysal, Cagri A</td>
<td>P340, P707</td>
</tr>
<tr>
<td>Valentin, Maria Oliva</td>
<td>402.1, 490.3</td>
</tr>
<tr>
<td>Valero, Rosalia</td>
<td>P336</td>
</tr>
<tr>
<td>Van Assche, Kristof</td>
<td>491.5</td>
</tr>
<tr>
<td>van Besouw, Nicole M.</td>
<td>403.5</td>
</tr>
<tr>
<td>van den Berg, Tamar A.J.</td>
<td>421.3, P125</td>
</tr>
<tr>
<td>van den Hoogen, Martijn W.F.</td>
<td>591.7</td>
</tr>
<tr>
<td>van der Zwan, Marieke</td>
<td>326.1, 403.7</td>
</tr>
<tr>
<td>Van Gelder, Teun</td>
<td>106.4</td>
</tr>
<tr>
<td>Van Raemdonck, Dirk</td>
<td>406.2</td>
</tr>
<tr>
<td>Vanhove, Bernard</td>
<td>103.2</td>
</tr>
<tr>
<td>Vazquez, Teresa</td>
<td>322.1, 423.11, P266</td>
</tr>
<tr>
<td>Vela, Maria</td>
<td>619.2</td>
</tr>
<tr>
<td>Venema, Leonie H.</td>
<td>P459</td>
</tr>
<tr>
<td>Ventura-Aguilar, Pedro</td>
<td>625.4, 625.5</td>
</tr>
<tr>
<td>Verma, Nirupama D</td>
<td>404.4</td>
</tr>
<tr>
<td>Vianna, Rodrigo</td>
<td>408.1</td>
</tr>
<tr>
<td>Vidal Campos, Silvia</td>
<td>393.1, 461.3</td>
</tr>
<tr>
<td>Vila-Santandreu, Anna</td>
<td>P755</td>
</tr>
<tr>
<td>Vileito, Alicia</td>
<td>P657</td>
</tr>
<tr>
<td>Villar-Arias, Alicia</td>
<td>P597</td>
</tr>
<tr>
<td>Vinaixa, Carmen</td>
<td>300.4</td>
</tr>
<tr>
<td>Vincenti, Flavio</td>
<td>465.1</td>
</tr>
<tr>
<td>Vionnet, Julien</td>
<td>P264</td>
</tr>
<tr>
<td>Visser, Isis J</td>
<td>390.4</td>
</tr>
<tr>
<td>Visseren, Thijmen</td>
<td>P487</td>
</tr>
<tr>
<td>Vittoraki, Angeliki</td>
<td>P307</td>
</tr>
<tr>
<td>Vogelfang, Horacio</td>
<td>P756</td>
</tr>
<tr>
<td>Voglova, Barbora</td>
<td>P561</td>
</tr>
<tr>
<td>von Websky, Martin W</td>
<td>367.2</td>
</tr>
<tr>
<td>Vučur, Ksenija</td>
<td>P009</td>
</tr>
<tr>
<td>Wadei, Hani M</td>
<td>P812</td>
</tr>
<tr>
<td>Wakabayashi, Taiga</td>
<td>415.11</td>
</tr>
<tr>
<td>Waller, Karen</td>
<td>590.1</td>
</tr>
<tr>
<td>Walsh, Grainne M.</td>
<td>361.1</td>
</tr>
<tr>
<td>Wang, Benny</td>
<td>300.2</td>
</tr>
<tr>
<td>Ward, Casey J</td>
<td>496.2, 592.1</td>
</tr>
<tr>
<td>Watanabe, Hironosuke</td>
<td>526.3, 605.4</td>
</tr>
<tr>
<td>Waterman, Amy</td>
<td>422.7, 524.4</td>
</tr>
<tr>
<td>Watson, Alicia R.</td>
<td>320.3</td>
</tr>
<tr>
<td>Webster, Angela C</td>
<td>397.4</td>
</tr>
<tr>
<td>Weimer, Rolf</td>
<td>316.7</td>
</tr>
<tr>
<td>Weinstock, Jan L.</td>
<td>P285</td>
</tr>
<tr>
<td>Werlin, Evan C</td>
<td>P881</td>
</tr>
<tr>
<td>West, Lori J</td>
<td>130.1, P304, P411</td>
</tr>
<tr>
<td>Wiering, Leke</td>
<td>515.3, P803</td>
</tr>
<tr>
<td>Wigfield, Christopher</td>
<td>255.1, 550.14, 569.1</td>
</tr>
<tr>
<td>Wisel, Steven</td>
<td>523.5</td>
</tr>
<tr>
<td>Wohlfahrtova, Mariana</td>
<td>504.2</td>
</tr>
<tr>
<td>Wolf, Eckhard</td>
<td>241.1</td>
</tr>
<tr>
<td>Wolfe, Cameron</td>
<td>221.2, 510.6</td>
</tr>
<tr>
<td>Womer, Karl L</td>
<td>P190</td>
</tr>
<tr>
<td>Wong, Germaine</td>
<td>104.3, 131.2, 350.8, 462.1</td>
</tr>
<tr>
<td>Woodie, E. Steve</td>
<td>309.3, 350.14</td>
</tr>
<tr>
<td>Woodside, Kenneth J</td>
<td>422.2</td>
</tr>
<tr>
<td>Wordsworth, Matthew</td>
<td>P469</td>
</tr>
<tr>
<td>Wright, Charles E</td>
<td>587.8</td>
</tr>
<tr>
<td>Wu, Huiling</td>
<td>586.7</td>
</tr>
<tr>
<td>Xie, Qinfen</td>
<td>P820, P822</td>
</tr>
<tr>
<td>Yamada, Kazuhiko</td>
<td>407.3, 526.4</td>
</tr>
<tr>
<td>Yamamoto, Shinji</td>
<td>587.3</td>
</tr>
<tr>
<td>Yamashiki, Noriyo</td>
<td>P499.1</td>
</tr>
<tr>
<td>Yang, Cheng</td>
<td>516.4, P427</td>
</tr>
<tr>
<td>Yanishi, Masaaki</td>
<td>P173</td>
</tr>
<tr>
<td>Yao, Ming Han</td>
<td>494.5, P551</td>
</tr>
<tr>
<td>Yarbug Karakayal, Feza</td>
<td>P066, P067</td>
</tr>
<tr>
<td>Yee, Seow Yeong</td>
<td>P228</td>
</tr>
<tr>
<td>Yeh, Heidi</td>
<td>407.</td>
</tr>
<tr>
<td>Yeo, Sangmok</td>
<td>P123</td>
</tr>
<tr>
<td>Yeung, Andrew</td>
<td>P643</td>
</tr>
<tr>
<td>Yew, Shiong</td>
<td>401.3, 616.4</td>
</tr>
<tr>
<td>Yildirim, Sedat</td>
<td>P150, P831</td>
</tr>
<tr>
<td>Yildiz, Abdulmecit</td>
<td>524.2, 539</td>
</tr>
<tr>
<td>Yokoyama, Naoki</td>
<td>587.5</td>
</tr>
<tr>
<td>Yolcu, Esma S.</td>
<td>320.1, 626.7</td>
</tr>
<tr>
<td>Yoon, Sojeong</td>
<td>P757</td>
</tr>
<tr>
<td>Yoshida, Kazunari</td>
<td>P114</td>
</tr>
<tr>
<td>Yoshikawa, Mikiko</td>
<td>401.5</td>
</tr>
<tr>
<td>Yoshikawa, Yuki</td>
<td>324.6</td>
</tr>
<tr>
<td>Yoshimoto, Syhei</td>
<td>497.3</td>
</tr>
<tr>
<td>Yoshizawa, Atsushi</td>
<td>P833, P860</td>
</tr>
<tr>
<td>You, Dongdo</td>
<td>P886</td>
</tr>
<tr>
<td>Young, Carl K</td>
<td>469.2</td>
</tr>
<tr>
<td>Yuan, Xiao-Peng</td>
<td>585.9, P049</td>
</tr>
<tr>
<td>Yun, Il Jin</td>
<td>395.4, P560</td>
</tr>
<tr>
<td>Zafar, Mirza Naqi</td>
<td>P302</td>
</tr>
<tr>
<td>Zahar, Jean Ralph</td>
<td>224.3</td>
</tr>
<tr>
<td>Zaky, Ziad</td>
<td>585.8</td>
</tr>
<tr>
<td>Zanetti, Helen K.</td>
<td>P369, P371</td>
</tr>
<tr>
<td>Zawierucha, Jacek</td>
<td>P100, P103</td>
</tr>
</tbody>
</table>